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Abstract
The Single combination budesonide/formoterol inhaler as Maintenance And Reliever
Therapy (SMART) regimen reduces severe asthma exacerbations, but it is uncertain
whether it increases the risk of adverse effects due to high corticosteroid and beta-
agonist doses with both short-term and cumulative exposure in patients at risk of
severe exacerbations. The primary hypothesis was that the SMART regimen would
reduce the risk of beta-agonist overuse. Secondary aims were to investigate whether
patients treated with the SMART regimen were less likely to seek medical review in
the setting of beta-agonist overuse and to determine whether any reduction in severe
asthma exacerbations would be at a cost of a higher systemic corticosteroid burden.
This 24-week, open-label, parallel-group, multicentre randomised controlled trial
randomised 303 asthma patients with a recent exacerbation to combination 200/6µg
budesonide/formoterol metered dose inhaler (MDI) according to the SMART
regimen (two actuations twice daily as maintenance with one extra actuation as-
needed for relief of symptoms) or a fixed-dose regimen (two actuations twice daily
as maintenance) with one to two actuations of 100µg salbutamol MDI as-needed for
relief of symptoms (the ‘Standard’ regimen), with electronic monitoring to measure
actual medication use. The use of electronic monitoring allowed beta-agonist
overuse to be applied as a marker of the risk of life-threatening asthma. The primary
outcome was the proportion of participants with at least one high beta-agonist use
episode (more than eight actuations per day of budesonide/formoterol in addition to
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the four maintenance doses in the SMART group or more than 16 actuations per day
of salbutamol in the Standard group).
There was no significant difference between groups in the proportion of participants
with at least one high use episode: SMART 84/151 (55.6%) versus Standard 68/152
(44.7%), relative risk (95% CI) 1.24 (0.99 to 1.56), p=0.058. There were fewer days
of high use in the SMART group [mean (SD) 5.1 days (14.3) versus 8.9 days (20.9),
relative rate (95% CI) 0.58 (0.39 to 0.88), p=0.01]. Of the participants who had at
least one high use episode, those in the SMART group had fewer days of high use
without medical review [mean (SD) 8.5 days (17.8) versus 18.3 days (24.8), relative
rate (95% CI) 0.49 (0.31 to 0.75), p=0.001]. The SMART regimen resulted in higher
inhaled corticosteroid exposure [mean (SD) 943.5µg budesonide per day (1502.5)
versus 684.3µg budesonide per day (390.5), ratio of means (95% CI) 1.22 (1.06 to
1.41), p=0.006], but reduced oral corticosteroid exposure [mean (SD) 77.5mg
prednisone (240.5) versus 126.6mg prednisone (382.1), p=0.011], with no significant
difference in composite systemic corticosteroid exposure [mean (SD) 793.7mg
prednisone equivalent per year (893.1) versus 772.1mg prednisone equivalent per
year (1062.7), ratio of means (95% CI) 1.03 (0.86 to 1.22), p=0.76]. Participants in
the SMART group had fewer severe asthma exacerbations [35 (weighted mean rate
per year 0.53) versus 66 (0.97), relative rate (95% CI) 0.54 (0.36 to 0.82), p=0.004].
The SMART regimen has a favourable risk/benefit profile in patients at risk of
severe asthma exacerbations.
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1Chapter One: Introduction
1.1 Thesis aim
In asthma patients who are not controlled on inhaled corticosteroid (ICS) therapy, the
standard treatment is a single combination ICS and long-acting beta-agonist (LABA)
inhaler for fixed-dose maintenance therapy with a short-acting beta-agonist (SABA),
such as salbutamol, for relief of symptoms.
An alternative approach is the Single combination inhaler as Maintenance And
Reliever Therapy (SMART) regimen, in which patients use a combination
budesonide/formoterol ICS/LABA inhaler as regular maintenance therapy and take
extra doses of the same inhaler for relief of symptoms. This method of using a single
budesonide/formoterol inhaler for both maintenance and relief is possible because
formoterol is a beta-2 agonist with high intrinsic activity which has an onset of action
comparable to salbutamol and a duration of action for over 12 hours. Formoterol, in
combination with budesonide, can therefore provide sustained bronchodilation when
used as maintenance treatment and may also be used as a reliever treatment.
Prior randomised controlled trials (RCT) have demonstrated that in patients with
poorly controlled asthma, treatment with the SMART regimen reduces severe asthma
exacerbations when compared to the ‘Standard’ regimen of the same fixed-dose
maintenance budesonide/formoterol with SABA for relief. The generalisability of
2this finding is limited for three reasons. Firstly, these trials excluded potentially
eligible patients with high baseline reliever medication use. Secondly, a reduction in
maintenance ICS dose occurred at randomisation, in patients with current asthma
symptoms. Thirdly, patients were required to demonstrate significant bronchodilator
reversibility in order to be eligible.
In addition, these studies used daily diaries to collect data on use of inhaled
medication, which is recognised to be an inaccurate measure of actual use of inhaled
therapy when compared to electronic monitoring. As a result, it is not possible to
determine if the reduction in severe exacerbations observed with the SMART
regimen is due to a reduction in non-adherence to regular budesonide/formoterol
therapy, or due to self-titrated increasing budesonide/formoterol use during
worsening asthma. It is also unknown if the SMART regimen may lead to a greater
delay in seeking medical care in the setting of beta-agonist overuse or whether it
results in a greater systemic corticosteroid burden.
The principal study that this thesis describes is a 24-week, multicentre, open-label,
randomised, parallel-group trial to study the efficacy and safety of the SMART
regimen compared to Standard therapy in 303 real-world asthma patients who were
at risk of severe exacerbations. The trial was designed to overcome the key limiting
issues described above and used electronic monitoring to measure actual patterns of
inhaler use.
Three supporting studies are also described. The first study investigated the accuracy
of self-report compared to electronic monitoring of inhaled asthma medication use,
3using data from a previously undertaken RCT of adherence to maintenance ICS and
LABA treatments. The second study was a six-month bench validation of the
accuracy of the electronic monitors that were used in the principal trial. The third
study reports on the performance of the electronic monitors used in the principal
trial, based on the use of pre-trial and within-trial validation protocols.
1.2 Thesis outline
Chapter One begins with a summary of the pharmacology and efficacy of ICS and a
review of the comparative pharmacology of beta-agonists. The first half of this
chapter then focuses on the evidence for the efficacy of formoterol in adult asthma
and the current evidence for the SMART regimen is critically appraised. The second
part of Chapter One focuses on the issues regarding the safety of beta-agonist drugs
in asthma and in particular, the potential mechanisms of adverse effects with the use
of formoterol. The methods used to measure adherence to inhaled treatment are also
reviewed. The chapter ends with the hypothesis for the study and a summary of the
aims for this thesis.
Chapter Two describes the design and findings of the first supporting study,
investigating the accuracy of self-report compared to electronic monitoring as
measures of use of inhaled asthma treatment. This study was a retrospective analysis
of a recently conducted RCT by the Medical Research Institute of New Zealand
4(MRINZ) research group, in which adherence to single and combination maintenance
ICS and LABA therapy was measured using electronic monitoring.
Chapter Three reports on the design and results of the six-month bench testing of the
Smartinhaler Tracker electronic monitors. This chapter is a validation of the
methods used for the principal RCT, and the findings were used to inform the study
protocols for the use of the electronic monitors in the principal study.
Chapter Four describes the design and methods for the randomised controlled trial
investigating the efficacy and safety of the SMART regimen in adult asthma patients
at risk of severe exacerbations (referred to as ‘the SMART study’ in this thesis).
Chapter Five details the pre-trial and within-trial quality control protocols for the use
of the electronic monitors in the SMART study. This Chapter also describes the
development and use of the computer software and website database used to manage
data recorded by the electronic monitors.
Chapter Six presents the results of the SMART study. This chapter also details the
performance of the electronic monitors in the trial.
Chapter Seven is a discussion of the findings, including the strengths of the study,
placing the study in context with prior research, and methodological limitations. The
Chapter ends with the overall conclusions from the SMART study.
51.3 Inhaled budesonide
1.3.1 Pharmacology
Inhaled budesonide is a corticosteroid with topical anti-inflammatory action, which
binds to glucocorticoid receptors present in airway cells and subsequently exerts its
anti-inflammatory action by altering gene transcription (Chung, Caramori and
Adcock, 2009; Lindmark, 2008). Budesonide acts by reducing airway inflammatory
cells and the release of inflammatory mediators (Brogden and McTavish, 1992;
Laitinen, Laitinen and Haahtela, 1992).
1.3.2 Therapeutic efficacy
Treatment with inhaled budesonide improves airway hyper-responsiveness, asthma
symptoms and lung function and reduces severe exacerbations of asthma (Pauwels et
al., 2003a; Wongtim et al., 1995; Haahtela et al., 1991; Juniper et al., 1990).
Regular use of ICS therapy also reduces the risk of death from asthma (Suissa et al.,
2000).
There is evidence for a dose-response therapeutic effect for budesonide (Masoli et
al., 2004), though most of the clinical benefits are derived at low to medium daily
maintenance doses (up to 800µg per day) (Adams and Jones, 2006). Patients with
more severe asthma may benefit from higher daily doses or increased frequency of
dosing (Adams and Jones, 2006; Toogood et al., 1982).
61.3.3 Systemic absorption
Lung absorption and gastro-intestinal absorption of ICS both contribute to systemic
availability (Barnes, 1998). Following systemic absorption, budesonide undergoes
extensive first-pass hepatic metabolism into low-activity metabolites (Lee and
Corren, 2008; Brogden and McTavish, 1992). Plasma half-life is relatively short at
two to three hours (Brogden and McTavish, 1992).
1.3.4 Adverse effects
The most common local side effects are dysphonia, oropharyngeal candidiasis, sore
throat and cough (Brogden and McTavish, 1992).
Systemic adverse effects are determined by the amount of drug that is systemically
bioavailable and include suppression of the hypothalamic-pituitary-adrenal (HPA)
axis, inhibition of bone metabolism and cataract formation (Barnes, 1995b). These
effects are unlikely to occur at the usual prescribed maintenance doses of
budesonide, but patients may be at greater risk of these adverse effects after high-
dose, prolonged exposure (Dluhy, 1998; Pedersen and O'Byrne, 1997; Barnes and
Pedersen, 1993). The risk of both short-term and long-term ICS-related adverse
events may therefore be greater with the SMART regimen in comparison to a fixed-
dose regimen with SABA for relief.
71.3.5 Bioequivalent doses of inhaled budesonide and oral prednisone for systemic
effect on HPA axis function
Stimulation tests are considered sensitive methods for assessing the effects of ICS on
HPA axis function (Barnes, Pedersen and Busse, 1998; Pedersen and O'Byrne,
1997).
A dose-response study compared the effect of budesonide (via Turbohaler) and 10mg
of prednisone over six weeks in asthma patients, using adrenocorticotropic hormone
(ACTH) infusion to assess HPA axis function (Aaronson et al., 1998). The
investigators calculated that 10mg oral prednisone was bioequivalent to 5mg of
inhaled budesonide, for systemic effect on adrenal function.
1.4 Beta-2 adrenoceptor structure and function
Beta-2 adrenoceptors are transmembrane proteins which, when activated by agonist
drugs, stimulate the production of the second messenger cyclic adenosine
monophosphate (cAMP) via G-proteins (Anderson, 2000; Barnes, 1995a). Increased
cAMP concentration, through a series of intracellular reactions, leads to smooth
muscle relaxation and bronchodilation (Anderson, 2000; Barnes, 1995a).
81.5 Pharmacological properties of beta-2 agonists
In order to understand the relative clinical efficacy and adverse effect profile of beta-
2 agonists, several important pharmacological properties need to be considered.
1.5.1 Intrinsic activity
Intrinsic activity refers to ‘the ability of a drug to activate its receptor independent of
its concentration’ (Cates, Lasserson and Jaeschke, 2009; Hanania et al., 2002).
Beta-agonists which completely activate the beta-2 adrenoceptor are called full
agonists (e.g. isoprenaline and adrenaline), whilst those that partially activate the
receptor are called partial agonists (e.g. formoterol, salbutamol and salmeterol)
(Hanania et al., 2002). Partial agonists are further classified as ‘strong partial
agonists’ (e.g. formoterol) and ‘weak partial agonists’ (e.g. salmeterol) on the basis
of their intrinsic activity (Hanania et al., 2002). Drugs with higher intrinsic activity
have the capacity for greater receptor activation and therefore greater maximal effect
(Hanania et al., 2002).
Beta-agonists with high and low intrinsic activities may be capable of eliciting
different clinical responses during stable and unstable asthma (Hanania et al., 2002).
For instance, during stable asthma where beta-adrenoceptor function may be
unimpaired, agonists with high and low intrinsic activity may provide similar levels
of bronchodilation and bronchoprotection (Hanania et al., 2002; Rabe et al., 1993).
On the other hand, during acute asthma or in patients with more severe disease,
impairment of beta-2 adrenoceptor function may occur (e.g. due to uncoupling of the
9receptor and G-protein), together with airway smooth muscle contraction (Anderson,
2000; Barnes, 1995a). In this situation, agonists with higher intrinsic activity may
elicit greater bronchodilation compared to those with lower intrinsic activity, and
may also provide greater protection against bronchoconstrictive stimuli (Palmqvist et
al., 1999; Molimard et al., 1998).
However, in the setting of worsening asthma where high doses of beta-agonists may
be used for relief of symptoms, agonists with higher intrinsic activity may also cause
a greater degree of extra-pulmonary beta-2 adrenoceptor-mediated adverse effects,
such as hypokalaemia (Hanania et al., 2002; Palmqvist et al., 1999; Newhouse et
al., 1996).
Furthermore, inhaled beta-2 agonists may also have intrinsic activity for activation of
the beta-1 adrenoceptor, resulting in the cardiac adverse effects associated with
chronotropy and inotropy (Bremner et al., 1996; Newhouse et al., 1996). Thus, a
situation arises whereby a beta-2 agonist may allow greater therapeutic effect due to
its high intrinsic activity at the beta-2 adrenoceptor in the lung, but may also increase
the risk of adverse effects due to high intrinsic activity at extra-pulmonary beta-2 or
beta-1 adrenoceptors.
Intrinsic activity is therefore an important determinant of the risk/benefit profile of
beta-agonist medication, particularly in the setting of acute asthma and high reliever
medication use.
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1.5.2 Selectivity
Selectivity refers to the ‘ability of a drug to bind to one receptor over another’ (Cates
et al., 2009). In the context of beta-agonists, selectivity may help to determine the
balance between a therapeutic effect (e.g. beta-2 adrenoceptor mediated
bronchodilation) versus an adverse effect (beta-1 adrenoceptor mediated
tachycardia). This risk/benefit profile may be more complicated, as some extra-
pulmonary adverse effects may also be beta-2 adrenoceptor mediated (e.g.
hypokalaemia) (Newnham et al., 1995), whilst cardiac responses may also be
associated with beta-2 receptor stimulation in the heart (Brodde and Michel, 1999;
Anderson, 1993).
1.5.3 Tachyphylaxis/Tolerance
Tachyphylaxis is defined as ‘the reduced responsiveness of a tissue to an agonist on
continued or repeated exposure to an agonist’ (Hanania et al., 2002). Tolerance is
often used synonymously with tachyphylaxis, though tolerance may be considered to
develop over a longer time period than tachyphylaxis (Rang, 2003).
Tolerance to both the pulmonary and systemic effects of beta-agonists may occur,
and drugs with higher intrinsic activity may produce greater tolerance than those
with lower intrinsic activity (Hanania et al., 2002). This may occur via a number of
mechanisms, including down-regulation of receptor function or a change in receptor
activation of second messenger systems (Rang, 2003).
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1.5.4 Comparative pharmacology of beta-agonists
The key comparative pharmacological properties are summarised in Table 1.1
(Baker, 2010; Hanania et al., 2002; Naline et al., 1994; Decker et al., 1982;
O'Donnell, 1972).
Formoterol has greater intrinsic activity than salbutamol, and is also more beta-2
selective. Thus, it may produce greater maximal therapeutic effect in the setting of
beta-agonist overuse.
These pharmacological properties will be further discussed when the safety of beta-
agonists are reviewed later.
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Table 1.1: Comparative pharmacology of beta-2 adrenoceptor agonists -
efficacy
Beta-agonist Intrinsic activity
at the beta-2
adrenoceptor *
(%)
Selectivity † In vitro onset
of action
(min) ‡
In vitro
duration of
action
(min) §
Isoprenaline 100.0 0.9 0.65 4.22
Fenoterol ۅ 42.0 26 3.52 7.21
Formoterol 20.0 204 2.14 33.9
Salbutamol ۅ 4.9 42 1.90 7.59
Salmeterol <2.0 - 6.40 102.2
*: Higher values are interpreted as greater ability for receptor activation and maximal effect.
†: Relative potency in trachea compared to atria of guinea-pig [this is a measure of the ratio
of pulmonary to cardiac adrenoceptor action; higher values suggests greater relative beta-2
selectivity]. Comparative values for salmeterol from similar experiments in human tissue
suggest that it has greater selectivity than formoterol. ‡: Time to attainment of 50% maximal
relaxation in human bronchus. §: Time from washing the preparation to attainment of 50%
UHFRYHU\RIEDVDOWRQHLQKXPDQEURQFKXVۅ6HOHFWLYLW\GDWDIURP2
'RQQHOO
[Summarised and adapted from Baker (2010); Hanania et al. (2002); Naline et al. (1994);
Decker et al. (1982); O'Donnell (1972)].
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1.6 Inhaled salbutamol
1.6.1 Pharmacology
Salbutamol is a short-acting, selective, partial beta-2 agonist with a dose-response
bronchodilatory effect (Price and Clissold, 1989). Maximal bronchodilation occurs
within 15 to 30 minutes, and the duration of effect is approximately four to six hours
(Price and Clissold, 1989). After systemic absorption, salbutamol is metabolised into
inactive compounds in the liver, with an elimination half-life of approximately four
hours (Price and Clissold, 1989).
1.6.2 Therapeutic efficacy
Salbutamol is the established treatment for relief of bronchoconstriction during
worsening asthma and acute severe asthma (Lemanske and Busse, 2003).
1.6.3 Adverse effects
Short-term adverse effects include tachycardia, palpitations, tremor and muscle
cramps (GlaxoSmithKline Limited, 2011; Price and Clissold, 1989). These effects
are generally self-limiting.
A prior study suggested that regular treatment with salbutamol may produce
tolerance to its bronchoprotective effects (Cockcroft et al., 1993). However,
subsequent clinical trials did not demonstrate a worsening in clinical control with
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regular salbutamol compared to as-required use (Dennis et al., 2000; Drazen et al.,
1996; Chapman, Kesten and Szalai, 1994). Current asthma guidelines recommend
that salbutamol is used ‘as-required’ for the relief of asthma symptoms and that
increasing use is a marker of poor asthma control (SIGN/BTS, 2012; GINA, 2011).
1.7 Pharmacology of inhaled formoterol
Formoterol is a long-acting, selective, beta-2 adrenoceptor agonist with high intrinsic
activity (Faulds, Hollingshead and Goa, 1991). It produces dose-dependent
bronchodilation, with a rapid onset of action of two to three minutes (Faulds et al.,
1991). Maximum bronchodilation occurs after two to four hours, with effects
persisting for at least 12 hours (Lindmark, 2008; Faulds et al., 1991). Elimination
half-life is approximately two hours (Faulds et al., 1991).
1.8 Therapeutic efficacy of formoterol
The efficacy of formoterol has been studied after short-term dosing, twice-daily
longer term dosing and with ‘as-needed’ reliever use. These will be considered in
turn below.
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1.8.1 Short-term dosing
Initial studies demonstrated a rapid increase in Forced Expiratory Volume in 1
second (FEV1) and a fall in specific airways resistance following dosing with
formoterol and established a dose-response effect on bronchodilation (Derom and
Pauwels, 1992; Lofdahl and Svedmyr, 1989).
The maximal increase in FEV1 over four hours is greater after dosing with 12
actuations (72µg) of formoterol compared with 18 actuations (1800µg) (Rosenborg
et al., 2002) or 24 actuations (2400µg) (Boonsawat et al., 2003) of salbutamol.
1.8.2 Speed of onset
Formoterol has a rapid onset of action, with up to 90% of its maximal
bronchodilation occurring within the first 10 minutes after inhalation (Tattersfield,
1993; Derom and Pauwels, 1992; Becker and Simons, 1989). When compared to
100µg and 200µg of salbutamol, dosing with formoterol 6µg and 12µg respectively
results in comparable increases in FEV1 at three minutes (Seberova and Andersson,
2000). Formoterol reverses bronchoconstriction induced by methacholine within
eight minutes, which is comparable to the effect of salbutamol (Politiek, Boorsma
and Aalbers, 1999) and provides symptomatic relief from dyspnoea within one
minute after inhalation (van der Woude, 2002).
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1.8.3 Duration of action
The duration of bronchodilation is greater after dosing with 12 to 24µg of formoterol
compared to dosing with 200µg salbutamol, and lasts for at least 12 hours (Derom
and Pauwels, 1992; Maesen et al., 1992; Sykes and Ayres, 1990).
Formoterol provides prolonged protection against methacholine-induced
bronchoconstriction for between 12 to 24 hours (Rabe et al., 1993; Ramsdale et al.,
1991). Peak bronchodilation occurs between three and five hours (Rosenborg et al.,
2002; Ringdal et al., 1998; Palmqvist et al., 1997; Sykes and Ayres, 1990).
1.8.4 Protection against bronchoconstrictor stimuli
Formoterol protects against the bronchoconstriction stimulus produced by histamine
(Sovijarvi et al., 1992), adenosine 5’-monophosphate (AMP) (Ketchell et al., 2002;
Nightingale, Rogers and Barnes, 1999), exercise (McAlpine and Thomson, 1990)
and hyperventilation (Malo et al., 1990). The protection against the late asthmatic
reaction to inhaled allergen is greater with formoterol than with salbutamol
(Palmqvist et al., 1992).
1.8.5 Longer-term dosing
Regular formoterol provides significantly greater protection against methacholine-
induced bronchoconstriction than on-demand salbutamol over a 24-week period and
was significantly superior with regards FEV1, peak expiratory flow rate (PEFR),
symptom scores and rescue medication use (FitzGerald et al., 1999).
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Regular formoterol improves symptoms, lung function and rescue medication use
when compared with placebo, regular terbutaline or regular salbutamol (Ekstrom et
al., 1998; Schreurs et al., 1996; Steffensen et al., 1995; Kesten et al., 1991).
1.8.6 Addition of formoterol to inhaled corticosteroids for maintenance therapy
A series of studies demonstrated the efficacy of formoterol when added to ICS
therapy (Gibson, Powell and Ducharme, 2007). Firstly, the addition of formoterol to
ICS significantly improved asthma symptoms and lung function compared to the
addition of placebo to ICS (van der Molen et al., 1997).
The Formoterol And Corticosteroid Establishing Therapy (FACET) investigators
(Pauwels et al., 1997) demonstrated the efficacy of formoterol as an add-on
maintenance therapy in patients with stable asthma. In this trial, the effects of adding
formoterol (12µg twice daily) to both lower (100µg twice daily) and higher (400µg
twice daily) doses of budesonide were studied. The addition of formoterol to either
low- or high-dose budesonide significantly reduced severe exacerbations compared
to low- or high-dose budesonide alone respectively. Low-dose budesonide and
formoterol in combination was also superior to higher dose budesonide in improving
asthma symptoms.
There were other important findings from this study. Increasing the budesonide dose
four-fold had a significantly greater impact on reducing asthma exacerbations than
the addition of formoterol to low-dose budesonide, suggesting that high doses of
inhaled corticosteroids may have greater efficacy in the reduction of severe
exacerbations.
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Of the patients in the two formoterol-treated groups, those treated with high-dose
budesonide plus formoterol (receiving 400µg budesonide/12µg formoterol twice
daily) experienced significantly fewer severe exacerbations than patients in the lower
dose budesonide plus formoterol group (receiving 100µg budesonide/12µg
formoterol twice daily), supporting the use of the higher-dose combination treatment
in patients with greater asthma severity.
The subsequent analysis by Tattersfield et al. (1999) described the change in
symptoms, PEFR and reliever medication use around the time of severe asthma
exacerbations. This graphical description of the time course of severe exacerbations
(Tattersfield et al., 1999) is important when considering the potential mechanisms of
the efficacy benefits seen with the SMART regimen, and is discussed further later.
Finally, the results from Group B in the OPTIMA study provided evidence for the
benefits of formoterol in addition to ICS in patients with mild but symptomatic
asthma (O'Byrne et al., 2001). Addition of formoterol to ICS reduced asthma
exacerbations and improved asthma control and lung function to a greater extent than
doubling the dose of ICS.
1.8.7 As-needed formoterol use as a reliever
Short-term studies demonstrated that formoterol had comparable efficacy to
salbutamol when used as a reliever treatment in stable (Wallin et al., 1990) and acute
asthma (Boonsawat et al., 2003).
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A large-scale double-blind RCT investigated the use of formoterol as a reliever
compared to terbutaline (Tattersfield et al., 2001). This trial, extending the findings
of the FACET study, compared 6µg of formoterol and 500µg of terbutaline when
used for relief of symptoms in patients on ICS who were symptomatic during run-in.
The most symptomatic patients (those using greater than 12 inhalations per day of
rescue medication during run-in) were excluded from study entry.
The time to first exacerbation was significantly prolonged in the formoterol group,
and there was a significant 45% reduction in severe asthma exacerbations. Patients
in the formoterol group had a significant reduction in reliever use during the study
period and significant increases in PEFR and pre-bronchodilator FEV1. Study
withdrawals and the occurrence and patterns of adverse events (AE) and serious
adverse events (SAE) were similar between the groups. Both groups used on
average 1.32 inhalations of study drug per occasion to relieve symptoms, suggesting
that patients in both groups perceived similar levels of symptomatic improvement
with their reliever therapy.
Two important issues require consideration regarding this study. Firstly, patients
who used greater than 12 inhalations per day or those who had a second severe
exacerbation during the study were withdrawn, limiting the generalisability of the
findings to asthma patients with high beta-agonist use, or patients who have more
severe asthma. Secondly, patients in this study were not receiving maintenance
LABA therapy.
20
This second issue was addressed by the subsequent RELIEF study (Pauwels et al.,
2003b), in which the effects of formoterol as a reliever were investigated in asthma
patients who were permitted maintenance LABA therapy.
The RELIEF investigators (Pauwels et al., 2003b) compared as-needed 6µg
formoterol with 200µg salbutamol over a six-month study period in patients with
asthma. 76% of patients were on maintenance ICS therapy and 31% on LABAs at
study entry. The time to first asthma exacerbation was significantly prolonged in the
formoterol group, with a significant 13% reduction in the risk of an exacerbation
requiring oral corticosteroids. There were significantly fewer days with asthma
symptoms in the formoterol group.
These studies established the efficacy of the symptom-driven use of formoterol as a
reliever medication. This concept was developed in studies investigating the as-
required, symptom-driven use of ICS and SABA therapy and ICS and LABA therapy
in mild asthma.
1.9 Use of as-needed ICS+SABA therapy in mild asthma
Three trials, two in adults (Calhoun et al., 2012; Papi et al., 2007) and one in
children (Martinez et al., 2011), have compared the efficacy of as-needed
ICS+SABA therapy with regular ICS therapy (with SABA as-needed) in mild
asthma. The adult trials will be discussed further.
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The first trial was a study of mild adult asthma patients, two thirds of whom were not
on regular ICS (Papi et al., 2007). Patients were well-controlled during run-in and
randomised to as-needed combination ICS/SABA (beclomethasone/salbutamol), as-
needed SABA (salbutamol), regular ICS (with salbutamol as-needed), or regular
ICS/SABA (with salbutamol as-needed). Patients were not provided with written
asthma self-management plans and were instructed to use their reliever treatments as
guided by their symptoms.
The risk of an asthma exacerbation was not significantly different between the as-
needed combination group and regular ICS group. Symptom-free days were not
significantly different between the as-needed combination group and both the regular
ICS and regular combination therapy groups. However, cumulative ICS dose was
significantly lower in the as-needed combination group compared to both the regular
therapy groups.
This study demonstrated that the symptom-driven use of combination ICS/SABA
therapy was comparable to regular ICS therapy in providing protection against
asthma exacerbations. This finding indicates that exposure to ICS at the time of
worsening asthma may be a potential advantage of the as-needed combination
therapy approach.
In a subsequent study of asthma patients who were controlled on low-dose ICS, a
symptom-driven strategy of as-required ICS+SABA was compared to guideline-
based titration of ICS therapy (Calhoun et al., 2012). This trial also included a third
comparator group, where maintenance ICS therapy was adjusted based on exhaled
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nitric oxide (FeNO). Patients were provided multiple blinded inhalers, and those in
the symptom-driven group were asked to take two actuations of ICS every time they
used two actuations of salbutamol for relief of symptoms.
Both the time to treatment failure and asthma exacerbation rates were not
significantly different between all three groups. Asthma symptoms were also not
significantly different between groups. Patients randomised to the symptom-driven
group had significantly lower average monthly ICS doses compared to both other
groups. These findings indicate that symptom-driven ICS+SABA therapy may be
considered as an alternative treatment approach to conventional maintenance asthma
therapy.
Two issues regarding the generalisability of the findings from this trial (Calhoun et
al., 2012) require consideration. Firstly, median adherence to treatment in the trial
was over 95%, which may be greater than that which occurs in the clinical setting
(Haynes et al., 2008). Additionally, as the ICS and SABA treatments in the
symptom-driven group were provided in separate inhalers, the benefits of this
approach may have been underestimated, compared to patients in whom symptom-
driven treatment can be provided in a single combination inhaler, whereby a dose of
ICS is delivered whenever the inhaler is used for relief of symptoms.
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1.10 Use of as-needed ICS/LABA therapy in mild asthma
The SOMA trial compared treatment with as-needed budesonide/formoterol with as-
needed formoterol in mild asthma patients (Haahtela et al., 2006). FeNO was
significantly reduced in the as-needed combination inhaler group. This study was
not powered to assess impact on asthma exacerbations, and further interpretation is
limited by the lack of a comparator group treated with regular ICS.
1.11 Rationale for combination ICS/LABA inhaler therapy
The preferred method to deliver ICS and LABA therapy is via a combination
ICS/LABA inhaler (SIGN/BTS, 2012). Treatment with combination inhaler therapy
is likely to be beneficial from two perspectives. It may encourage improved
adherence with ICS (Marceau et al., 2006; Stoloff et al., 2004) and protect against
LABA monotherapy (Morales et al., 2012; Barnes, 2002). Adherence to asthma
therapy will be considered further.
1.11.1 Adherence to inhaled asthma therapy
The term ‘adherence’ refers to ‘the extent to which the patient’s behaviour matches
agreed recommendations from the prescriber’ (Horne, 2006). This term implies
shared decision-making and suggests a partnership between the patient and health-
care provider in reaching an agreed treatment plan. Poor adherence to maintenance
inhaled therapy can be defined using specific cut-offs; for example, less than 60% or
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80% of prescribed doses taken. However, given that overuse of maintenance therapy
or overuse of reliever therapy may also represent poor adherence, adherence is more
accurately described as a spectrum of use and with differing patterns of treatment
use, which may vary over time (Foster, Lavoie and Boulet, 2011).
Poor adherence to ICS therapy is common amongst asthma patients (Williams et al.,
2007; Bender, Pedan and Varasteh, 2006) and is a key factor associated with poor
outcomes. Prior studies have demonstrated that poor adherence to ICS is associated
with lower lung function as asthma severity increases (Kandane-Rathnayake et al.,
2009), increased risk of Emergency Department (ED) visits for severe exacerbations
(Williams et al., 2004) and fatal outcome (Suissa et al., 2000). The impact of poor
adherence is particularly relevant in difficult-to-treat and severe asthma (Heaney and
Horne, 2012).
Various strategies to improve adherence have been suggested (Haynes et al., 2008).
Non-pharmacological methods include improved patient education, use of asthma
self-management skills, closer follow-up and medication reminders (Boulet et al.,
2012; Foster, Lavoie and Boulet, 2011). Pharmacological strategies include
simplification of treatment regimens (for example, by reducing the number of
inhalers) and the use of combination ICS/LABA therapy as a method to increase
exposure to ICS (Boulet et al., 2012; Murphy et al., 2012; Stempel et al., 2005).
1.11.2 Asthma self-management plans
Written asthma self-management plans are a key component of the non-
pharmacological management of asthma and their use is advocated in global asthma
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guidelines (SIGN/BTS, 2012; GINA, 2011). Asthma self-management plans
generally share some common features: they provide information on maintenance
therapy during periods of good control; there is guidance on symptoms which signify
worsening asthma and specific instructions as to how to adjust medication use in this
setting; and information on when to seek urgent medical help (FitzGerald and
Gibson, 2006; Holt et al., 2005). Peak-flow and symptom-based plans are
equivalent in their effect (Gibson and Powell, 2004; Powell and Gibson, 2003).
The use of an asthma self-management plan with regular patient review is associated
with an improvement in health outcomes for patients (Gibson et al., 2003). This is
likely to be due to a combination of factors: increased adherence to maintenance
therapy, improved recognition of deteriorating symptoms and earlier treatment with
systemic corticosteroids in the setting of acute exacerbations (Beasley, Cushley and
Holgate, 1989).
The provision of written asthma self-management plans, with access to both peak-
flow and symptom-based versions, therefore represents conventional clinical practice
and may be considered an important feature of a real-world study. Given that peak-
flow and symptom-based plans provide similar benefits, patients could be supported
in continuing with their pre-study self-management strategy. In addition, use of
asthma self-management education incorporating inhaler technique training would
also reflect optimal clinical practice.
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1.11.3 Therapeutic options with inhaled combination budesonide/formoterol
Combination budesonide/formoterol therapy has been studied with three patterns of
use: fixed maintenance dosing with SABA as a reliever; adjustable maintenance
dosing (AMD) with SABA as a reliever; and as maintenance and reliever therapy
(SMART). These will be considered in turn.
1.12 Fixed maintenance budesonide/formoterol dosing with SABA for relief
Combination budesonide/formoterol treatment reduces exacerbation rates and
improves PEFR, FEV1 and asthma control compared with ICS alone (Noonan et al.,
2006; Bateman et al., 2003; Buhl et al., 2003; Lalloo et al., 2003; Tal et al., 2002).
The combination of budesonide/formoterol is also effective in improving PEFR and
asthma symptoms when compared with budesonide plus formoterol delivered via
separate inhalers (Noonan et al., 2006; Zetterstrom et al., 2001), and provides
sustained bronchodilation for at least 24 hours when administered on a single
occasion (Masoli et al., 2006). Fixed-dose budesonide/formoterol MDI is
comparable to fixed-dose fluticasone/salmeterol in protecting against asthma
exacerbations and improving asthma symptoms and lung function (Busse et al.,
2008).
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1.13 Adjustable maintenance dosing with SABA for relief
1.13.1 Increasing the dose of ICS during worsening asthma
There is conflicting evidence as to the beneficial effect of temporarily increasing the
dose of ICS during an exacerbation (FitzGerald et al., 2004; Foresi, Morelli and
Catena, 2000). Although doubling the dose of ICS in worsening asthma does not
appear to reduce asthma exacerbations (Harrison et al., 2004), there is evidence to
suggest that quadrupling the dose may be effective in preventing exacerbations
(Oborne et al., 2009; Foresi et al., 2000). In addition, increasing the frequency of
ICS dosing from two to four times a day, whilst maintaining the same total daily
dose, is beneficial in unstable asthma (Toogood et al., 1982).
Furthermore, treatment with high-dose ICS (for example, 400µg every 30 minutes
for two hours) is effective in improving PEFR and FEV1 in acute asthma compared
to systemic corticosteroids (Rodrigo, 2005; Rodrigo and Rodrigo, 1998). Thus, an
increase in ICS dosing frequency combined with an asthma self-management plan
may have a role in improving outcomes in worsening asthma.
This concept can be incorporated into an adjustable maintenance dosing plan that
allows the patient to alter their ICS/LABA therapy based on their symptoms or
PEFR. Thus, patients may use low medication doses (e.g. one inhalation twice daily)
during periods of well-controlled asthma and increase their maintenance therapy in
response to worsening symptoms (e.g. to four inhalations twice daily). Relief of
symptoms is still provided by use of a SABA.
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1.13.2 Budesonide/formoterol AMD plans
Studies comparing budesonide/formoterol prescribed as AMD or as fixed-dose
therapy have demonstrated that AMD may reduce asthma exacerbations and improve
asthma control, at lower overall medication doses (Aalbers et al., 2004; Ind et al.,
2004; FitzGerald et al., 2003).
1.14 Primary SMART studies
The primary SMART studies refer to the seven large-scale studies which compared
the budesonide/formoterol SMART regimen with the following treatments: double
fixed-dose budesonide (Rabe et al., 2006b; Scicchitano et al., 2004) and quadruple
fixed-dose budesonide (O'Byrne et al., 2005) for maintenance therapy, with
terbutaline for relief; same fixed-dose budesonide/formoterol with terbutaline (Rabe
et al., 2006a; O'Byrne et al., 2005) or formoterol (Rabe et al., 2006a) for relief;
higher fixed-dose budesonide/formoterol with terbutaline for relief (Kuna et al.,
2007); and fixed-dose fluticasone/salmeterol with terbutaline (Bousquet et al., 2007;
Kuna et al., 2007) or salbutamol (Vogelmeier et al., 2005) for relief.
These studies are discussed in terms of their efficacy outcomes related to asthma
exacerbations. The effect of the SMART regimen on asthma symptoms, lung
function and reliever medication use are also summarised. The key features and
outcomes from these studies are shown in Tables 1.2, 1.3, 1.4 and 1.5.
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Table 1.2: Efficacy of the SMART regimen on asthma exacerbations (A)
Study Maintenance
treatment
(µg) *
PRN reliever Number
of
patients
Mean daily
budesonide
dose (µg) †
Time to first SE
(SMART v
comparators)
Severe exacerbations
Scicchitano 2004
(STEP)
B/F (2 x 200/6
od)
B/F (200/6) 947 583 Prolonged
(p<0.001)
170 (18%) ‡
[HR (95% CI) 0.61 (0.50 to 0.74), p<0.001]
B (400 bd) Terbutaline 943 800 259 (27%) ‡
O’Byrne 2005
(STAY)
B/F (100/6 bd) B/F (100/6) 925 300 Prolonged v both
other groups
(p<0.001)
0.36 §
[HR (95% CI) 0.53 (0.44 to 0.65), p<0.001
v B/F+T)
B/F (100/6 bd) Terbutaline 909 200 0.68 §
B (400 bd) Terbutaline 926 800 0.68 §
Rabe 2006b
(STEAM)
B/F (2 x 100/6
od)
B/F (100/6) 355 300 Not stated 0.08 §
(p<0.001)
B (400 od) Terbutaline 342 400 0.35 §
Rabe 2006a
(SMILE)
B/F (200/6 bd) B/F (200/6) 1113 604 Prolonged v both
groups
(p=0.0048 v F
and p<0.0001 v T)
0.19 §
[HR (95% CI) 0.52 (0.44 to 0.63),
p<0.0001 v B/F+T]
B/F (200/6 bd) F (6) 1140 400 0.29 §
B/F (200/6 bd) Terbutaline 1141 400 0.37 §
*: metered dose at randomisation; †: metered dose used during study period; ‡: number of participants (% of group) with event; §: events/patient/year;
v: versus; HR: hazard ratio; B: budesonide; F: formoterol; T: terbutaline; od: once daily; bd: twice daily; SE: severe exacerbation; PRN: ‘as-required’.
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Table 1.3: Efficacy of the SMART regimen on asthma exacerbations (B)
Study Maintenance
treatment (µg) *
PRN reliever Number
of
patients
Mean daily
budesonide
dose (µg) †
Time to first SE
(SMART v
comparators)
Severe exacerbations
Vogelmeier 2005
(COSMOS)
B/F (2 x 200/6 bd)
‡
B/F (200/6) 1067 816 Prolonged
(p=0.0051)
0.24 §
(p=0.0025)
FL/SM (250/50
bd) ‡
Salbutamol  ۅ 
Kuna 2007
(COMPASS)
B/F (200/6 bd) B/F (200/6) 1107 604 Prolonged v both
groups (p=0.023 v
B/F+T and p=0.0034
v FL/SM+T)
0.24 §
(p=0.0048 v B/F+T and p<0.001 v
FL/SM+T)
B/F (400/12 bd) Terbutaline 1105 800 0.32 §
FL/SM (2 x
125/25 bd)
7HUEXWDOLQH  ۅ 
Bousquet 2007
(AHEAD)
B/F (2 x 200/6 bd) B/F (200/6) 1154 990 HR 0.82, p=0.12 0.25 §
(p=0.039)
FL/SM (500/50
bd)
7HUEXWDOLQH  ۅ 
*: metered dose at randomisation; †: metered dose used during study period; ‡:PDLQWHQDQFHGRVHWLWUDWLRQDOORZHGHYHQWVSDWLHQW\HDUۅGDLO\IOXWLFDVRQH
dose; v: versus; HR : hazard ratio; B: budesonide; F: formoterol; FL: fluticasone; SM: salmeterol; od: once daily; bd: twice daily; PRN: ‘as-required’.
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Table 1.4: Efficacy of the SMART regimen on asthma control, reliever use and lung function (A)
Study Maintenance
treatment
(µg)*
PRN
reliever
Asthma control (%
days)
Mean reliever use
(inhs/day)
Mean treatment
morning PEFR
(L/min)
Mean treatment
FEV1 (L)
Scicchitano 2004
(STEP)
B/F (2 x 200/6
od)
B/F (200/6) 38.3
(p<0.001)
0.90
(p<0.001)
372
(p<0.001)
2.54
(p<0.001)
B (400 bd) Terbutaline 29.3 1.42 348 2.45
O’Byrne 2005
(STAY)
B/F (100/6 bd) B/F (100/6) 45
(NS v B/F+T;
p<0.001 v B+T)
0.73
(p<0.001 v both grps)
355
(p<0.001 v both
grps)
2.51
(p<0.001 v B/F+T)
B/F (100/6 bd) Terbutaline 44 0.84 346 2.43
B (400 bd) Terbutaline 37 1.03 339 2.41
Rabe 2006b
(STEAM)
B/F (2 x 100/6
od)
B/F (100/6) 47.4
(p=0.0012)
1.04
(p<0.001)
379
(p<0.001)
0.210 †
(p<0.001)
B (400 od) Terbutaline 38.8 1.48 345 0.062 †
Rabe 2006a
(SMILE)
B/F (200/6 bd) B/F (200/6) -0.63 ‡
(p<0.0001 v B/F+T;
p=0.0009 v B/F+F)
-0.84 †
(p<0.0001 v both
grps)
15.3 †
(p<0.0001 v B/F+T;
p=0.004 v B/F+F)
0.06 †
(p<0.0001 v B/F+T;
p=0.00014 v B/F+F)
B/F (200/6 bd) F (6) -0.53 ‡ -0.67 † 10.6 † 0.01 †
B/F (200/6 bd) Terbutaline -0.49 ‡ -0.64 † 7.9 † -0.02 †
*: metered dose at randomisation; †: treatment change from run-in; ‡: mean change in ACQ-5 score from baseline; inhs: inhalations; v: versus; NS = not
statistically significant; B: budesonide; F: formoterol; T: terbutaline; od: once daily; bd: twice daily; PEFR: peak expiratory flow rate; L: litre; grps: groups;
PRN: ‘as-required’.
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Table 1.5: Efficacy of the SMART regimen on asthma control, reliever use and lung function (B)
Study Maintenance
treatment (µg)*
PRN
reliever
Asthma control
(% days)
Mean reliever
use (inhs/day)
Mean treatment
morning PEFR
(L/min)
Mean treatment
FEV1 (L)
Vogelmeier 2005
(COSMOS)
B/F
(2 x 200/6 bd) §
B/F (200/6) -0.64 ‡
(p=0.069)
0.58
(p<0.001)
1RWUHSRUWHG ۅ
(p=0.066)
FL/SM
(250/50 bd) §
6DOEXWDPRO Á  1RWUHSRUWHG ۅ
Kuna 2007
(COMPASS)
B/F
(200/6 bd)
B/F (200/6) -0.85 ‡
(NS v both grps)
1.02
(NS v both grps)
363
(NS v both grps)
2.69
(NS v both grps)
B/F (400/12 bd) Terbutaline -0.86 ‡ 1.05 362 2.66
FL/SM
(2 x 125/25 bd)
Terbutaline -0.90 ‡ 0.96 367 2.67
Bousquet 2007
(AHEAD)
B/F
(2 x 200/6 bd)
B/F (200/6) -0.76 ‡
(p=0.59)
0.95
(p=0.36)
359
(p=0.67)
2.52
(NS)
FL/SM (500/50
bd)
Terbutaline -0.77 ‡ 1.01 359 2.49
*: metered dose at randomisation; †: treatment change from run-in; ‡: mean change in ACQ-5 score from baseline; §: maintenance dose titration allowed;
ۅ3UHEURQFKRGLODWRU16 QRWVWDWLVWLFDOO\VLJQLILFDQWLQKVLQKDODWLRQVv: versus; B: Budesonide; F: Formoterol; T: Terbutaline; FL: Fluticasone; SM:
Salmeterol; od: once daily; bd: twice daily; PEFR: peak expiratory flow rate; L: litre; grps: groups; PRN: ‘as-required’.
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1.14.1 SMART versus higher fixed-dose budesonide with terbutaline for relief
In a double-blind trial, patients were randomised to two actuations per day of
200/6µg budesonide/formoterol as maintenance (400/12µg per day total) with extra
doses for relief (the SMART group) or 800µg per day of budesonide with terbutaline
for relief (Scicchitano et al., 2004). This study recruited symptomatic patients with
asthma with a recent exacerbation and used diary cards to record medication use.
Patients were required to demonstrate bronchodilator reversibility to terbutaline at
baseline. Patients with high reliever medication use (greater than 10 reliever
actuations per day) and those with frequent asthma exacerbations (three or more
courses of systemic corticosteroids in the prior six months) were excluded from
study entry. Average baseline ICS dose was approximately 750µg per day.
Time to first severe exacerbation was significantly prolonged in the SMART group
and there was a significant 39% reduction in the risk of a severe exacerbation with
the SMART regimen (Table 1.2). There were a significantly greater proportion of
asthma control days in patients on the SMART regimen (Table 1.4). Reliever
overuse (defined as greater than 10 budesonide/formoterol inhalations per day)
occurred in 2% of patients in the SMART group.
In another double-blind study, patients were randomised to one of three treatment
groups: two actuations per day of 100/6µg budesonide/formoterol as maintenance
(200/12µg per day total) with extra doses for relief (the SMART group); 800µg per
day of budesonide with terbutaline for relief (fourfold higher budesonide group); or
two actuations per day of 100/6µg budesonide/formoterol as maintenance (200/12µg
per day total) with terbutaline for relief (fixed-dose group) (O'Byrne et al., 2005).
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Eligible patients had a history of one or more asthma exacerbations in the preceding
year and were symptomatic during run-in. Patients were required to demonstrate
bronchodilator reversibility. Patients with high baseline reliever use, defined as 10
or more reliever inhalations in a day, were excluded. Average baseline ICS dose was
approximately 620µg per day in the SMART and budesonide groups and 28% of the
patients were on LABAs at baseline. Medication use was self-reported in diary
cards.
Comparing SMART with four-fold higher budesonide treatment, the time to first
severe exacerbation was significantly prolonged by treatment with the SMART
regimen (Table 1.2). There was a significant 47% reduction in severe asthma
exacerbations in the SMART group compared to the budesonide group. There were
a significantly greater proportion of asthma control days in the SMART group (Table
1.4).
Rabe et al. (2006b) randomised patients to two actuations per day of 100/6µg
budesonide/formoterol as maintenance (200/12µg per day total) with extra doses for
relief (the SMART group) or 400µg of budesonide per day with terbutaline for relief.
This study required patients to demonstrate bronchodilator reversibility or peak flow
variability at baseline and used diary cards to record medication use. Patients were
symptomatic during run-in but did not have high baseline reliever use, defined as 10
or more inhalations per day. Average baseline ICS dose was approximately 430µg
per day. 10% of patients randomised to the budesonide group were treated with
LABAs prior to study entry.
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Treatment with the SMART regimen reduced severe exacerbations requiring medical
intervention by 76% (Table 1.2). There were a significantly greater proportion of
asthma control days in the SMART group (Table 1.4). Reliever overuse, defined as
greater than 10 as-needed budesonide/formoterol inhalations per day, occurred in 3%
of patients in the SMART group.
Considered together, these studies demonstrated the superiority of the SMART
regimen compared to higher fixed-dose budesonide therapy in reducing asthma
exacerbations and improving asthma control. Studies in which the comparator
groups were also treated with maintenance LABA therapy are now considered.
1.14.2 SMART versus same fixed-dose budesonide/formoterol with terbutaline or
formoterol for relief
As discussed in the previous section, the study by O’Byrne et al. (2005) also
compared SMART therapy with the same fixed-dose of budesonide/formoterol for
maintenance with terbutaline for relief. Patients in the fixed-dose group were treated
with 200/12µg of budesonide/formoterol per day. The baseline daily ICS dose in the
fixed-dose group was approximately 600µg and 29% of the group used LABAs prior
to study entry.
Treatment with the SMART regimen significantly prolonged the time to the first
severe exacerbation and reduced severe exacerbations by 47% compared to fixed-
dose therapy (Table 1.2). Treatment with the SMART regimen also significantly
prolonged the time to second and third severe exacerbations compared to fixed-dose
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therapy. There was no significant difference between groups in the proportion of
asthma control days (Table 1.4). FEV1 was significantly higher in the SMART
group (Table 1.4). As the minimal clinically important difference for FEV1 may be
between 100 to 200ml (Tepper et al., 2012), the absolute difference of 80ml between
groups can be considered of borderline clinical significance. There were fewer days
of high reliever use, defined as greater than eight reliever inhalations per day, in the
SMART group (26 episodes in 925 participants in the SMART group versus 142
episodes in 909 participants in the fixed-dose group). Mean budesonide exposure
was approximately 100µg per day higher in the SMART group.
This study suggested that treatment with the SMART regimen was superior to the
same fixed-dose budesonide/formoterol treatment (with SABA for relief) in reducing
asthma exacerbations and that SMART may be of particular benefit in patients with
repeated exacerbations.
In another double-blind trial, patients were randomised to one of three treatment
regimens: two actuations per day of 200/6µg budesonide/formoterol as maintenance
(400/12µg per day total) with extra doses for relief (the SMART group); two
actuations per day of 200/6µg budesonide/formoterol as maintenance (400/12µg per
day total) with terbutaline for relief (terbutaline as-needed group); or two actuations
per day of 200/6µg budesonide/formoterol as maintenance (400/12µg per day total)
with 6µg formoterol for relief (formoterol as-needed group) (Rabe et al., 2006a).
Patients were required to demonstrate bronchodilator reversibility at baseline and had
suffered at least one severe asthma exacerbation in the preceding year. As
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previously, patients were symptomatic during run-in but were excluded if they used
more than 10 reliever inhalations in a day. The patients in this study had poorly-
controlled asthma at baseline, as measured by an Asthma Control Questionnaire
(ACQ)-5 score of 1.9 at baseline. Baseline ICS dose was approximately 760µg per
day across the three groups and 60% of patients were on LABAs pre-study.
Medication use was measured by diary cards.
Treatment with the SMART regimen significantly prolonged the time to first severe
exacerbation compared to both the formoterol and terbutaline as-needed groups
(Table 1.2). Severe exacerbations were significantly reduced by 33% with SMART
compared to formoterol as-needed and by 48% compared with terbutaline as-needed.
Severe exacerbations requiring an ED visit or hospital admission were also
significantly reduced by 27% with the SMART regimen compared with formoterol
as-needed and by 39% compared with terbutaline as-needed.
ACQ-5 scores were significantly lower in the SMART group compared to both the
other treatment groups (Table 1.4), reflecting a greater improvement in asthma
control. FEV1 was significantly higher in the SMART group compared to both the
other treatment groups (Table 1.4), though the difference between the SMART and
comparator groups, of approximately 50ml to 80ml, may not be of clinical
significance (Tepper et al., 2012). High reliever medication use was reduced in the
SMART group, with 70/1107 (6.3%) and 130/1138 (11.4%) of patients in the
SMART and terbutaline as-needed groups respectively using four or more reliever
inhalations on more than 100 study days. In a sub-group analysis of this study, the
risk of high reliever use (defined as greater than six inhalations per day) was
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significantly reduced by 49% with SMART compared to terbutaline as-needed (Buhl
et al., 2012). Mean budesonide dose was approximately 200µg per day higher in the
SMART group.
This trial also provided data regarding the efficacy of formoterol as a reliever
treatment compared to terbutaline as a reliever, in patients on maintenance
budesonide/formoterol therapy. In keeping with prior studies (Pauwels et al., 2003b;
Tattersfield et al., 2001), patients randomised to formoterol as-needed had
significantly fewer asthma exacerbations. This finding indicates that the reduction in
severe exacerbations observed with the SMART regimen is partly attributable to the
as-needed formoterol component of the treatment plan and also suggests that there is
an added benefit of the combination of budesonide/formoterol as a reliever, above
that provided by formoterol as a reliever alone.
These two studies (Rabe et al., 2006a; O'Byrne et al., 2005) had several key
limitations which affect their generalisability to clinical practice. Firstly, patients
with high baseline reliever medication use were excluded from study entry.
Secondly, patients were required to demonstrate significant bronchodilator
reversibility. Thirdly, patients were selected on the basis of having asthma
symptoms during run-in and a history of prior asthma exacerbations. However,
patients subsequently randomised to the fixed-dose budesonide/formoterol
comparator groups then had an ICS dose reduction. This led to the criticism that
these patients were symptomatic but not on an appropriate level of maintenance
therapy (Cates and Lasserson, 2009), thereby not reflecting current clinical practice
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guidelines which recommend a treatment intensity appropriate to the level of asthma
control (SIGN/BTS, 2012; GINA, 2011).
Thus, the findings from these two studies (Rabe et al., 2006a; O'Byrne et al., 2005)
have limited generalisability to the ‘real-world’ use of the SMART regimen. These
studies (Rabe et al., 2006a; O'Byrne et al., 2005) also suggest that the reduction in
severe asthma exacerbations with the SMART regimen is at the cost of higher ICS
exposure.
1.14.3 SMART versus higher fixed-dose budesonide/formoterol with terbutaline
for relief
The study by Kuna et al. (2007) was designed to test the hypothesis that the SMART
regimen may be as effective as higher fixed-dose maintenance ICS/LABA therapy.
Patients were randomised to one of three treatment regimens: two actuations per day
of 200/6µg budesonide/formoterol as maintenance (400/12µg per day total) with
extra doses for relief (the SMART group); two actuations per day of 400/12µg
budesonide/formoterol as maintenance (800/24µg per day total) with terbutaline for
relief (higher fixed-dose budesonide/formoterol group); or two actuations per day of
125/25µg fluticasone/salmeterol as maintenance with terbutaline for relief (fixed-
dose fluticasone/salmeterol group).
In keeping with the design of the studies discussed above, patients were required to
demonstrate bronchodilator reversibility at baseline and were excluded if they had
high baseline reliever medication use. Baseline ICS dose was approximately 750µg
per day across the three groups and 50% of patients were on LABAs pre-study.
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In the comparison between SMART and higher fixed-dose budesonide/formoterol,
treatment with the SMART regimen significantly prolonged the time to first severe
exacerbation and significantly reduced severe exacerbations by 28% (Table 1.3).
The improvement in ACQ-5 scores and lung function was not significantly different
between these two groups (Table 1.5).
The reduction in severe asthma exacerbations in the SMART group was achieved
with 25% lower ICS exposure compared to the fixed-dose budesonide/formoterol
group. This finding suggests that self-titrated increasing budesonide/formoterol use
by patients on the SMART regimen in response to worsening symptoms may
contribute to the greater efficacy in reducing asthma exacerbations.
1.14.4 SMART versus fixed-dose salmeterol/fluticasone with terbutaline or
salbutamol for relief
In the study by Kuna et al. (2007) described in the previous section, treatment with
the SMART regimen was also compared with fixed-dose fluticasone/salmeterol with
terbutaline as a reliever.
SMART therapy significantly prolonged the time to the first severe exacerbation
compared to fluticasone/salmeterol (Table 1.3), with a significant 39% reduction in
severe exacerbations. ACQ-5 score and lung function were not significantly
different between these two groups (Table 1.5).
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In the comparison between the fixed-dose budesonide-formoterol group and the
fixed-dose fluticasone/salmeterol group, there was no significant difference in the
time to first severe exacerbation or the rate of severe exacerbations.
The findings from this study (Kuna et al., 2007) suggest that the as-needed use of
budesonide/formoterol with the SMART regimen is an important contributing factor
in reducing severe asthma exacerbations, rather than the actual nature of the
component products within a fixed-dose combination treatment regimen.
In an open-label real-world study, patients were randomised to two actuations twice
daily of 200/6µg of budesonide/formoterol as maintenance (800/24µg per day total)
with extra doses for relief (the SMART group) or two actuations per day of 250/50µg
fluticasone/salmeterol as maintenance with salbutamol for relief (fixed-dose
fluticasone/salmeterol group) (Vogelmeier et al., 2005). Maintenance dose titration
according to asthma control was permitted in both groups. The protocol did not
require reversibility testing for eligibility and patients were also not required to keep
daily diaries in an effort to reflect the real-world situation.
The time to first severe exacerbation was significantly prolonged in patients on the
SMART regimen and there was a significant 22% reduction in severe exacerbations
(Table 1.3). In keeping with prior findings (Kuna et al., 2007), asthma symptoms
and lung function were not significantly different between the two groups (Table
1.5).
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In another study, patients were randomised to two actuations twice daily of 200/6µg
of budesonide/formoterol as maintenance (800/24µg per day total) with extra doses
for relief (the SMART group) or two actuations per day of 500/50µg
fluticasone/salmeterol as maintenance with terbutaline for relief (fixed-dose
fluticasone/salmeterol group) (Bousquet et al., 2007). The comparator group were
therefore on a higher maintenance dose of ICS compared to the two studies discussed
previously (Kuna et al., 2007; Vogelmeier et al., 2005). Patients with high baseline
reliever use were excluded. Daily diaries were used to record medication use.
Time to the first severe exacerbation was not significantly different between the two
groups, although there was a significant 21% reduction in the rate of severe
exacerbations in the SMART group (Table 1.3). ACQ-5 scores and lung function
were not significantly different between the groups (Table 1.5).
This study also analysed the relationship between a day of high reliever use and the
subsequent development of severe asthma exacerbations. Treatment with the
SMART regimen was associated with a significant 41% reduction in the rate of
severe exacerbations occurring in the 28 days after a day of high reliever use, defined
as a day of greater than four reliever inhalations. This suggests that the as-needed
use of budesonide/formoterol in response to worsening symptoms may contribute to
the reduction in severe exacerbations observed with the SMART regimen. However,
the interpretation of these findings is limited by the imprecision of self-report as a
measure of medication use. This issue will be discussed in more detail in later
sections.
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1.15 The budesonide/formoterol SMART regimen and asthma control
1.15.1 Asthma control measurements
One of the criticisms (Chapman et al., 2010) of the SMART clinical trial programme
is that a number of the studies reported differing components of asthma control (e.g.
night-time awakenings, symptom-free days, or reliever-free days) separately (Rabe et
al., 2006b; O'Byrne et al., 2005; Scicchitano et al., 2004), thus limiting
interpretations of the impact of the SMART regimen on asthma control. Four studies
(Bousquet et al., 2007; Kuna et al., 2007; Rabe et al., 2006a; Vogelmeier et al.,
2005) did however use the ACQ-5 as a validated composite score of asthma control.
In order to overcome this criticism, post-hoc analyses have suggested that the
SMART regimen is comparable to conventional treatment regimens in achieving
controlled or partly-controlled asthma, as defined by the Global Initiative for Asthma
(GINA) (Bateman et al., 2010).
1.15.2 Dissociation between asthma control and asthma exacerbations
It is interesting to observe that treatment with the SMART regimen is associated with
a reduction in severe exacerbations, but with lesser impact on improving day-to-day
asthma control compared to fixed-dose budesonide/formoterol with terbutaline for
relief. In order to suggest possible explanations for this observation, it is necessary
to define asthma control and asthma exacerbation.
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Asthma control may be divided into periods of clinical control (‘stable asthma’),
deteriorating control and clinical exacerbation (Reddel et al., 1999; Tattersfield et
al., 1999). During periods of stable asthma, symptoms may be relatively infrequent
and reliever medication use may be stable at a low or minimal level (Reddel et al.,
1999; Cockcroft and Swystun, 1996). During periods of deteriorating control,
symptoms may increase, together with an increase in reliever medication use and
increased PEFR variability (Reddel et al., 1999; Tattersfield et al., 1999). Asthma
exacerbations may be characterised by a peak in asthma symptoms and reliever use,
followed by a gradual improvement (Reddel et al., 1999; Tattersfield et al., 1999).
There may, however, be dissociation in the relationship between asthma control and
asthma exacerbations and in clinical practice, these periods may not be as well
defined as described above.
In support of this concept, in the FACET study (Pauwels et al., 1997), severe
exacerbations were reduced to a greater extent by a fourfold higher ICS dose than by
the addition of a LABA to low-dose ICS. However, episode-free days, which were a
marker of well-controlled asthma, were significantly increased by the addition of
LABA to low-dose ICS, but not by treatment with fourfold higher ICS dose. This
suggests that treatment regimens may have differing impact on asthma symptoms
and asthma exacerbations.
Further evidence for the dissociation between asthma control and exacerbations
comes from the study by Papi et al. (2007) discussed previously. Patients in the
symptom-driven treatment group (as-needed ICS/SABA inhaler) and regular
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combination treatment group (regular ICS/SABA inhaler with SABA for relief) had
similar improvements in asthma symptom scores during the study. However,
significantly fewer asthma exacerbations occurred in the as-needed group.
Considered together, the dissociation between asthma control and asthma
exacerbations may be one explanation for the observation that treatment with the
SMART regimen is effective in reducing severe exacerbations, and has lesser impact
in improving day-to-day asthma control compared to the same fixed-dose of
budesonide/formoterol with SABA for relief.
1.16 Possible mechanisms for the reduction in severe exacerbations with the
SMART regimen
1.16.1 Altering the time course and severity of an asthma exacerbation
The findings from the FACET study (Tattersfield et al., 1999; Pauwels et al., 1997)
suggest that asthma exacerbations develop over seven-to-ten days, over which time
asthma symptoms gradually worsen and reliever medication use increases. This
occurs gradually from 10 days prior to an exacerbation and then more rapidly in the
five days preceding the exacerbation (Figure 1.1). This may provide a ‘window of
opportunity’ of five to 10 days of worsening symptoms (Lindmark, 2008), during
which increasing anti-inflammatory and bronchodilator therapy with
budesonide/formoterol in response to worsening symptoms may alter the progression
of, and potentially prevent, the development of severe exacerbations.
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Figure 1.1: Time course of an asthma exacerbation
Change in symptoms, peak flow and reliever medication use in the 14 days pre and post
severe asthma exacerbations (Day 0). Data has been standardised and expressed as a %
change from Day -14. [Reprinted with permission from the American Thoracic Society.
Copyright © 2012 American Thoracic Society. Figure 2: (Tattersfield et al., 1999)
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET
International Study Group. Am J Respir Crit Care Med, 160 (2), 594-599. Official journal of
the American Thoracic Society.]
There is indirect evidence for this hypothesis from sub-group analyses (Buhl et al.,
2012) of severe exacerbations occurring in a 21 day ‘window’ after an episode of
high reliever medication use, in patients randomised to SMART (400/12µg
maintenance per day) or the same fixed-dose budesonide/formoterol for maintenance
with terbutaline for relief. Following an episode of high reliever use, defined as
greater than six reliever inhalations per day, there was a non-significant 45%
reduction in severe exacerbations occurring in the subsequent 21 days with the
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SMART regimen compared to the fixed-dose regimen. During this period, average
ICS dose was almost three times higher in the SMART group (1363µg per day
versus 500µg per day).
These findings suggest that the increased use of budesonide/formoterol during
periods of worsening asthma may affect the development of subsequent severe
exacerbations.
1.16.2 Possible pharmacological effects of high-dose budesonide and formoterol
therapy during worsening asthma
The precise mechanisms by which increasing budesonide/formoterol use during
worsening asthma attenuates the progression of the exacerbation are uncertain, but
several possibilities are suggested (Barnes, 2007).
Use of repeated multiple doses of ICS has substantial efficacy in reducing hospital
admission rates in acute asthma, possibly due to topical effects of ICS on airway
vasculature (Rodrigo, 2006). The decrease in airway blood flow following
treatment with inhaled budesonide may help to reduce airway inflammation in acute
asthma (Mendes et al., 2003). This ‘non-genomic’ effect of ICS therapy may be
rapid in onset and have a dose-response relationship (Rodrigo, 2006).
Formoterol has substantial efficacy as a bronchodilator in acute asthma (Rodrigo et
al., 2010). The dose-dependent prolonged bronchodilator efficacy of formoterol
(Derom and Pauwels, 1992) may provide time for the genomic anti-inflammatory
effects of ICS (Rodrigo, 2006). In addition, there is some evidence that treatment
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with formoterol may have anti-inflammatory effects that contribute to its clinical
efficacy (Reddel et al., 2011; Gravett et al., 2010; Ketchell et al., 2002). The
combination of budesonide and formoterol may also act synergistically (Roth et al.,
2002; Anderson, 2000).
These findings suggest that increasing use of budesonide/formoterol during
worsening asthma may provide an additive beneficial effect on airway inflammation
and bronchodilation.
1.16.3 Increasing exposure to ICS in poorly adherent patients
Use of a combination budesonide/formoterol inhaler for both maintenance and relief
may increase exposure to ICS in patients poorly adherent to maintenance therapy, as
patients would receive a dose of ICS whenever they used their inhaler for
symptomatic relief. This increase in ICS dose may translate to a reduction in severe
exacerbations.
A real-world RCT of SMART versus ICS (plus SABA) therapy in poorly adherent
asthma patients in primary care supports this hypothesis (Sovani et al., 2008).
Average daily budesonide dose was significantly increased by almost 200µg per day
in the SMART group (Sovani et al., 2008), though this study was not powered to
detect differences between groups in severe exacerbations.
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1.17 Airway inflammation with the budesonide/formoterol SMART regimen
Two trials have investigated the impact of the SMART regimen on airway
inflammation (Pavord et al., 2009; Sears et al., 2008).
In a sub-group analysis from a conventional best practice (CBP) study, Sears et al.
(2008) compared sputum eosinophils in patients treated with the SMART regimen
(mean ICS dose of 748µg per day during the study) or CBP (mean ICS dose of
1015µg per day during the study). Sputum eosinophils decreased with treatment in
both groups and there was no significant difference between the groups. The authors
concluded that the SMART regimen produces comparable effects on airway
inflammation compared to guideline-based care.
In a study comparing the SMART regimen (mean 604/18µg dose per day during the
study) with higher fixed-dose budesonide/formoterol treatment with terbutaline for
relief (mean 1600/24µg dose per day during the study) over 52 weeks of treatment,
there was a non-significant increase in sputum eosinophils in the SMART group
from 1.6% to 1.9%, but a significant reduction in eosinophil counts in the fixed-dose
group from 2.2% to 1.2% (Pavord et al., 2009). This resulted in a significant
difference between groups in favour of the fixed-dose group. Biopsy eosinophils
were also significantly higher in the SMART group. There were, however, no
differences in clinical outcomes, including severe exacerbations, lung function or
reliever medication use.
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Concern has been raised that these findings may signal that the SMART regimen is
associated with worsening airway inflammation compared to conventional fixed-
dose asthma therapy (Chapman et al., 2010). However, it is important to note that all
patients in the trial by Pavord et al. (2009) had asthma symptoms and reduced peak
flow during run-in and that those randomised to the SMART regimen then had an
ICS dose reduction (baseline dose of 741µg), whereas patients randomised to fixed-
dose therapy had an ICS dose increase (baseline dose of 867µg). Whilst it can be
concluded that a fixed four-fold higher dose of budesonide/formoterol is more
effective than low-dose SMART in controlling airway inflammation under these
conditions, this finding cannot be extrapolated to clinical practice, whereby ICS dose
reduction in symptomatic patients is not advocated.
There is currently insufficient evidence to determine the long-term impact of the
SMART regimen on airway inflammation when compared with the same fixed-dose
of maintenance budesonide/formoterol therapy with SABA for relief.
1.18 Real-world budesonide/formoterol SMART studies
1.18.1 Conventional best practice (CBP) studies
A number of ‘real-world’ studies have been undertaken, comparing SMART with
CBP (Riemersma, Postma and van der Molen, 2012; Quirce et al., 2011; Soes-
Petersen et al., 2011; Louis et al., 2009; Sears et al., 2008). CBP was generally
defined as any guideline-based asthma therapy, with the exception of SMART.
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Participants in the SMART group typically could not have maintenance dose
adjustments, whilst investigators were free to adjust therapy in the CBP group.
These studies were open-label in design, recruited mild to moderate asthma patients,
and used daily dairies to record medication use. A recent prior asthma exacerbation
was not a required entry criterion. In keeping with the real-world designs,
participants were also not required to demonstrate bronchodilator reversibility and
were not excluded on the basis of high baseline reliever medication use; however,
smokers with a greater than 10 pack-year history were not eligible.
Participants had a baseline ACQ-5 score of approximately 1.3 to 1.4 and had higher
lung function and lower baseline reliever use compared to patients in the SMART
double-blind trials discussed previously.
A summary of the key efficacy findings are shown in Table 1.6. In contrast to the
primary SMART studies, there was a lack of significant difference in severe
exacerbations between the SMART and CBP groups (Table 1.6). Asthma symptoms,
as measured by ACQ-5, were comparable or, in some cases, improved to a greater
degree by the SMART regimen compared to CBP (Table 1.6). The principal
findings were that ICS exposure was reduced and that there was a lower medication
cost associated with treatment with the SMART regimen.
A pooled analysis of six CBP trials reported that the SMART regimen did not
prolong the time to first severe exacerbation, but that there was a modest 15%
reduction in severe exacerbations (Demoly et al., 2009).
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Table 1.6: SMART conventional best practice studies
Study Maintenance
treatment *
Reliever
treatment
Number of
patients
Time to first SE
HR (95% CI):
SMART versus
comparator
Rate of SE,
events/patient/year
[RR (95% CI)]
ACQ-5 score:
SMART versus
comparator (95%
CI)
Riemersma 2012 B/F (2 x 100/6 od) B/F (100/6) 54 - 16.4 (p=0.80) ‡ -0.06 (-0.3 to 0.2),
p=0.67CBP † Non-SMART 48 16.8 ‡
Quirce 2011 B/F (200/6 bd) † B/F (200/6) 328 0.748 (0.433 to
1.292), p=0.2974
0.16 [0.753 (0.44 to
1.26)], p=0.2869
-0.12 (-0.23 to -
0.01), p=0.0292
CBP † Non-SMART 326 0.22
Soes-Petersen 2011 B/F (200/6 bd) B/F (200/6) 931 0.79 (0.56 to 1.12),
p=0.189
0.16 [0.74 (0.54 to
1.01)], p=0.058
-0.09 (-0.15 to -
0.03), p=0.003
CBP † Non-SMART 923 0.22
Louis 2009 B/F (200/6 bd) B/F (200/6) 450 HR not provided,
p=0.75
0.074 (p=0.09) -0.12 (-0.20 to
0.04), p=0.0026CBP † Non-SMART 458 0.13
Sears 2008 B/F (200/6 bd) B/F (200/6) 772 0.99 (0.70 to 1,41),
p=0.95
0.19 [0.92 (0.67 to
1.28)], p=0.63
1.27 to 1.08
(p=0.46 for
difference between
groups)
CBP † Non-SMART 766 0.21 1.24 to 1.09
*: Metered dose in µg; † maintenance dose titration allowed; ‡ days of mild exacerbation per year; B/F: budesonide/formoterol via Turbohaler; od: once daily;
bd: twice daily; SE: severe asthma exacerbation; HR: hazard ratio; RR: relative rate; CBP: conventional best practice (treatment with any guideline-based
therapy, except SMART); ACQ-5: Asthma Control Questionaire-5 score.
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Interestingly, the benefit of the SMART regimen in reducing exacerbations appeared
to be more evident in patients who were at GINA Step 4 at study entry (i.e. likely to
have more severe asthma) (Demoly et al., 2009). This finding is consistent with a
post-hoc analysis of the SMART double-blind clinical trial programme (Bateman et
al., 2011).
Though these studies were designed to replicate real-world practice, there are two
limitations which affect their generalisability to the clinical setting. Firstly, as they
were undertaken in patients with greater baseline control and lesser asthma severity
than the primary SMART studies, it is not possible to determine if the SMART
approach retains its efficacy benefit in reducing severe exacerbations in real-world
patients with moderate to severe asthma, including patients at risk of severe
exacerbations. Secondly, as the comparator CBP groups received a range of
treatments, it is not possible to determine the differential efficacy of the SMART
approach versus specific comparator regimens, such as the same fixed-dose of
budesonide/formoterol maintenance therapy with SABA for relief.
1.18.2 Cost effectiveness studies
A number of analyses investigating the cost effectiveness of the treatments in the
open-label trials have been performed (Goossens et al., 2009; Wickstrom et al.,
2009; Miller and FitzGerald, 2008; Stallberg et al., 2008; Price, Wiren and Kuna,
2007; Lundborg et al., 2006). These have suggested that the direct costs (e.g.
medication costs, healthcare visit costs) and indirect costs (e.g. loss of productivity
due to sick days) are reduced with the use of the SMART regimen.
54
1.18.3 Future studies
A search of clinicaltrials.gov suggests that there are other real-world studies
currently being undertaken or that have been recently completed (e.g. ‘A comparison
of Symbicort single inhaler therapy and conventional best practice for the treatment
of persistent asthma [NCT00628758]’; ‘Real life effectiveness of Symbicort
maintenance and reliever therapy in asthma patients across Asia’ [NCT00939341]).
These studies may provide further data on the effectiveness of the SMART regimen
in real-world settings.
1.19 Low versus high maintenance doses with the budesonide/formoterol
SMART regimen
A large-scale real-world study compared the efficacy of ‘low-dose’ SMART
treatment (200/6µg one actuation twice daily plus as-needed) versus ‘high-dose’
treatment (200/6µg two actuations twice daily plus as-needed) (Aubier et al., 2010).
High-dose treatment significantly prolonged the time to first severe exacerbation. A
significantly greater proportion of high-dose patients had an improvement of greater
than 0.5 points on the ACQ-5 score, which is considered the threshold for clinical
significance (Juniper et al., 2006). Reliever medication use was also significantly
reduced by high-dose treatment. Low baseline lung function was a predictor of
improved response with high-dose treatment.
In sub-group analyses of this trial, patients whose pre-study baseline ICS doses were
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high-dose SMART regimen (800/24µg maintenance treatment per day) did not suffer
any loss of asthma control (Aubier et al., 2011). High-dose SMART treatment also
provided greater protection from asthma exacerbations in patients who smoked (van
Schayck et al., 2012).
These findings indicate that in a clinical trial of the SMART regimen in real-world
asthma patients at risk of severe exacerbations, which may include patients with low
baseline lung function, high baseline ICS dose and patients who smoke, the use of
200/6µg two actuations twice daily (corresponding to BTS Step 3 or GINA Step 4)
as the maintenance budesonide/formoterol dose may be considered the preferred
option.
1.20 Systematic reviews and meta-analyses of trials of the SMART regimen
A number of systematic reviews of trials of the SMART regimen have been
published (Lee and Corren, 2008; McCormack and Lyseng-Williamson, 2007).
These have generally suggested that the SMART approach is advantageous in
reducing severe exacerbations in patients with uncontrolled asthma and that this
treatment strategy is well tolerated.
Three meta-analyses have investigated the efficacy and safety of the SMART
regimen with comparator treatments of the same fixed-dose maintenance ICS/LABA
treatment (Edwards et al., 2010; Agarwal et al., 2009; Cates and Lasserson, 2009)
or higher fixed-dose ICS/LABA treatment (Edwards et al., 2010; Agarwal et al.,
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2009) with SABA for relief in adult patients. A fourth meta-analysis (Sears and
Radner, 2009) has specifically investigated the safety of the SMART regimen in
clinical trials. A summary of the key results for the efficacy outcomes are shown in
Table 1.7.
The meta-analyses confirmed that the SMART regimen reduces asthma
exacerbations requiring corticosteroids compared to the same fixed-dose
budesonide/formoterol therapy (with SABA for relief) (Table 1.7). A comprehensive
analysis of the methodological processes used in the SMART clinical trial
programme confirmed that this finding is consistent between trials, but highlighted
the requirement for further data on the benefits and risks of this regimen in ‘real-
world’ patients (Braido et al., 2011).
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Table 1.7: Meta-analyses of the SMART studies in adults – efficacy
Study Comparators Number
of trials
included
Outcome SMART v
higher
fixed-dose
ICS:
RR/OR
(95% CI)
SMART v
same
fixed-dose
B/F:
RR/OR
(95% CI)
SMART v
higher
fixed-dose
B/F:
RR/OR
(95% CI)
SMART v
higher
fixed-dose
FL/SM:
RR/OR
(95% CI)
Edwards 2010 Equivalent or up
to fourfold higher
maintenance ICS
dose
6 a) Risk of severe
exacerbations [oral
FRUWLFRVWHURLGVIRUGD\V
emergency visit, and/or
hospitalisation]
0.59 (0.51
to 0.68),
p<0.00001
0.57 (0.49
to 0.66),
p<0.00001
0.74 (0.58
to 0.96),
p=0.02
0.76 (0.64
to 0.90),
p=0.002
b) Oral corticosteroids for
asthma exacerbations
0.59 (0.50
to 0.68),
p<0.00001
0.58 (0.49
to 0.67),
p<0.00001
0.68 (0.51
to 0.90),
p=0.008
0.75 (0.62
to 0.91),
p=0.004
Cates 2009 Same fixed-dose
ICS/LABA
2 a) Asthma exacerbations
requiring hospitalisation
- 0.68 (0.40
to 1.16) *
- -
b) Oral corticosteroids for
asthma exacerbations
- 0.54 (0.44
to 0.65) *
- -
Agarwal 2009 Fixed-dose ICS
or ICS/LABA or
conventional best
practice (CBP)
8 Odds of severe
exacerbations [as defined by
the individual trial
protocols]
0.52 (0.45
to 0.61) *
0.65 (0.53 to 0.8) *
*: p values not reported; v: versus; RR: relative risk or rate; OR: odds ratio; ICS: inhaled corticosteroid; B/F: budesonide/formoterol; FL/SM:
fluticasone/salmeterol.
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1.21 Regulatory approval for the budesonide/formoterol SMART regimen
In the United Kingdom, the SMART regimen is approved for patients who are poorly
controlled on ICS alone (BTS Step 2) or as an alternative treatment plan for
‘selected’ patients on low to medium dose ICS and LABA (BTS Step 3) (SIGN/BTS,
2012). The GINA guidelines suggest that the SMART regimen may be used as an
alternative to fixed low-dose ICS and LABA therapy (GINA Step 3) (GINA, 2011).
These guidelines do not recommend the use of the SMART regimen in patients who
are uncontrolled at higher treatment steps, who may also be at risk of severe
exacerbations. In addition, there are recommendations cautioning against the use of
the SMART regimen in patients with high reliever medication use, poor adherence,
or difficult to control asthma (Taylor et al., 2008). This may be as a consequence of
concerns regarding the safety and efficacy of the SMART regimen in these ‘real-
world’ patients.
The SMART regimen is approved for use with budesonide/formoterol via Turbohaler
and not with budesonide/formoterol via MDI (AstraZeneca Limited, 2011a).
1.22 Maintenance and reliever treatment with beclometasone/formoterol
combination MDI
A recently published trial has investigated the use of combination
beclometasone/formoterol via MDI as part of a maintenance and reliever regimen in
adult patients with asthma (Papi et al., 2013). In this double-blind study, patients
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were randomised to receive 12 months of treatment with either two actuations per
day of 100/6µg beclometasone/formoterol via MDI as maintenance (200/12µg per
day total) with extra doses for relief (maintenance and reliever group) or the same
dose of beclometasone/formoterol for maintenance with 100µg of salbutamol for
relief (salbutamol as-needed group).
Patients were required to demonstrate bronchodilator reversibility at baseline, had at
least one severe asthma exacerbation in the preceding year and were eligible if they
were not fully controlled after two weeks of 200/12µg per day of
beclometasone/formoterol during run-in. Baseline ACQ-7 score was approximately
1.9 in both groups. Average ICS dose at study entry was approximately 1130µg per
day (beclometasone non-extrafine equivalent) and 80% of patients were on LABAs.
Patients recorded their use of rescue medication on an electronic daily diary and were
asked to contact study investigators if six rescue actuations per day for two
consecutive days were used.
Treatment with the maintenance and reliever regimen significantly prolonged the
time to first severe asthma exacerbation and significantly reduced severe
exacerbations by 34%. Severe exacerbations requiring an ED visit or hospital
admission were also significantly reduced by 33% with the SMART regimen.
These findings suggest that in addition to the use of budesonide/formoterol with the
SMART regimen, other combination ICS/rapid-onset LABA inhaler preparations,
including those delivered by MDI, may also be effective in reducing severe
exacerbations in adults with moderate to severe asthma.
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1.23 Inhaled formulations for budesonide/formoterol
Budesonide/formoterol at the 200/6µg dose is formulated as a Dry Powder Inhaler
(DPI) (Symbicort Turbohaler) and as a heptafluoropropane (HFA) MDI (called
‘Vannair’ in New Zealand) (Lyseng-Williamson and Simpson, 2008; McCormack
and Lyseng-Williamson, 2007). The Turbohaler formulation is registered for use in
asthma in many countries including New Zealand, Australia, Canada and those of the
European Union. As of 2013, the MDI formulation is registered for use in asthma in
New Zealand, Australia, the USA and Switzerland (AstraZeneca Limited, 2011a).
This MDI formulation is not available elsewhere in Europe (AstraZeneca Limited,
2011a).
1.24 Therapeutic equivalence for the MDI and Turbohaler
budesonide/formoterol formulations
1.24.1 Pharmacokinetic comparisons
Systemic bioavailability of budesonide from the 200/6µg MDI formulation is
comparable to that from the 200/6µg Turbohaler formulation in healthy volunteers
(AstraZeneca Limited, 2011a). The Product Information for the MDI formulation
states that ‘Vannair 200/6µg MDI delivers the same amount of budesonide and
formoterol as Symbicort Turbohaler 200/6µg’ (AstraZeneca Limited, 2011b).
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1.24.2 Long-term therapeutic equivalence
Two long-term safety and efficacy clinical trials have demonstrated the therapeutic
equivalence of budesonide/formoterol via MDI and Turbohaler in adults (Morice et
al., 2008; Morice et al., 2007).
1.24.3 Short-term therapeutic equivalence
To my knowledge, acute bronchodilator equivalence studies for
budesonide/formoterol via MDI and Turbohaler have not been published. However,
there is a comparable acute bronchodilator effect between budesonide/formoterol via
MDI and formoterol via Turbohaler (Table 1.8) (Kaiser et al., 2008; Miller, Senn
and Mezzanotte, 2008; Corren et al., 2007; Noonan et al., 2006). This provides
indirect evidence that budesonide/formoterol delivered via MDI or Turbohaler may
be therapeutically equivalent when used acutely for relief of asthma symptoms.
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Table 1.8: Short-term bronchodilator comparison studies of formoterol via DPI and MDI
Study Comparators Dosing regimen Trial
design
Outcome
Corren 2007 B/F MDI 100/6µg
F DPI 6µg
2 actuations
2 actuations
RCT, DB Mean increase in 12-hour FEV1 was 0.41L in
B/F group and 0.44L in F group (NS)
Kaiser 2008 B/F MDI 200/6µg
F DPI 6µg
2 actuations
2 actuations
5&7'% RISDWLHQWVLQERWKJURXSVKDGD
increase in FEV1 within 60 min (NS); median
WLPHWRLQFUHDVHLQ)(91was 10min in
B/F group and 8min in F group (NS)
Miller 2008 B/F MDI 100/6µg
F DPI 6µg
1, 2, 4 actuations
1, 2, 4 actuations
RCT,
crossover
No significant differences between same-dose
formoterol treatments in average 12-hour
FEV1, maximum FEV1, and FEV1 at 12 hours
Noonan
2006
B/F MDI 200/6µg
F DPI 6µg
2 actuations
2 actuations
RCT, DB Mean increase in 12-hour FEV1was 0.37L in
B/F group and 0.35L in F group (NS)
B/F: budesonide/formoterol; F: formoterol; MDI: metered dose inhaler; DPI: dry powder inhaler; DB: double blind; RCT: randomised
controlled trial; NS: non statistically significant difference between groups; L: litres.
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1.25 Thresholds of high beta-agonist use requiring medical review
1.25.1 SABA thresholds defined by self-management plans
Salbutamol is usually prescribed at a dose of one to two inhalations as-required
(GlaxoSmithKline Limited, 2011). The New Zealand Asthma and Respiratory
Foundation 2004 asthma self-management plan recommends that patients seek
medical review when reliever use is every two to three hours (Holt, Masoli and
Beasley, 2004) (i.e. eight to 24 actuations per 24-hours). The Asthma UK Personal
Asthma Action Plan recommends medical review when reliever use is every four
hours or more often (Asthma UK, 2011).
Based on these recommendations, more than 16 actuations of salbutamol per 24-
hours may be considered as the threshold of SABA use that requires medical review.
1.25.2 Budesonide/formoterol thresholds defined by self-management plans
The Symbicort SMART asthma action plan recommends that medical review is
required if more than 12 actuations of budesonide/formoterol per 24-hours are used
in the setting of worsening asthma (National Asthma Council Australia, 2013).
If a patient is prescribed two actuations twice daily (four actuations total) of
budesonide/formoterol as maintenance therapy, then the use of more than eight
actuations in excess of the four maintenance doses per 24-hours (i.e. more than 12
actuations in total) is the threshold requiring medical review.
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1.25.3 Beta-agonist thresholds used in clinical trials
In the TRUST trial of regular versus as-needed salbutamol, 1600µg per day of
salbutamol (i.e. 16 actuations of salbutamol 100µg per actuation) was chosen as the
dose of salbutamol for the regular treatment group (Dennis et al., 2000). A prior
study investigating the safety of as-needed formoterol defined a maximum threshold
of 12 actuations of formoterol (72µg) per day (Tattersfield et al., 2001). If four
actuations per day (6µg per actuation) are taken as maintenance therapy, then this
allows an additional eight doses to be taken for relief of symptoms.
Considered together, the ratio of reliever actuations per day requiring medical review
can be interpreted as more than eight budesonide/formoterol actuations (for SMART)
to more than 16 salbutamol actuations (for Standard therapy) (i.e. an actuation ratio
of 1:2).
1.26 Short-term bronchodilator equivalence of salbutamol and formoterol
The short-term bronchodilator equivalence of salbutamol and formoterol varies
according to the dosing regimen (single versus repeated dosing), medication
formulation (Turbohaler versus MDI) and study setting (acute asthma versus stable
asthma) (Hampel, Martin and Mezzanotte, 2008; Balanag et al., 2006; Rubinfeld et
al., 2006; Ankerst et al., 2005; Boonsawat et al., 2003; Rosenborg et al., 2002;
Seberova and Andersson, 2000). The key bronchodilator comparison studies are
summarised in Table 1.9.
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Table 1.9: Short-term bronchodilator comparison studies of salbutamol and formoterol
Study Comparators Dosing
regimen
Formoterol to
salbutamol
actuation ratio*
Study
setting
Trial
design
Outcome: formoterol versus salbutamol
Ankerst
2005 †
F: 12µg
S: 200µg
Single
dose
2:2 (1:1) Stable
asthma
DB, P,
RCT,
crossover
8% v 9% mean increase in FEV1 at 3 minutes
(NS, no p value)
Balanag
2006 ‡
B/F: 800/24µg
S: 800µg
2 doses 8:16 (1:2) Acute
asthma
DB, P, RCT 30% v 32% mean increase in FEV1 at 90
minutes (p=0.66)
Boonsawat
2003
F: 24µg
S: 800µg
3 doses 12:24 (1:2) Acute
asthma
DB, RCT 37% v 28% mean increase in FEV1 at 75
minutes (p=0.18)
Hampel
2008 §
B/F: 200/12µg
S: 200µg
Single
dose
2:2 (1:1) Stable
asthma
DB, RCT,
crossover
0.2L v 0.3L mean increase in FEV1 at 3 minutes
(NS)
Rosenborg
2002
F: 6, 24, 72µg
S: 200,1800µg
Single
dose
4:18 (1:4.5) Stable
asthma
DB, RCT,
crossover
Comparable increase in FEV1 at 30 minutes
between 24µg F and 1800µg S (no p value)
Rubinfeld
2006
F: 24µg
S: 800µg
2 doses 8:16 (1:2) Acute
asthma
DB, RCT 6.6% v 9.3% increase in FEV1% predicted at 45
minutes (p=0.24)
Seberova
2000
F: 6, 12µg
S: 100, 200µg
Single
dose
2:2 (1:1) Stable
asthma
DB, RCT,
crossover
11.8% v 11.4% increase in FEV1 at 3 minutes
between 12µg F and 200µg S (NS, no p value)
*: actuation ratio calculated on the basis of 6µg formoterol per actuation and 100µg salbutamol per actuation; †: F via MDI; ‡: B/F via Turbohaler; §: B/F via MDI; F:
formoterol; B/F: budesonide/formoterol; S: salbutamol; DB: double blind; P: placebo controlled; RCT: randomised controlled trial; NS: non-statistically significant difference
between groups; v: versus; L: litre.
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The multiple-dose comparison studies of budesonide/formoterol or formoterol and
salbutamol in acute asthma (Balanag et al., 2006; Rubinfeld et al., 2006; Boonsawat
et al., 2003) support a short-term bronchodilator equivalence of 6µg formoterol to
200µg salbutamol (a 1:2 actuation ratio respectively) (Table 1.9).
1.27 History of asthma mortality epidemics
The previous sections have reviewed the differences in the efficacy of formoterol and
salbutamol. There are also potential differences in the risks associated with the use
of these two drugs and these will now be considered.
Asthma mortality peaks occurred during the 1960s and 1970s and with both
‘epidemics’, the use of beta-agonists with high intrinsic activity have been
implicated.
1.27.1 Isoprenaline forte in the 1960s
An increase in asthma mortality occurring in England and Wales was initially
described in the 1960s (Speizer, Doll and Heaf, 1968). Subsequently, an increase in
mortality rates were observed in persons aged five to 34 in at least six developed
countries, including Australia and New Zealand (Crane, 1993). There were
conflicting views as to the cause of the epidemic (Stolley and Schinnar, 1978; Inman
and Adelstein, 1969), but its occurrence correlated with the introduction of a high-
dose inhaled preparation of the beta-agonist isoprenaline (isoprenaline forte) in these
countries (Stolley and Schinnar, 1978).
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One suggested mechanism for an increased risk of death included direct cardio-
toxicity due to therapy with a beta-agonist with high intrinsic activity for cardiac
adrenoceptors (Stolley and Schinnar, 1978; O'Donnell and Wanstall, 1974). This
risk may have been potentiated by the presence of tissue hypoxia (Collins et al.,
1969). Another suggested mechanism for an increased risk of death was the
potential for patients to delay in seeking medical care during worsening asthma
(Fraser et al., 1971), due to the symptomatic relief provided by the high intrinsic
activity of isoprenaline forte at pulmonary beta-2 adrenoceptors (O'Donnell and
Wanstall, 1974).
1.27.2 Fenoterol in the 1970s
The second peak in mortality occurred in New Zealand in the mid-1970s (Beasley et
al., 1990). A series of case-control studies implicated the recent introduction of a
high-dose preparation of inhaled fenoterol (Grainger et al., 1991; Pearce et al., 1990;
Crane et al., 1989), a beta-agonist with high intrinsic activity at beta-1 and beta-2
adrenoceptors (Giles, Williams and Finkel, 1973). This increase in mortality
correlated with an increase in New Zealand sales of fenoterol and death rates reduced
when the sales of fenoterol were restricted (Pearce and Hensley, 1998).
Studies in healthy volunteers and stable asthma patients demonstrated that fenoterol
had greater maximal inotropic and chronotropic effects than salbutamol after
multiple, repeat dosing, and caused a greater maximum hypokalaemic effect
(Bremner et al., 1996; Windom et al., 1990b). A subsequent study in patients
presenting to the ED with acute asthma and comparing cumulative doses of up to 16
actuations of fenoterol or salbutamol, confirmed the significantly greater effect of
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fenoterol on serum potassium and cardiac parameters (Newhouse et al., 1996). In
addition, regular use of fenoterol has been associated with worse asthma control
compared to as-required use (Sears et al., 1990).
As previously, there were conflicting views regarding causality between fenoterol
and asthma death (Beasley, 2006; Garrett et al., 1996).
Formoterol, like fenoterol and isoprenaline, has high intrinsic activity for cardiac
adrenoceptors, whilst salbutamol has a lesser ability to activate cardiac adrenoceptors
(Table 1.10) (Decker et al., 1982; Giles et al., 1973). Considering that formoterol
shares this pharmacological property of high intrinsic activity with two beta-agonists
implicated in epidemics of asthma mortality, it is important to review the
mechanisms for adverse events that were suggested with the use of isoprenaline and
fenoterol, and to consider their relevance to the use of budesonide/formoterol with
the SMART regimen (Cates et al., 2009; Johnston and Edwards, 2009; Hancox,
2006; Nelson, 2006; Tattersfield, 2006; Lipworth, 2001; Beasley et al., 1999;
Tattersfield, 1994; Wong et al., 1990; Sears and Rea, 1987).
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Table 1.10: Comparative pharmacology of beta-2 adrenoceptor agonists - safety
Beta-agonist Intrinsic
activity in the
trachea *
Intrinsic
activity in
the atrium †
Isoprenaline 1.00 1.00
Fenoterol 1.07 0.89
Formoterol 0.94 0.94
Salbutamol 0.91 0.75
*: Ratio of the maximal response of each beta-agonist compared to the maximal response of
isoprenaline, in guinea-pig trachea [value for isoprenaline is 1.0; higher values suggest
greater intrinsic activity for pulmonary adrenoceptors].
†: Ratio of the maximal response of each beta-agonist compared to the maximal response of
isoprenaline, in guinea-pig atria [value for isoprenaline is 1.0; higher values suggest greater
intrinsic activity for cardiac adrenoceptors].
[Summarised and adapted from Decker et al. (1982) and Giles et al. (1973)].
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1.28 Potential mechanisms for adverse effects with the use of formoterol
1.28.1 Direct drug toxicity in the setting of beta-agonist overuse
Formoterol’s higher intrinsic activity at cardiac adrenoceptors may increase its
potential to cause cardiac adverse effects such as tachycardia and myocardial rhythm
disturbances when compared to salbutamol, particularly in the setting of beta-agonist
overuse. In addition, this risk may be potentiated by the presence of myocardial
hypoxia, if this occurred during a severe or life-threatening asthma attack.
As previously discussed, due to its higher intrinsic activity at the beta-2
adrenoceptor, formoterol may also have a greater potential for hypokalaemia, which
may contribute to an increased risk of cardiac arrhythmias.
1.28.2 Delay in seeking medical help in the setting of worsening asthma
The greater maximal bronchodilatory effect of formoterol, coupled with its
prolonged duration of action, may result in greater delays in seeking medical help for
patients using the SMART regimen during worsening asthma compared to a
Standard fixed maintenance dose regimen with salbutamol for relief. Delay in
seeking medical help might also increase the risk of development of hypoxia prior to
medical review and further exacerbate any direct toxic effects.
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1.28.3 Tolerance to treatment
Tolerance to the bronchodilator effects of formoterol may result in a reduced
response to the effects of budesonide/formoterol when used for relief of symptoms
during worsening asthma. Alternatively, tolerance may reduce the protection that
budesonide/formoterol provides against bronchoconstrictor stimuli. Tolerance will
be discussed in further detail in section 1.30.
1.28.4 Beta-agonist overuse as an indirect marker of risk of life threatening
asthma
A number of studies have demonstrated that beta-agonist overuse is a marker of risk
of death (Abramson et al., 2001; Suissa, Blais and Ernst, 1994; Suissa et al., 1994;
Spitzer et al., 1992). Beta-agonist overuse is also a marker of intensive care
admission for asthma (Eisner et al., 2001) and ED visit or hospitalisation for asthma
(Schatz et al., 2005).
1.29 Evidence for direct toxicity with high-dose formoterol use
There are dose-dependent adverse effects on cardiovascular and biochemical
parameters following cumulative dosing with formoterol in asthma patients (Burgess
et al., 1998). Thus, 16 actuations (6µg per actuation) produced significantly greater
maximal increases in QTc and reductions in serum potassium, than doses of two,
four or eight actuations, and for a greater duration of time (Burgess et al., 1998).
Compared to treatment with two doses, 16 doses of formoterol increased QTc by
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23ms and reduced serum potassium by 0.4mmol/L (Burgess et al., 1998), suggesting
a clinically relevant effect. Increases in cardiac contractility, which is a measure of
myocardial oxygen demand, were also significantly greater after 16 actuations
compared with two actuations (Burgess et al., 1998).
In a study in healthy volunteers, the maximal increases in heart rate, QTc and cardiac
contractility were similar following cumulative dosing with 20 actuations of
formoterol (6µg per actuation) or salbutamol (100µg per actuation) (Bremner et al.,
1993). However, the increases in cardiac contractility and heart rate persisted for a
longer duration of time in formoterol-treated patients (Bremner et al., 1993). In
addition, the maximal decreases in serum potassium, as well as the duration of this
reduction, were greater following treatment with formoterol than salbutamol
(Bremner et al., 1993). Thus, patients using high doses of budesonide/formoterol
with the SMART regimen may have a greater ‘at-risk’ period of physiological
disturbance.
Conversely, short-term studies testing lower doses of formoterol have demonstrated
conflicting results regarding the risk of drug toxicity. One study used eight
actuations of formoterol (6µg per actuation) (Rubinfeld et al., 2006) and another
study used four actuations of budesonide/formoterol (400/12µg per actuation)
(Balanag et al., 2006) for the treatment of acute asthma in the ED, in patients without
significant concomitant disease. Comparator groups were treated with 16 actuations
(100µg per actuation) of salbutamol in both trials (Balanag et al., 2006; Rubinfeld et
al., 2006). Changes in serum potassium and QTc were not significantly different
between formoterol and salbutamol-treated patients. However, in another study of
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cumulative dosing with 12 actuations (6µg per actuation) of formoterol in acute
asthma, minimum serum potassium was significantly lower in formoterol-treated
patients compared to patients receiving 24 actuations (100µg per actuation) of
salbutamol (Boonsawat et al., 2003).
Clinical adverse events following treatment with formoterol have also been reported
in certain studies. Angina considered to be related to the study medication was
reported in one patient who had received six formoterol actuations (Ind et al., 2002),
whilst atrial fibrillation (AF) was reported in another study in which a patient
received 12 daily doses of formoterol (72µg per day) for three consecutive days
(Totterman et al., 1998).
It is important to recognise that the studies described above were generally
undertaken in carefully selected patients under strictly controlled conditions and that
maximum dose was limited. In a real-world setting with patients who have co-
morbid conditions and who may self-administer beta-agonist doses in excess of those
tested above during worsening asthma (Windom et al., 1990a), these short-term
studies have demonstrated that there remains the potential for risk of direct adverse
effects with the SMART regimen.
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1.30 Tolerance
The effects of pulmonary tolerance may manifest in a number of ways (Tattersfield,
1993). In addition, the use of concomitant ICS does not necessarily protect against
the development of these effects (Anderson, 2000; Taylor and Hancox, 2000).
1.30.1 Reduction in bronchodilator effect after regular formoterol treatment
A significant attenuation in the bronchodilator response to single (Yates et al., 1995)
and cumulative (Newnham et al., 1995) dosing with formoterol has been
demonstrated in short-term studies in which patients were treated with regular
formoterol or placebo. In a six-month study in which patients received 24µg per day
of formoterol, the bronchodilator response 30 minutes following formoterol dosing
was initially reduced, before remaining stable for the remaining study period
(FitzGerald et al., 1999). In the FACET study, the addition of formoterol to
budesonide resulted in an immediate increase in morning PEFR, followed by a
gradual decrease in the following 14 days, before reaching a steady-state level
(Pauwels et al., 1997).
These studies demonstrate that tolerance to the bronchodilator effect of formoterol
may occur after repeated dosing. In theory, this may reduce the effectiveness of
extra actuations of budesonide/formoterol when taken for relief of symptoms for
patients on the SMART regimen.
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1.30.2 Reduction in response to SABA following regular formoterol treatment
There is evidence to suggest that whilst patients are on treatment with regular
formoterol, there is significant tolerance to the bronchodilator effects of salbutamol
in the presence of acute bronchoconstriction (Haney and Hancox, 2005a; Haney and
Hancox, 2005b; Jones et al., 2001). This finding is important, as the response to
rescue SABA therapy in the setting of acute asthma may be reduced (Haney and
Hancox, 2007; Haney and Hancox, 2006). If adherence to maintenance
budesonide/formoterol therapy is increased by use of the SMART regimen, then
tolerance may pose a greater risk for patients on this regimen, particularly in the
setting of worsening asthma requiring rescue SABA use, as might occur in the ED.
1.30.3 Reduced protection following bronchoconstrictor challenge
Loss of protection to the bronchoconstrictor challenges of AMP (Aziz et al., 1998b)
and methacholine (Lipworth et al., 1998; Yates et al., 1995) have been demonstrated
in patients receiving formoterol for one to two weeks. This effect was also noted
after three months of treatment with formoterol but was not progressive (FitzGerald
et al., 1999).
1.30.4 Rebound increase in bronchial reactivity after cessation of formoterol
treatment
Following cessation of regular formoterol treatment, PC20 values for methacholine-
induced bronchoconstriction remained above baseline values (FitzGerald et al., 1999;
Yates et al., 1995), suggesting that a rebound increase in bronchial hyper-
responsiveness may not occur once formoterol therapy is stopped.
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1.30.5 Masking of worsening asthma
Concerns have been raised that LABA therapy may mask underlying deteriorating
airway inflammation, particularly if patients are exposed to LABA monotherapy
(Morales et al., 2012; Rodrigo and Castro-Rodriguez, 2012). This was the suggested
mechanism in a patient who developed severe asthma after stopping ICS therapy but
continuing with formoterol monotherapy (Arvidsson et al., 1991). This risk should
theoretically be diminished by the use of combination ICS/LABA inhaler therapy
(Beasley, Fingleton and Weatherall, 2013).
1.31 Tolerance to the extra-pulmonary effects of formoterol
Following regular treatment with formoterol, tolerance to the systemic effects of
subsequent cumulative dosing has been demonstrated. Thus, the hypokalaemic and
cardiac effects of repeated high dosing with formoterol, such as may occur during
worsening asthma with the SMART regimen, are diminished if the patient is taking
regular formoterol (van den Berg et al., 1998; Newnham et al., 1995). This may
provide some protection from direct drug toxicity, though there is some evidence to
suggest that use of concomitant ICS re-sensitises cardiac beta-2 adrenoceptors and
may diminish the protective effect that extra-pulmonary tolerance may provide
(Jackson and Lipworth, 2004; Aziz, McFarlane and Lipworth, 1998a).
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1.32 Polymorphisms in the beta-2 adrenoceptor gene and the risk of adverse
outcomes with formoterol treatment
In recent years, the beta-2 adrenoceptor gene (ADRB2) has been sequenced and
polymorphisms occurring at amino acid position 16 (Gly16Arg) may be considered a
‘risk factor’ for adverse outcomes with LABA therapy in asthma (Kazani, Wechsler
and Israel, 2010). Alterations in the amino acid composition of the beta-2
adrenoceptor from glycine to arginine at this position may alter the function of the
receptor in response to binding with formoterol, and therefore predispose to a
diminished clinical response (Szefler et al., 2012; Kazani et al., 2010).
In patients receiving either the SMART regimen or a fixed-dose
budesonide/formoterol regimen with SABA for relief, the occurrence of severe
asthma exacerbations were not affected by Gly16Arg genotype (Bleecker et al.,
2007). In addition, Gly16Arg genotype did not predict the response to either therapy
in terms of improvements in lung function or symptom scores (Bleecker et al., 2007).
These findings suggest that genetic polymorphisms are unlikely to be the sole
determinants of adverse outcomes associated with LABA therapy. Further studies
are required to examine the impact of ADRB2 genotype on response to asthma
therapy (Lipworth et al., 2013; Sayers, 2013).
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1.33 Safety in long-term clinical trials with formoterol
No differences in the occurrence or patterns of AEs or SAEs were noted between the
formoterol and terbutaline-treated groups in the first large-scale study of the use of
formoterol as a reliever therapy (Tattersfield et al., 2001). However, patients with
high baseline reliever use (greater than 12 inhalations per day of rescue medication
during run-in) and patients with serum potassium values outside the reference range
were excluded from study entry. In addition, patients who experienced more than
one severe exacerbation in the study were withdrawn.
A previous analysis suggested a dose-response relationship for an increased risk of
serious asthma events (including life-threatening asthma) with 48µg of formoterol
per day compared to 24µg per day (Mann et al., 2003). Though this finding was not
replicated in a subsequent prospective safety study (Wolfe et al., 2006), one patient
in this study had a myocardial infarction considered to be related to formoterol
treatment (24µg per day) and over 1% of patients on formoterol suffered from
‘cardiac disorders’ (Wolfe et al., 2006).
RELIEF (Pauwels et al., 2003b) was a safety and efficacy study of the use of
formoterol as a reliever treatment compared to the use of salbutamol. There were no
significant differences in the proportions of patients with AEs, cardiovascular-related
AEs, SAEs or deaths between groups and there was a significant reduction in the
number of asthma-related AEs in the formoterol-treated group. There were no
restrictions on study entry based on baseline reliever medication use, though patients
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who were enrolled were asked to contact study investigators if they used greater than
12 inhalations per day.
Clinically relevant adverse events have been reported in the individual primary
SMART studies. O’Byrne et al. (2005) reported that there were study
discontinuations due to cardiovascular adverse events and one patient suffered from
AF thought to be related to SMART therapy in another study (Scicchitano et al.,
2004). One SAE related to treatment with the SMART regimen was reported in
another study, though there were no further details in the manuscript (Vogelmeier et
al., 2005).
Considered together, these findings indicate that clinically significant adverse events
associated with the use of formoterol as a reliever therapy may occur in the setting of
controlled clinical trials.
1.34 Systematic reviews and meta-analyses of treatment with salmeterol in
asthma
When examining the risk of occurrence of rare events, such as asthma-related death
or cardiac-related death, meta-analyses of trials may help to assess the risk of these
events (Weatherall et al., 2010a).
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The importance of concurrent ICS therapy in reducing the risk of mortality when
LABAs are used in asthma was demonstrated by a systematic review and meta-
analysis of regular treatment with salmeterol (Table 1.11) (Weatherall et al., 2010b).
In this meta-analysis, regular treatment with salmeterol monotherapy, whereby
concomitant ICS therapy was not mandated, significantly increased the risk of
asthma-related death compared to treatment with placebo (Table 1.11). When the
analysis was performed in trials in which salmeterol was used with ICS at baseline,
the risk of asthma mortality was reduced. When the analysis was restricted further to
trials in which patients received salmeterol and ICS in a single combination inhaler,
there were no reported asthma deaths (Weatherall et al., 2010b).
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Table 1.11: Risk of asthma death from a meta-analysis of randomised controlled
trials of salmeterol use in asthma
Comparator Odds ratio (95% CI) for
asthma death
Salmeterol monotherapy
versus placebo
7.3 (1.8 to 29.4)
Salmeterol with ICS versus
ICS
2.1 (0.6 to 7.9)
Salmeterol/fluticasone in a
combination inhaler versus
ICS
0 deaths in 22,600 patients
These findings support the guidance against using LABA monotherapy in asthma
patients (SIGN/BTS, 2012) and suggest that the concomitant use of ICS and
salmeterol, particularly in the form of a combination ICS/LABA inhaler, is not
associated with an increased risk of death.
1.35 Systematic reviews and meta-analyses of treatment with formoterol in
asthma
Recent systematic reviews and meta-analyses have attempted to determine if there is
an increased risk of asthma-related death with formoterol versus non-LABA therapy
or, if this risk persists when formoterol is administered in combination with ICS,
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compared to ICS alone. This second question is more clinically relevant in view of
current recommendations that LABAs should always be co-prescribed with ICS
(SIGN/BTS, 2012). A summary of meta-analyses of RCTs investigating these two
questions are presented in Table 1.12 and Table 1.13 (Nelson et al., 2010; Beasley et
al., 2009b; Cates et al., 2009; Sears et al., 2009; Wijesinghe et al., 2009; Cates,
Cates and Lasserson, 2008; Levenson, 2008).
In all of the meta-analyses of mortality risk with formoterol, there has been
insufficient power to determine a statistically significant difference between groups,
due to the low overall rates of death or asthma-related deaths in the groups. These
studies have suggested a non-significant 1.5 to 4.5-fold increased risk of asthma-
related mortality in patients treated with formoterol compared to non-LABA treated
patients across four analyses (Table 1.12) (Beasley et al., 2009b; Sears et al., 2009;
Wijesinghe et al., 2009; Cates et al., 2008). Importantly, the risk of asthma-related
mortality is non-significantly increased to between 2.32 and 7.34 in patients on
concomitant formoterol and ICS versus ICS alone (Table 1.13) (Beasley et al.,
2009b; Cates et al., 2009; Sears et al., 2009).
This finding is in contrast to the meta-analysis of trials in which patients were treated
with salmeterol discussed previously (Weatherall et al., 2010b) and suggests that
concomitant ICS and formoterol prescription may not protect against the risk of
asthma-related mortality.
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Table 1.12: Summary of meta-analyses of RCTs comparing formoterol versus non-LABA treatment in asthma - safety
Study All cause mortality Asthma-related mortality Composite asthma endpoint †
Cates 2008* OR (95% CI) 4.50 (0.41 to
49.49), NS
OR (95% CI) 4.54 (0.07 to
285.25), NS
-
Levenson 2008 [Formoterol] RD (95% CI) -0.38 (-1.12 to
0.36), NS
No deaths RD (95% CI) 3.80 (-1.8 to 9.40), NS
Levenson 2008 [Symbicort] No deaths No deaths RD (95% CI) 7.49 (-1.47 to 16.44), NS
Sears 2009 RR (95% CI) 0.95 (0.50 to
1.92), NS
RR (95% CI) 1.57(0.31 to
15.1), NS
-
Beasley 2009 - RR (95% CI) 2.53 (0.45 to
26), NS
-
Wijesinghe 2009 OR (95% CI) 1.1 (0.6 to 2.2),
NS
OR (95% CI) 2.7 (0.5 to
26.7), NS
-
Nelson 2010 RR (95% CI) 0.64 (0.14 to
2.92), NS
No deaths -
Comparisons are for formoterol versus non-LABA treatments (non-LABA treatments could include ICS, SABA or placebo); *: formoterol versus
placebo; †: composite of asthma death, asthma intubation and asthma hospitalisation; NS: non-statistically significant; RR: relative risk; OR: odds
ratio; RD: risk difference.
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Table 1.13: Summary of meta-analyses of RCTs comparing formoterol with ICS versus ICS treatment in asthma - safety
Study All cause mortality Asthma-related mortality
Cates 2009 OR (95% CI) 5.83 (0.78 to 43.77), NS OR (95% CI) 7.34 (0.15 to 369.72), NS
Sears 2009 RR (95% CI) 1.14 (0.53 to 2.73), NS RR (95% CI) 2.32 (0.30 to 105), NS
Beasley 2009 - RR (95% CI) 3.67 (0.41 to 174), NS
Comparisons are for formoterol with ICS versus ICS; NS: non-statistically significant;
RR: relative risk; OR: odds ratio.
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A summary of the safety meta-analyses of RCTs of the SMART regimen are shown
in Table 1.14 (Cates and Lasserson, 2009; Sears and Radner, 2009). The meta-
analysis of the double-blind SMART clinical trial programme had insufficient power
to rule out an effect on asthma mortality (Sears and Radner, 2009) (Table 1.14).
1.36 Implications of the formoterol meta-analyses and risk of asthma-related
mortality
The above meta-analyses may be interpreted in a variety of ways but one possible
explanation may be that current studies are insufficiently powered to detect a
mortality risk with formoterol treatment (Beasley et al., 2009a). These studies (Sears
and Radner, 2009; Wijesinghe et al., 2009), which were based on data from
controlled clinical trials, may also underestimate the actual risk of asthma death that
occurs in the clinical setting (Wijesinghe et al., 2009). This is because the risk of
treatment with formoterol may be greater in real-world asthma patients compared to
participants in carefully controlled clinical trials (Wijesinghe et al., 2009). With this
in mind, there remains the possibility that asthma-related mortality may be increased
by the use of formoterol and that this risk is not abolished by concomitant ICS use.
One possible explanation for this may relate to formoterol’s high intrinsic activity,
which could predispose to an increased risk of adverse effects, particularly in patients
using high doses for relief of symptoms.
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Table 1.14: Meta-analyses of the SMART clinical trial programme in adults -
fatal events
Study Comparator All-cause mortality,
SMART v
comparator
RR/OR (95% CI)
Asthma-related
mortality, SMART
v comparator
RR/OR (95% CI)
Cates 2009 Same fixed-dose
ICS/LABA+SABA
0.34 (0.05 to 2.14) 0.33 (0.01 to 8.13)
Sears 2009 All double-blind
RCTs
0.70 (0.21 to 2.30) 0.25 versus 0.16 *
Sears 2009 Open-label RCTs 1.38 versus 1.72 * 0 versus 0 *
*: This is a rate per 1000 treatment years (SMART versus comparators) with no statistical
comparisons reported; RR: relative risk; OR: odds ratio.
1.37 Current concerns regarding the use of LABAs
Based on concerns regarding the potential increased risk of asthma-related death with
LABAs including budesonide/formoterol (Kramer, 2009; Levenson, 2008), the
Federal Drug Administration have imposed a ‘black-box’ restriction on the
prescription of these drugs in the United States (Chowdhury and Dal Pan, 2010).
There are conflicting viewpoints regarding the safety of LABAs in asthma (Rodrigo
and Castro-Rodriguez, 2012; Sears, 2013; Drazen and O'Byrne, 2009) but large-
scale clinical trials are now underway to assess the risk posed by the prescription of
ICS/LABA therapy (Chowdhury, Seymour and Levenson, 2011).
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1.38 Measurement of use of inhaled asthma therapy
The following sections will now review the possible methods to measure the use of
inhaled asthma therapy.
The traditional method to measure adherence to inhaled asthma treatments is by
patient self-report (for example, in response to a questionnaire) (Janson et al., 2008;
Krishnan et al., 2004; Bender et al., 2000), or a daily diary of medication use (Rabe
et al., 2006a; O'Byrne et al., 2005; Ind et al., 2002; van der Molen et al., 1997).
Alternatives include measuring medication canister weight before and after patient
use (Tashkin et al., 1991), prescription refill records from pharmacies and/or primary
care clinics (Salamzadeh et al., 2005; Williams et al., 2004), drug level monitoring
(Horn, Clark and Cochrane, 1990; Horn et al., 1989), physician estimate of
medication use (Braunstein, Trinquet and Harper, 1996) and electronic monitoring of
medication use (Yeung et al., 1994; Gong et al., 1988).
The utility of each of these methods has been reviewed (Cochrane, 2000; Cochrane,
Horne and Chanez, 1999; Bender, Milgrom and Rand, 1997) and is summarised in
Table 1.15 and Table 1.16. Use of canister weight, refill records, drug level
monitoring, self-report and physician estimate do not provide data on actual day-to-
day use of medication. Daily diaries and electronic monitors of medication use can
provide data on patterns of use and are discussed further.
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Table 1.15: Comparison of methods to measure use of inhaled asthma therapy (A)
Method Description Advantages Limitations
Self-report Patient answers a
questionnaire relating to
medication use, generally
for a pre-defined period of
use (e.g. 24 hours or one
week)
x Simple to administer
x Minimal resources required to
collect data
x Quick and cheap to undertake
x Accuracy limited by recall bias
x Response may be affected by
the patient reporting what they
perceive their clinician wishes
to see
x Of limited use in collecting data
on patterns of medication use
Daily diary Patient completes a daily
diary of medication use;
diary may be in an
electronic format (e.g.
Personal Digital Assistant)
x Can provide data on medication
use over a prolonged period of
time
x Data on symptoms and lung
function may be collected
simultaneously
x Requires the patient to
remember to complete the diary
on a daily basis
x Risk of missing data due to non-
completion by patient
x Of limited use in collecting data
on patterns of medication use
Canister weight Medication canisters
weighed before and after
MDI use by the patient;
change in weight is a
measure of medication use
x Objective measurement of total
number of doses used
x Cheap to perform
x Minimal additional resources
required to collect data
x Does not provide data on
patterns of medication use
x Labour intensive
Prescription refill Pharmacy and/or primary
care clinic records
analysed for prescription
refills for medication
x Useful in collecting data on
adherence to therapy over
months/years
x Cheap to undertake
x Does not provide data on
patterns of medication use
x Requires access to external
databases (e.g. pharmacy)
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Table 1.16: Comparison of methods to measure use of inhaled asthma therapy (B)
Method Description Advantages Limitations
Drug level
monitoring
Direct measurement of
drug level in blood and/or
urine
x Provides a quantifiable value
which may be tracked with
follow-up
x May help to confirm treatment
use
x Requires repeated blood and/or
urine samples, making this
impractical for use with most
patients
x Access to specialist laboratory
testing required, which is not
routinely available
x Does not provide data on
patterns of medication use
Physician estimate Estimate of medication
use based on physician’s
perception
x Quick and requires no
additional resource
x Inaccurate and unreliable
Electronic
monitor
Electronic monitor records
inhaler actuation (to the
nearest second); data can
be downloaded at intervals
x Can provide accurate data on
actual patterns of medication
use
x May be used to record treatment
use over a prolonged period e.g.
weeks/months
x Does not require a change in
patient behaviour
x Data accuracy may be affected
if an invalidated and/or
unreliable monitor is used
x May not record medication
inhalation
x Expensive and may require
additional quality control
processes
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1.38.1 Daily diary versus electronic monitoring
Daily diaries can be used by patients to record medication use. They have, however,
been shown to be unreliable methods to quantify medication usage when compared
to electronic monitoring (Milgrom et al., 1996; Rand and Wise, 1994; Spector et al.,
1986). Use of treatment is generally over-reported with this method, possibly
because patients document what they perceive their clinician wishes to see. In
addition, daily dairy use over a six-month study period may be impractical and may
be limited by non-completion and subsequent missing data. Requiring patients to
complete a daily dairy, even if provided in an electronic format such as a Personal
Digital Assistant, requires a change from usual behaviour and may affect the
generalisability of data collected by this method. Use of daily diaries is therefore
recognised to be a poor guide to actual use of medication. Electronic monitors have
the advantage of being objective (Cochrane et al., 2000) and provide accurate data on
patterns of actual medication use (Perrin et al., 2010). A recent critical appraisal has
highlighted the need for electronic monitoring to obtain objective data on the actual
use of treatment by patients on the SMART regimen (Chapman et al., 2010).
1.38.2 Electronic monitoring of medication use
Several electronic monitors have been developed over the past 30 years, for use with
both MDIs and DPIs (Ingerski et al., 2011; Denyer, 2010). The first such monitor
was the Nebulizer Chronolog, which attached to and recorded actuations from MDIs
(Coutts, Gibson and Paton, 1992; Gong et al., 1988; Spector et al., 1986). Other
monitors have been developed, including the Doser CT, MDI Log, SmartMist and
the SmartTrack (Foster et al., 2012b; Weinstein, 2005; Julius, Sherman and
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Hendeles, 2002; Rand et al., 1992). Several of these monitors continue to be
available for use in clinical trials (Foster et al., 2012b; Spaulding et al., 2012; Apter
et al., 2011; Rand et al., 2007). Each device has its own strengths and limitations
and Table 1.17 is a summary of their key features.
The Turbuhaler Inhalation Computer, an electronic monitor for use with Turbohaler
DPIs, was developed for use in the 1990s, but was found to be highly unreliable
(Bosley, Parry and Cochrane, 1994). The monitor contained a microphone, which
recorded the ‘click’ heard when the inhaler was loaded by a patient, as well as the
noise associated with inhalation, and used this to record that a dose had been taken.
76/215 (35.3%) of monitors malfunctioned in the trial, with resulting impact on data
interpretation (Bosley, Parry and Cochrane, 1994).
At the time of PhD commencement in 2010, validated and reliable monitors for use
with the Symbicort Turbohaler (budesonide/formoterol DPI) were not available.
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Table 1.17: Key features of electronic monitoring devices
Monitor Function Features Accuracy Disadvantages
Smartinhaler
Tracker
(Nexus6, NZ)
Plastic casing into which the
MDI medication canister is
inserted
x Records date and time stamp to
the nearest second
x Data downloadable
x Can be re-used
x Stores up to 3200 logs
98-99% x Medication canister needs to be
securely inserted for accurate recording
x Vulnerable to moisture
x Inhalation not recorded
SmartTrack
(Nexus6, NZ)
Plastic casing which fits
around a standard MDI
canister and sleeve
x Records date and time stamp to
the nearest second
x Rechargeable battery
x Monitor is transferable
97-99% x Not available at the time of PhD
commencement
x Initial validation study published in
2012; further data on reliability
required
Doser CT
(MediTrack
Products,
USA)
Plastic sleeve that is placed
on top of a MDI canister.
Pressure-actuated sensor
records MDI canister
depression
x LCD counters display total
actuations remaining and total
number of actuations per day
x Records data for 45 days
x Transferable
94% x No date or time record; records number
of actuations only
x Unable to download data to a computer
x Inhalation not recorded
MDI Log
(Life Link
Monitoring,
USA)
Monitor which is
permanently attached to the
MDI and records actuation
and inhalation
x Records date and time of
actuation
x Records inhalation
x Data downloadable
90% x MDI must be sent to manufacturer for
installation of the monitor
x Monitor is not transferable between
inhalers
SmartMist
(Aradigm
Corp, USA)
Device which encloses the
entire inhaler except the
mouthpiece
x Records time and date
x Gives technique error feedback
x Data downloadable
100% x Significantly alters the appearance of
the inhaler
x May be considered too
large/inconvenient by some patients
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1.38.3 Covert electronic monitoring of inhaler use
There is a potential ethical issue regarding the use of covert electronic monitoring,
whereby participants are not informed that their inhaler use is being monitored, as
this may breach the requirement to provide fully informed consent (Riekert and
Rand, 2002; Rand and Sevick, 2000). Covert monitoring may however reduce the
occurrence of bias due to a change in patient behaviour and medication usage
patterns, which is a possible consequence of participant awareness of being
monitored. Prior studies have used this approach, whereby participants are not aware
of the detailed capabilities of the electronic monitors that they are using during the
study (Tashkin et al., 1991; Gong et al., 1988; Spector et al., 1986). In clinical trials
investigating patterns of medication use, which may subsequently help to provide
information on the risks and benefits of treatments used in clinical practice,
collection of data using covert monitoring is acceptable provided the risk to
participants is minimal (Riekert and Rand, 2002; Rand and Sevick, 2000).
1.38.4 Accuracy of electronic monitors
The validity of an electronic monitor refers to the ability of the monitor to actually
measure inhaler actuations as per its intended design. This can be achieved by
comparing measurements recorded by the monitor with those from one of the other
measures of medication use described above, or with another validated electronic
monitor of alternative design. However, given the limitations with non-electronic
measurement techniques and because electronic monitoring is likely to represent the
‘gold standard’ (i.e. the most accurate of the methods), demonstrating validity
requires careful validation processes.
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Validity can be established in a number of ways. Laboratory (‘bench’) testing under
standardised conditions is the usual first step. Actuations recorded by the electronic
monitor are compared to a diary log (Spector et al., 1986). The advantage of this
approach is that information on monitor performance in a variety of domains can
subsequently be used to inform clinical trial protocols. A disadvantage is that the
monitors are not exposed to ‘real-world’ conditions.
‘Field’ testing involves testing of monitor accuracy in a small sample of patients over
a short time-frame. This is generally undertaken after initial bench testing.
Recordings made by the monitor may be compared to a daily dairy of medication use
kept by the patient (Foster et al., 2012b). An advantage of this approach is that it
may provide information on monitor performance when exposed to ‘real-world’
conditions during use by asthma patients. A disadvantage is that data interpretation
may be limited by inaccuracies with the daily diary method. An alternative method
to validate the total number of doses recorded by the monitor may be to compare
with canister weight. This, however, does not provide information on validity in
recording patterns of use of medication.
1.38.5 Dose dumping
Dose dumping is the term used to describe the observation that some participants,
who are aware that the total number of inhaler doses used is being electronically
measured, intentionally actuate their inhalers in quick succession, to simulate
adherence to treatment and the trial protocol. As the electronic monitor is able to
record actuation date/time in addition to the total number of doses over a study
period, it is possible to identify days on which this pattern of use is observed.
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This practice was first described in a trial where ipratropium or placebo MDI use was
electronically monitored in a subset of COPD participants in the Lung Health Study
5DQG HW DO   ,Q WKLV VWXG\ GRVH GXPSLQJ ZDV GHILQHG DV  DFWXDWLRQV
within three hours. Using this definition, approximately 12-15% of their participants
had at least one dose dumping episode over four months. The authors (Rand et al.,
1992) observed that these episodes generally occurred either on the day of the
scheduled study visit or in the preceding few days.
In a study of adherence to non-bronchodilator MDI asthma therapy using the
Nebulizer Chronolog electronic monitor, ‘multiple simultaneous actuations’ (MSA)
ZHUHGHILQHGDVDFWXDWLRQVZLWKWKHVDPHWLPHVWDPS0DZKLQQH\HWDO
11/34 (32%) of participants were observed to have at least one day with MSA over
three months. 37% of days with MSA occurred either on the day of, or the day
preceding, a study visit. The authors suggested that this behaviour might have
indicated an attempt to convince the investigators that trial processes and medication
use were being adhered to. They also suggested that in trials using electronic
monitoring, measures to limit the impact of dose dumping data on the analysis
required further consideration.
A study investigating adherence to a maintenance combination anti-
inflammatory/SABA MDI (nedocromil/salbutamol) used Nebulizer Chronologs to
measure MDI use in 202 asthma patients (Braunstein et al., 1996). Dose dumping
was observed on the day of the study visit. The removal of electronic actuation data
on the day of the study visit was suggested as a measure to limit the impact of this
erroneous data on the final analysis.
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In a prior study of adherence to maintenance therapy using the Tracker electronic
PRQLWRUVGRVHGXPSLQJZDVGHILQHGDVDFWXDWLRQVZLWKLQWKUHHKRXUV&KDUOHVHW
al., 2007). This was observed on 53 occasions, with 12 episodes (23%) occurring on
the day of the study visit.
In summary, it is of importance that trials utilising electronic monitoring of MDI use
consider the impact that dose dumping may have on data collection and the final
analysis. There is, however, no consensus definition for dose dumping which can be
applied to clinical trials. Furthermore, high-dose use of inhaled therapy for actual
therapeutic use, rather than dose dumping, might be observed in more severe asthma
patients, in patients who are high reliever medication users and in trials where
monitoring of both maintenance and reliever asthma treatments are performed.
Consequently, it may be difficult to separate dose dumping from actual therapeutic
use of the inhaler by implementing a specific threshold value as used in the trials
above. An alternative approach is to remove electronic data on the day of study
visits prior to the final analysis, as dose dumping may occur on these days.
1.39 Smartinhaler Tracker electronic monitors
The Smartinhaler Tracker (Nexus6 Limited, Auckland, New Zealand) is a battery-
powered electronic monitor that records the date and time of MDI actuations. The
monitor comprises of a plastic casing (the monitor), into which a conventional
medication canister can be inserted. The monitor casing incorporates a battery,
switch and electronics which record the number, date and time (to the nearest
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second) of the depression of the canister during actuation. Thus, the monitor
combined with a medication canister can be used to measure use of inhaled therapy
delivered via an MDI.
A connection point is incorporated into the base of the casing, allowing the monitor
to be connected via a USB cable to a computer. Using dedicated computer software,
inhaler actuation data can be viewed, saved onto the computer or a compact disc
(CD) or transferred to a website-based database via the internet.
The Trackers are manufactured of plastic with similar properties to the commercial
MDI sleeves and with actuator designs which replicate those of their commercial
counterparts, in order to effect comparable drug delivery. Drug output and particle
size testing conducted by an independent laboratory have previously been undertaken
for the Ventolin Tracker and equivalent drug delivery to the commercial counterpart
has been demonstrated (Nexus6 Limited, 2011).
1.39.1 Bench validation studies
The monitor has been validated for use in two laboratory studies. The first study
tested the accuracy of 10 Trackers over 30 days, simulating maintenance or ‘low’
reliever medication use (two actuations performed twice per day) (Burgess et al.,
2006). Tracker performance in recording doses from salbutamol MDIs (100µg per
dose – Ventolin) was assessed in this study (two of the 10 monitors). Tracker
accuracy was compared with a diary log and with a previously validated electronic
monitor of alternative design, the Doser CT. In addition, accuracy of the Trackers in
recording rapidly-performed actuations (30 times in quick succession) was assessed.
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Five of the Trackers were 100% accurate in recording maintenance/low reliever
actuations, when compared to the diary or Doser CT. In the remaining five Trackers,
either the first or both the first and second doses were not recorded, but the
remainder of actuations were all recorded correctly. When the set-up process for the
monitors was repeated so that all Trackers were actuated during the process of
loading a medication canister, the subsequent doses were correctly recorded. All
date/time logs were 100% accurate when compared to the diary. No erroneous
additional actuations were recorded by any of the Trackers at any point. The
Trackers recorded 30 actuations in rapid succession with 100% accuracy.
Thus, with correct initial setup of the monitor, which involves actuating the monitor
during canister loading, this study established the validity of the Tracker monitors in
recording the number, date and time of salbutamol MDI actuations in the bench
setting.
The second study investigated the accuracy of Tracker monitors in measuring
actuations of budesonide/formoterol MDIs (200/6µg per dose - Vannair) (Chan et al.,
2009). Three monitors were tested over 48 hours, with both maintenance/low
reliever dosing and 30 doses performed in rapid succession. Tracker accuracy was
compared with a diary log. A spacer fit test was also undertaken.
Two of the three monitors were 100% accurate in recording maintenance/low
reliever doses. One monitor recorded one extra actuation on two occasions during
this period, most likely related to an incomplete depression of the canister during
actuation. All rapid actuations were correctly recorded. Date/time logs were
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recorded 100% accurately. The overall accuracy in recording actuations was 98%
and good spacer fit was documented.
This study demonstrated the validity of the Tracker monitors in recording the
number, date and time of budesonide/formoterol MDI actuations in the bench setting.
1.39.2 Smartinhaler Tracker use in clinical studies
The Smartinhaler Tracker has been utilised to measure adherence to therapy and
patterns of medication use in clinical studies in both adults (Turton, Glasgow and
Brannan, 2012; Perrin et al., 2010; Charles et al., 2007) and children (Klok et al.,
2012; Burgess, Sly and Devadason, 2010; Burgess et al., 2008; Burgess et al.,
2007).
Trackers with an audiovisual reminder function were used in a six-month RCT of
fluticasone MDI involving 110 adults (Charles et al., 2007). This study established
the feasibility of using covert electronic monitoring with the Tracker in a clinical trial
setting. Participants were not told that their medication usage was being recorded, as
this may have had the potential to change patient behaviour and therefore affect
interpretation of the data collected. This approach received Ethics approval as it was
unlikely to lead to patient harm and would improve the accuracy of the data obtained.
A six-month RCT involving 111 adults investigated adherence with single or
combination ICS/LABA inhaler therapy, using Trackers to monitor treatment with
fluticasone, salmeterol or fluticasone/salmeterol MDIs (Perrin et al., 2010).
Monitors were downloaded out of sight of participants at study visits, in order to
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preserve the practice of covert monitoring. The Trackers, whilst remaining patient-
specific, were re-used by reloading with new medication canisters at study visits.
Turton et al. (2012) investigated the feasibility of using bronchial hyper-
responsiveness as an aid to asthma management in 13 adults in primary care and
used Trackers to measure ICS use by MDI. In two of these patients, device
malfunction resulted in data loss (Turton et al., 2012).
In summary, the Tracker has been validated for use in laboratory studies and its
utility in the clinical trial setting has been established in long-term studies.
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1.40 Hypothesis
Inhaled corticosteroid/long-acting beta-agonist therapy delivered from a combination
inhaler is the mainstay of treatment in patients with moderate to severe asthma
(SIGN/BTS, 2012; GINA, 2011). It can be prescribed either in accordance with a
‘Standard’ fixed maintenance dose regimen together with a short-acting beta-agonist
for relief of symptoms, or according to the ‘SMART’ (Single combination inhaler as
Maintenance And Reliever Therapy) regimen, in which a combination
budesonide/formoterol inhaler is used for both maintenance and as-needed reliever
use. Randomised controlled trials show that in moderate to severe asthma, treatment
with the SMART regimen leads to a reduction in severe asthma exacerbations when
compared with the Standard regimen (Rabe et al., 2006a; O'Byrne et al., 2005). The
generalisability of this finding is limited by the reduction in maintenance ICS dose
which occurred at randomisation and the eligibility criteria for these studies which
excluded patients who had high baseline use of their reliever medication. As there
was no robust data on actual patterns of medication use, it is not possible to
determine whether the reduction in severe exacerbations with the SMART regimen is
due to more regular ICS exposure through as-needed reliever use in otherwise poorly
adherent patients, or self-titrated budesonide/formoterol use during worsening
asthma. Also, it is unknown if the SMART regimen leads to delays in seeking
medical care in the setting of severe exacerbations, or whether it may result in a
greater systemic corticosteroid load.
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This thesis reports on the results of a randomised controlled trial of SMART versus
Standard therapy in asthma patients at risk of severe exacerbations, using electronic
monitoring to determine patterns of actual medication use. Use of electronic
monitoring allowed beta-agonist overuse to be applied as a marker of risk of life-
threatening asthma (Abramson et al., 2001; Eisner et al., 2001; Suissa, Blais and
Ernst, 1994; Spitzer et al., 1992). The primary hypothesis was that treatment with
the SMART regimen would lead to a reduction in the risk of high beta-agonist use.
Secondary aims were to investigate whether patients treated with the SMART
regimen were less likely to seek medical review in the setting of beta-agonist overuse
and to determine whether any reduction in severe asthma exacerbations would be at a
cost of a higher systemic corticosteroid burden.
1.41 Aims of this thesis
x To determine the accuracy of self-reported use of inhaled asthma therapy
versus electronic monitoring of inhaler use, from a retrospective analysis of a
previously undertaken RCT.
x To validate the long-term accuracy of the Tracker electronic monitors used in
the principal RCT, during bench testing.
x To determine whether budesonide/formoterol when prescribed as per the
SMART regimen will reduce the risk of high beta-agonist use compared to
Standard therapy in real-world asthma patients with a recent exacerbation,
using electronic monitoring to measure actual medication use. The rationale
103
for this aim was that prior studies using self-report to measure medication use
have suggested that beta-agonist overuse is reduced by treatment with the
SMART regimen compared to the same fixed-dose of budesonide/formoterol
with SABA for relief (Rabe et al., 2006a; O'Byrne et al., 2005).
x To determine if the SMART regimen leads to an increased risk of high beta-
agonist use without medical review. The rationale for this aim was that the
greater intrinsic efficacy of formoterol together with its prolonged duration of
bronchodilatory action, as compared to salbutamol, may result in greater
delays in seeking medical assistance for patients using the SMART regimen
during worsening asthma compared to use of the Standard regimen. Delay in
seeking medical review during severe exacerbations of asthma may
contribute to a fatal outcome (Fraser et al., 1971).
x To determine whether budesonide/formoterol used as per the SMART
regimen reduces severe asthma exacerbations when compared to Standard
therapy in at risk asthma patients.
x To determine if the SMART regimen increases the systemic corticosteroid
burden compared to the Standard regimen. The rationale for this aim was
that treatment with the SMART regimen may allow exposure to high doses of
ICS and for a prolonged duration, which may contribute to an increased
systemic corticosteroid burden.
x To report on the performance of the Tracker electronic monitors in the
principal RCT, based on the use of pre-trial and within-trial quality control
protocols.
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Chapter Two: Accuracy of self-report versus electronic monitoring of MDI use
2.1 Introduction
Improving adherence to asthma therapy is a key priority to enhance asthma care
(Holgate et al., 2008; National Heart, Lung, and Blood Institute, 2007; Horne,
2006). Identifying non-adherence to prescribed maintenance inhaled treatment, such
as ICS or LABA, is therefore the first step in the process of improving patients’
adherence to treatment (Heaney and Horne, 2012). In addition, assessment of the use
of ‘reliever’ inhaled therapy, such SABAs, is a key element of monitoring current
asthma control (SIGN/BTS, 2012; National Heart, Lung, and Blood Institute, 2007;
Nathan et al., 2004; Juniper et al., 1999).
Patient self-report is the traditional method of measuring use of inhaled asthma
therapy (Pauwels et al., 1997; Greening et al., 1994). Self-report is an easy, cheap
and convenient method but has several significant limitations. Firstly, self-report
relies on the patient’s recollection of events, which may become inaccurate over
time. Secondly, information obtained via self-report may be inaccurate, due to
misrepresentation of use by the patient. Patients may therefore report what they
perceive their physician wishes to hear, in an effort to appear adherent to prescribed
maintenance treatment and/or not over-reliant on SABA treatment. Thirdly, self-
report does not allow information to be collected on patterns of use of medication.
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Electronic monitoring of inhaled asthma medication has been developed and
validated as a reliable and accurate method to collect data on treatment adherence
(Apter, Tor and Feldman, 2001; Simmons et al., 1998). Various comparisons of
self-report versus electronic monitoring have been undertaken (Bender et al., 2000;
Berg, Dunbar-Jacob and Rohay, 1998; Spector et al., 1986). These studies have
demonstrated the superiority of electronic monitoring over self-report as a measure
of medication use and have also shown that patients generally tend to overestimate
their adherence to maintenance treatment. It is therefore important to recognise the
limitations of self-report, particularly the potential discrepancy between what is
reported and the actual use of treatments.
In a recently published 24-week, prospective RCT of adherence with single or
combination ICS/LABA therapy in asthma, 111 patients were randomised to receive
fluticasone and salmeterol twice daily, either as a combination ICS/LABA inhaler or
as separate inhalers, to take in addition to their usual reliever therapy (Perrin et al.,
2010). Adherence to treatment during the study period was measured using covert
electronic monitoring of MDI actuation utilising Smartinhaler Tracker electronic
monitors. Additionally, data on adherence to treatment in the one week prior to
study visits were also collected by self-report questionnaire. This allowed a direct
comparison between self-report and electronic monitoring for the week prior to study
visits.
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2.2 Hypothesis
The hypothesis was that self-report was not an accurate measure of actual use and
that patients who under-used would over-report their use of maintenance inhaled
therapy.
2.3 Aim
The primary aim of this analysis was to investigate the association between self-
report and actual medication use as measured by electronic monitoring for single and
combination ICS and LABA MDI therapy.
2.4 Methods
This was a retrospective analysis of a prospective RCT (Australian and New Zealand
Clinical Trials Registration number ACTRN12606000508572) investigating
treatment adherence with single and combination ICS and LABA therapy. Full
details of the trial have previously been published (Perrin et al., 2010).
The RCT involved adults with stable asthma aged 16 to 65 who were randomised to
receive one of the two following treatment regimens for a duration of 24 weeks:
125µg fluticasone and 25µg salmeterol in a combination inhaler, two actuations
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twice daily (total four actuations per day); or, 125µg fluticasone and 25µg salmeterol
in two separate inhalers, two actuations twice daily (total four actuations per day for
each inhaler). Treatment adherence was monitored using Smartinhaler Tracker
electronic monitors.
Participants were seen in the clinic on five occasions over the 24-week study period.
Randomisation occurred at Visit 1 and Visits 2 to 5 were every six weeks thereafter.
Participants were not informed that the electronic monitor could record MDI
actuations and were not advised that adherence to treatment was the primary
outcome for the study. At Visits 2 to 5, data from the monitors were downloaded to
a computer, out of sight of participants. Monitors were cleaned, reloaded with new
medication canisters and returned to participants. Participants were also asked to
complete a self-report questionnaire on treatment use in the seven days prior to the
clinic visit using the following wording: ‘During the past week, it is estimated that
you will have used 28 puffs of (each) of your study inhalers. How many puffs of your
inhaler have you taken during the last week?’
For this analysis, electronic monitoring data for the week prior to study Visits 2 to 5
were extracted for each participant. Doses that were identified as being dose
dumping were removed from the analysis. As per the original study, dose dumping
was defined as six or more actuations within a five-minute period. Self-report data
that was incomplete or unanswered was also not included in the analysis.
Comparison was made between self-reported medication use and actual use as
measured by electronic monitoring at visits where both complete self-report data and
electronic monitoring data were available.
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2.4.1 Statistical methods
Measurement of agreement between the electronic monitor record of actuations and
self-report at each visit used Bland-Altman plots with calculation of limits of
agreement (Myles and Cui, 2007; Bland and Altman, 1999; Bland and Altman,
1986). Bland-Altman plots summarise agreement by relating the difference between
two measurements to the average of two measurements, in this case electronic
monitoring and self-report. The differences represent bias of one measurement with
respect to the other and the variability in the differences are represented on a plot,
together with limits of agreement defined as plus or minus two Standard Deviations
(SD) of the differences.
In addition, mixed linear models examined the extent to which variability in
electronic monitoring and self-report was due to variability between different
patients or variability within patients. In these models, there are fixed effects for
visit and whether the inhaler count was by electronic monitor versus self-report, as
well as an interaction between these two effects to test if differences depended on the
particular visit, and random effects for participants. Variance components and
calculation of the intra-class correlation (ICC) coefficient from the analyses illustrate
the proportion of variability due to the different participants and left-over variability
representing variability within participants. ICC varies from zero to one and a value
close to one is consistent with most of variability coming from different participants.
SAS version 9.2 was used.
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2.5 Results
There were 111 participants randomised (54 participants allocated to the separate
inhaler group and 57 participants to the combination inhaler group). The
characteristics of the study participants are summarised in Table 2.1.
Table 2.1: Characteristics of trial participants
Single inhalers group Combination inhaler
group
Age, years 49.2±11.2 45.4±13.8
FEV1, Litres 2.51±0.81 2.60±0.75
FEV1 % predicted 79.9±19.6 82.3±18.3
ACQ-7 score 1.3±0.7 1.2±0.7
Adherence (%) * 73.7±36.0 † /
76.7±30.5 ‡
82.4±24.5
Plus/minus values are mean ± SD. *: Adherence (defined as the number of doses taken as a
percentage of those prescribed) in the final 6-week period of the study; †: fluticasone single
inhaler; ‡: salmeterol single inhaler. FEV1: Forced Expiratory Volume in 1 second (Litres).
ACQ-7: Asthma Control Questionnaire-7.
There were 104 episodes of dose dumping which were not included in the analysis.
Paired data from 198 of a potential 216 (91.7%) study visits for the separate inhaler
group and 211 of a potential 228 (92.5%) study visits for the combination inhaler
group were included in the analyses. Data from 35 visits were not included due to
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incomplete self-report questionnaires (three visits), monitor malfunction, damage and
non-return of the inhalers at study visits (19 visits), or participant withdrawal (13
visits).
2.5.1 Fluticasone separate inhaler
Across the four study visits, the mean ± SD of the average of electronic monitoring
and self-report was between 22.6 ± 6.2 and 24.3 ± 8.3 actuations (Table 2.2). The
mean ± SD of electronic monitoring use minus self-report was between -4.6 ± 10.1
and -8.4 ± 12.2 actuations (Table 2.2). Figure 2.1 (a-d) shows Bland-Altman plots
for the four study visits. Limits of agreement for electronic monitoring and self-
report were wide, ranging between 20.2 and 25.6 actuations. The percentage of
participants whose self-reported use was the prescribed 28 puffs was between 62%
and 69%. Participants who under-used fluticasone were more likely to over-report
actual use, whilst those who over-used were more likely to under-report. The greater
the degree of under-use, the greater the magnitude of over-report and the greater the
degree of over-use, the greater the magnitude of under-report.
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Table 2.2: Self-report and electronic monitoring for the fluticasone separate
inhaler
Variable Visit 2 * Visit 3 † Visit 4 ‡ Visit 5 §
Self-reported use of 28 puffs,
number of participants (%)
34 (69.4) 32 (62.8) 33 (67.4) 31 (63.3)
Self-report, number of
actuations
27.1±5.3 26.5±6.4 26.4±6.0 27.4±5.5
Electronic monitor, number
of actuations
20.5±10.0 22.0±12.2 18.7±11.1 19.0±10.8
Electronic monitor minus
self-report, number of
actuations
-6.6±11.1 -4.6±10.1 -7.8±12.8 -8.4±12.2
Average electronic monitor
and self-report, number of
actuations
23.8±5.8 24.3±8.3 22.6±6.2 23.2±6.0
Limits of agreement, number
of actuations
Plus/minus
22.2
Plus/minus
20.2
Plus/minus
25.6
Plus/minus
24.4
*: N=49; †: N=51; ‡: N=49; §: N= 49. Plus/minus values are mean ± SD.
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Figure 2.1: Bland Altman plots for the difference between electronic monitor
and self report, against the mean of electronic monitor and self report, for the
fluticasone inhaler
a) Visit 2
Numbers are actuations
: Mean difference between electronic monitor and self-report
: Limits of agreement (plus or minus 2 SD of the mean difference between
electronic monitor and self-report)
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d) Visit 5
There was no evidence that the difference between electronic monitor and self-report
was different at the different visits, p for interaction 0.37. The estimated difference
for electronic monitoring minus self-report averaged over all visits was -6.8
actuations (95% CI -8.4 to -5.2). The variance components for patient variability
was 10.36 and residual variability 67.5, ICC 0.13.
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2.5.2 Salmeterol separate inhaler
Across the four study visits, the mean ± SD of the average of electronic monitoring
and self-report was between 23.4 ± 6.5 and 23.8 ± 6.4 actuations (Table 2.3). The
mean ± SD of electronic monitoring use minus self-report was between -3.9 ± 10.1
and -7.0 ± 11.1 actuations (Table 2.3). Figure 2.2 (a-d) shows Bland-Altman plots
for the four study visits. Limits of agreement for electronic monitoring and self-
report were wide, ranging between 16.8 and 22.2 actuations. The percentage of
participants whose self-reported use was the prescribed 28 puffs was between 60%
and 67%. Participants who under-used salmeterol were more likely to over-report
actual use, whilst those who over-used were more likely to under-report. The greater
the degree of under-use, the greater the magnitude of over-report and the greater the
degree of over-use, the greater the magnitude of under-report.
There was no evidence that the difference between electronic monitor and self-report
was different at the different visits, p for interaction 0.40. The estimated difference
for electronic monitoring minus self-report averaged over all visits was -5.0
actuations (95% CI -6.4 to -3.6). The variance components for patient variability
was 14.06 and residual variability 50.31, ICC 0.22.
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Table 2.3: Self-report and electronic monitoring for the salmeterol separate
inhaler
Variable Visit 2 * Visit 3 † Visit 4 ‡ Visit 5 §
Self-reported use of 28 puffs,
number of participants (%)
33 (67.4) 30 (60.0) 32 (65.3) 31 (62.0)
Self-report, number of
actuations
26.3±3.2 25.9±4.7 25.7±4.2 26.9±3.8
Electronic monitor, number
of actuations
21.3±9.9 21.7±10.6 21.8±10.4 19.9±11.5
Electronic monitor minus
self-report, number of
actuations
-5.0±8.4 -4.2±10.4 -3.9±10.1 -7.0±11.1
Average electronic monitor
and self-report, number of
actuations
23.8±6.0 23.8±6.4 23.7±6.2 23.4±6.5
Limits of agreement, number
of actuations
Plus/minus
16.8
Plus/minus
20.8
Plus/minus
20.2
Plus/minus
22.2
*: N=49; †: N=50; ‡: N=49; §: N=50. Plus/minus values are mean ± SD.
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Figure 2.2: Bland Altman plots for the difference between electronic monitor
and self report, against the mean of electronic monitor and self report, for the
salmeterol inhaler
a) Visit 2
Numbers are actuations
: Mean difference between electronic monitor and self-report
: Limits of agreement (plus or minus 2 SD of the mean difference between
electronic monitor and self-report)
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d) Visit 5
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2.5.3 Fluticasone/salmeterol combination inhaler
Across the four study visits, the mean ± SD of the average of electronic monitoring
and self-report was between 24.3 ± 5.7 and 25.0 ± 6.0 actuations (Table 2.4). The
mean ± SD of electronic monitoring minus self-report was between -2.2 ± 8.4 and -
4.3 ± 9.0 actuations (Table 2.4). Figure 2.3 (a-d) shows Bland-Altman plots for the
four study visits. Limits of agreement for electronic monitoring and self-report were
wide, ranging between 15.8 and 18.0 actuations. The percentage of participants
whose self-reported use was the prescribed 28 puffs was between 63% and 70%.
Participants who under-used fluticasone/salmeterol were more likely to over-report
actual use, whilst those who over-used were more likely to under-report. The greater
the degree of under-use, the greater the magnitude of over-report and the greater the
degree of over-use, the greater the magnitude of under-report.
There was no evidence that the difference between electronic monitor and self-report
was different at the different visits, p for interaction 0.58. The estimated difference
for electronic monitoring minus self-report averaged over all visits was -3.4
actuations (95% CI -4.6 to -2.3). The variance components for patient variability
was 11.64 and residual variability 35.20, ICC 0.25.
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Table 2.4: Self-report and electronic monitoring for the fluticasone/salmeterol
combination inhaler
Variable Visit 2 * Visit 3 † Visit 4 ‡ Visit 5 §
Self-reported use of 28 puffs,
number of participants (%)
37 (69.8) 34 (66.7) 36 (67.9) 34 (63.0)
Self-report, number of
actuations
26.5±4.1 26.5±4.9 26.0±3.6 27.1±4.3
Electronic monitor, number
of actuations
23.4±9.5 22.2±9.0 23.8±8.7 23.0±7.6
Electronic monitor minus
self-report, number of
actuations
-3.1±8.3 -4.3±9.0 -2.2±8.4 -4.1±7.9
Average electronic monitor
and self-report, number of
actuations
25.0±6.0 24.3±5.7 24.9±5.1 25.0±4.8
Limits of agreement, number
of actuations
Plus/minus
16.6
Plus/minus
18.0
Plus/minus
17.4
Plus/minus
15.8
*: N=53; †: N=51; ‡: N=53; §: N=54. Plus/minus values are mean ± SD.
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Figure 2.3: Bland Altman plots for the difference between electronic monitor
and self report, against the mean of electronic monitor and self report, for the
fluticasone/salmeterol combination inhaler
a) Visit 2
Numbers are actuations
: Mean difference between electronic monitor and self-report
: Limits of agreement (plus or minus 2 SD of the mean difference between
electronic monitor and self-report)
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d) Visit 5
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2.6 Discussion
This study demonstrates that self-report of single and combination ICS and LABA
inhaler use was inaccurate in adult asthma patients with relatively high levels of
adherence in the setting of an RCT. Participants who under-used their inhaler
therapy were more likely to over-report actual use, whereas those who over-used
their inhaler therapy were more likely to under-report actual use. Furthermore, the
greater the degree of under-use, the greater the magnitude of over-report and
likewise, the greater the degree of over-use, the greater the magnitude of under-
report. These findings illustrate the limitations of self-reported inhaler use and
justify the use of electronic monitoring as the preferred option to measure patterns of
inhaled asthma medication use in a clinical trial.
Several conclusions can be drawn from these results. The limits of agreement were
wide, ranging from plus or minus 15.8 to 25.6 inhalations, illustrating the inaccuracy
of self-report when compared to actual use as measured by electronic monitoring. In
addition, self-report consistently over-estimated actual inhaler use by a mean of 2.2
to 8.4 inhalations over a one-week period, with the difference between self-report
and electronic monitoring similar with the different medications. These finding are
consistent with studies correlating electronic data with self-report of medication use
(Foster et al., 2012a; Burgess et al., 2008) and demonstrate the superiority of
electronic monitoring compared to self-report.
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Patients who under-used their maintenance treatments tended to over-report their use.
This may be particularly relevant when using self-report to assess medication use in
patients with poor asthma control, when knowledge of adherence to current treatment
is important prior to modifying a management regimen. Conversely, participants
who over-used their treatment tended to under-report their medication use. Although
not assessed in this study, over-use of inhaled asthma medication is most likely to
occur with bronchodilator medications which are prescribed to be taken as-required
for relief of symptoms (Patel, Perrin and Beasley, 2011; Beasley et al., 2009b;
Diette et al., 1999; Windom et al., 1990a). Thus, the use of self-report to assess
‘reliever’ medication use in patients who over-use their medications is likely to
underestimate actual use in this setting.
The greater the degree of under-use of treatment by patients, the greater the
magnitude of over-reporting of their use. Similarly, the greater the degree of over-
use of treatment, the greater the magnitude of under-reporting of their use. These
findings have implications for trials investigating patterns of use of inhaled therapy,
as self-report may be particularly unreliable in identifying those patients who either
markedly under- or over-use their treatments.
The self-report questionnaire used in this study prompted the participants with the
number of inhalations that were prescribed i.e. 28 inhalations during the seven day
period. Approximately two-thirds of patients entered this value in the self-report
questionnaire, indicating full adherence to prescribed treatment. This may have
relevance to the phrasing of self-report questionnaires in a clinical setting, whereby a
prompt of the correct answer might affect the response from the patient. The
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importance of the approach used during questioning when discussing medication
adherence with patients has recently been highlighted in another study (Foster et al.,
2012a). Alternatively, electronic monitoring may be used in place of self-report
questionnaire in the clinical trial setting.
Though study participants were not explicitly informed about the capabilities of the
electronic monitors used in the trial, there is a possibility that some patients became
aware that their medication use was being monitored, which may have affected their
behaviour. One consequence of this may have been the occurrence of dose dumping,
whereby patients actuated their inhaler numerous times within a short period of time
in order to simulate adherence to medication use. This is a recognised limitation of
electronic monitoring in general (Simmons et al., 2000). This pattern of medication
use was identified and removed prior to analysis, in order to minimise that possibility
of erroneous data being included in the analysis. The definition of dose dumping (six
or more actuations within a five minute period) was more stringent than that used
previously (Rand et al., 1992), as this current analysis involved monitoring of fixed-
dose maintenance therapy rather than as-required short-acting bronchodilator
therapy. However, the identification of dose dumping is limited by the lack of a
consensus definition. For patients in whom reliever medication is electronically
monitored, this approach may lead to data from actual ‘high use’ of medication being
erroneously removed from the analyses. An alternative approach may be to remove
data on the day of study visits prior to performing the analyses, as dose dumping may
occur on the day of the study visit (Rand et al., 1992).
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2.7 Conclusions
Electronic monitoring is more accurate than self-report in measuring inhaled asthma
medication use. Self-report represents the standard method used in clinical practice
to assess medication adherence. Knowledge of its limitations will enable clinicians
to better understand information provided by this measure of medication use,
especially when used to make treatment decisions. In clinical trials where patterns of
use of medication are being investigated, the use of electronic monitoring is the
preferred option to collect data on actual use of treatment (Foster et al., 2012a; Rand
et al., 2012).
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Chapter Three: Smartinhaler Tracker electronic monitor six-month
validation study
3.1 Introduction
The Smartinhaler Tracker (‘Tracker’) is an electronic monitor for use with MDIs
which records the date and time (to the nearest second) of MDI actuations. This data
are stored on the monitor and can then be uploaded, via the internet, to a website-
based database via a USB computer connection and dedicated computer software
(Connection Centre, Nexus6 Limited, Auckland, New Zealand).
During the data upload process, a backup copy of the data on the monitor (in
Microsoft Excel format) is automatically copied to the computer hard-drive.
Therefore, the three elements of the monitoring system are the monitor itself, the
database of medication usage retrieved from the monitor and the interface between
the two. Satisfactory functioning of all three elements is required for data accuracy.
The Tracker has previously been validated for use in short-term bench studies (Chan
et al., 2009; Burgess et al., 2006) but no data exist on the accuracy of the monitors
over prolonged periods or the reliability of all three elements of the monitoring
system, when tested under laboratory conditions.
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3.2 Hypothesis
The hypothesis was that provided pre-use checks of monitor function were
performed, the Tracker monitors would be highly reliable in recording the number,
date and time of MDI actuations when tested over a six-month period under
standardised laboratory conditions.
3.3 Aims
The aims of this validation study were:
1. To perform pre-use checks to identify faulty monitors prior to
commencing six-month testing.
2. To determine the accuracy of the Tracker monitors in recording the
number of MDI actuations over 24-weeks of use, with both ‘high’ and
‘low’ use actuations.
3. To determine the accuracy of the monitor clock.
4. To determine the accuracy of the monitor in recording time and date logs.
5. To determine monitor accuracy in retaining medication usage data over
an eight-week period.
6. To assess functioning of the monitor after an eight-week period without
use.
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7. To assess the reliability of monitors to not record spurious actuations
during an eight-week period without use.
8. To determine the battery life of the monitors over the testing period.
9. To assess the performance of the software used to upload data from the
monitors and the accuracy of the website database.
10. To relate these validation study findings to the use of the monitors in the
SMART study clinical trial, in order to provide guidance for the trial
protocols to maximise data integrity.
3.4 Methods
A total of 22 Tracker monitors were included in this 24-week validation study. Half
were loaded with Vannair (budesonide/formoterol 200/6µg per actuation,
AstraZeneca Limited, Auckland, New Zealand) medication canisters (Figure 3.1) and
half with Ventolin (salbutamol 100µg per actuation, GlaxoSmithKline Limited,
Auckland, New Zealand) medication canisters (Figure 3.2). Testing was undertaken
at 0, 8, 16 and 24 weeks, to replicate study windows in a 24-week clinical trial. MDI
testing was undertaken in a dedicated office area and under standardised conditions
each time by two persons together (Mitesh Patel and Richard Beasley).
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Figure 3.1: Smartinhaler Tracker for budesonide/formoterol (VannairMDI)
Connection point to
computer via USB cable
Unique monitor
identification number
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Figure 3.2: Smartinhaler Tracker for salbutamol (Ventolin MDI)
Connection point to
computer via USB cable
Unique monitor
identification number
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One investigator was responsible for inhaler actuation whilst the other investigator
maintained a paper diary of the number, date and time of actual actuations
performed. This method was utilised to minimise the chance of investigator error
affecting the interpretation of electronic actuation data.
The key elements of monitor function that were tested are summarised in Table 3.1.
3.4.1 Pre-use checks (Week 0)
22 monitors (11 Vannair and 11 Ventolin) were reset, loaded with a medication
canister and then reset again. The reset function was performed by connecting the
monitor to the computer via a USB connection and utilising the Connection Centre
software; this cleared data from the memory of the monitors and updated the monitor
clock. At every canister re-load during the testing process, the monitor was actuated
simultaneously in order to ensure correct canister insertion. Monitors were then
actuated as follows: two actuations separated by 10 to 20 seconds, repeated once at
least two hours later, for two days (total eight actuations). This pattern was chosen to
act as an initial screen to identify malfunctioning devices early in the testing process.
The monitors were uploaded and the number of actuations together with the date and
time of recordings analysed. Functioning monitors went on to complete the
remaining testing process.
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Table 3.1: Monitor functions tested over the 24-week period
Monitor function tested Week
0
Week
8
Week
16
Week
24
Reset * X X
Loading with medication canister † X X
Initial screen of monitor ‡ X
Low use actuations § X X X
+LJKXVHDFWXDWLRQVۅ ; ;  ;
Actuation time and date X X X
Upload of data to website X X X
Preview of data ¶ X X
Erroneous actuation check during
8-week period without use
X
Storage of electronic data for an 8-
week period
X
Accuracy of monitors in recording
actuations after 8 weeks of no use
X
Comparison of uploaded website
data to diary data
X X
Comparison of computer backup
data to diary data
X X
Monitor clock accuracy over 8
weeks
X
Monitor battery charge X
*: Data cleared from monitor memory and clock synchronised with computer; †:
the monitor was actuated during every canister reload to ensure correct insertion; ‡:
initial screen comprised of 2 actuations performed twice per day for 2 days (n=176
actuations); §: low use actuations comprised of 2 actuations performed twice per
GD\RQD WRWDORIGD\VRYHU WKHZHHNSHULRG Q DFWXDWLRQV ۅKLJKXVH
actuations comprised of 8 actuations performed three times per day on a total of 3
days over the 24-week period (n=1440 actuations); ¶: visual inspection of data on
monitor without uploading of data to website.
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3.4.2 High use (Week 0)
Eight actuations were performed, repeated on two other occasions on the same day,
with each actuation separated by 10 to 20 seconds (total 24 actuations). This pattern
was chosen to reflect ‘high’ reliever medication usage, for instance, around the time
of worsening asthma control.
3.4.3 Low use (Week 0)
Two actuations separated by 10 to 20 seconds, repeated once at least two hours later
on the same day (total four actuations). This pattern was chosen to reflect
maintenance or ‘low’ reliever medication use. Monitors were uploaded and canisters
removed and re-inserted to simulate canister change. A reset was performed and
checked to ensure no actuations were recorded and the monitors were then stored in a
locked cabinet without use for eight weeks.
3.4.4 Week 8
The stored monitors were ‘previewed’ to identify any extra doses that may have been
erroneously recorded whilst the monitors were not in use. The preview function
allows data on the monitors to be viewed on a computer, without uploading to the
central database. The monitors were then reset and previewed to ensure that reset
had occurred correctly. Testing for four consecutive days occurred as follows. Days
1 and 2: two actuations separated by 10 to 20 seconds, repeated once at least two
hours later on the same day (‘low use’). Day 3: eight actuations were performed,
repeated on two other occasions on the same day, with each actuation separated by
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10 to 20 seconds (‘high use’). Day 4: two actuations separated by 10 to 20 seconds,
repeated once at least two hours later on the same day (‘low use’). Monitors were
previewed for data accuracy and then stored for eight weeks with the data stored on
the monitor.
3.4.5 Week 16
All data from the monitors was uploaded to the website, thereby checking the
accuracy of data retention on the monitors from the previous eight-week period.
This also tested the process of data backup to the computer hard drive, the
performance of the Connection Centre software and transfer to the website database.
The medication canisters were removed and re-inserted. The monitors were
previewed and any recorded actuations noted. The monitors were then stored for
eight weeks in a locked cabinet without use.
3.4.6 Week 24
Monitors were tested for four consecutive days as per the process in Week 8. This
tested the accuracy of monitor function after an eight-week period without use and
after a canister change. Data was then uploaded to the website and analysed for
accuracy. A measurement of clock discrepancy between the time recorded by the
Tracker and an external ‘real-time’ clock was made. Battery charge was recorded.
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3.5 Results
The results of the 24-week testing for all 22 monitors are summarised in Table 3.2.
3.5.1 Pre-use checks
Two of 22 Smartinhalers (9%) failed during the initial screen (one each of
budesonide/formoterol and salbutamol) and were subsequently removed from further
testing. One of these monitors (loaded with budesonide/formoterol) recorded a
correct number of actuations but all date/time logs were incorrect. The first two
actuations were recorded at the correct date but a time that was incorrect by four
hours in the future. The next two actuations, which were performed two hours later,
were recorded as having occurred over 12 hours after the actual time. The other
monitor (loaded with salbutamol) recorded the correct number and time of doses, but
with an incorrect date for all actuations. The date was incorrect by 10 years in the
past.
3.5.2 Accuracy of recording the number of MDI actuations
Overall accuracy in recording the number of actuations performed throughout the
entire testing period was 99.7% (2170 of 2176 doses correctly recorded). During
simulated maintenance or low reliever use, accuracy of recorded actuations was
98.9% (554 of 560 doses correctly recorded (i.e. six low use doses not recorded).
During simulated high use, all actuations were correctly recorded (all 1440 doses
recorded).
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Table 3.2: Results of the testing process
Monitor function tested Accuracy
Number of monitors completing full testing
period (%)
20 (91%) *
Overall accuracy in recording number of
actuations over 24 weeks (%)
2170 recorded of 2176
actuations performed (99.7%)
Accuracy during low use † (%) 554 recorded of 560 actuations
performed (98.9%)
Accuracy during high use † (%) 1440 recorded of 1440
actuations performed (100%)
Accuracy at Week 24 (%) versus
Accuracy at Weeks 0 to 16 † (%)
Week 24: 716 recorded of 720
actuations performed (99.4%)
Weeks 0 to 16: 1278 recorded
of 1280 actuations performed
(99.8%)
Accuracy in recording actuation time & date ‡
(%)
2160 actuations accurate of
2176 performed (99.3%)
Number of extra actuations recorded (% of total) 8 extra actuations § (0.37%)
Number of monitors in which extra or missed
actuations occurred during testing
2 Ventolin Trackers
Number of erroneous actuations during 8 weeks
without use
0
Data retention for 8 weeks (%) 100%
Accuracy after 8 weeks of no use (%) 716 recorded of 720 actuations
performed (99.4%)
Accuracy of website data (%) 100%
Accuracy of computer backup of data (%) 100%
0HDQ6'PRQLWRUFORFNDFFXUDF\PPVVۅ 
Battery charge at Week 24 Full charge for all monitors
*: 1 Vannair and 1 Ventolin monitor failed during Week 0 Initial Screen
†: Accuracy in recording the number of actuations performed
‡: Accommodating clock drift
§: 4 during testing period and 4 outside of testing period (at the time of computer
connection)
ۅEstimate of discrepancy between monitor clock and actual time occurring over 8 weeks
m: minutes; s: seconds
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The total number of extra actuations erroneously recorded was eight (0.37% of total
number of actuations performed). Of these eight extra actuations, four (50%) were
recorded at the time of computer connection (e.g. preview or upload) and outside of
the testing period. A further three occurred during low use actuation and one during
high use actuation. The extra or missed actuations that occurred during testing were
in the same two salbutamol Trackers.
Monitor accuracy at Week 24 (716 recorded of 720 actuations performed) was
comparable to that during the first 16 weeks of use (1278 recorded of 1280
actuations performed).
3.5.3 Accuracy of the monitor clocks
An estimate of mean ± SD time drift between the actual time and the Tracker clock
times was 5 min 10 seconds ± 52 seconds over an eight-week period.
3.5.4 Accuracy in recording date and time of actuations
Accommodating the drift in monitor clocks over time, overall accuracy in the 22
monitors in recording date and time was 99.3% (2160 actuations correct of 2176
performed). With identification and removal of the two faulty monitors during the
pre-use checks, all the 20 monitors completing the full 24-week testing period were
100% accurate in recording date and time.
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3.5.5 Accuracy in retaining data over an eight-week period
Monitors were 100% accurate in retaining stored electronic logs for an 8-week
period, with no additional logs recorded during this period.
3.5.6 Function after an eight-week period without use
716 of 720 actuations (99.4%) were recorded correctly after an eight-week period
without use.
3.5.7 Reliability in not recording spurious actuations during an eight-week period
without use
None of the monitors recorded spurious logs during an eight-week period without
use.
3.5.8 Battery life during the testing period
Battery charge was at full capacity (4 bars out of 4) in all monitors over the 24-week
period.
3.5.9 Performance of the computer software and website database
Data accuracy on the backup Excel files saved onto the hard drive of the computer
and on the website database was compared with the written diary; transfer and
storage of data was 100% accurate. The Connection Centre software performed
reliably to preview, upload and reset the monitors.
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3.6 Discussion
This study has demonstrated that the Smartinhaler Tracker electronic monitors are
accurate devices for measuring inhaled asthma medication use over a 24-week
period, in a strictly controlled laboratory setting, providing initial pre-use checks are
performed. The study has provided information on the monitors’ reliability and
accuracy in a variety of domains and builds on prior knowledge gained from
electronic monitoring use (Spector et al., 1986). Additionally, the validation process
tested three key elements of data acquisition: monitor accuracy, integrity of the
stored database of information retrieved from the electronic monitor and the software
interface between the monitor and the database. The information gained from this
validation process has helped to guide the clinical trial protocols to identify
malfunctioning devices, both before and during patient use, in the primary RCT.
The Smartinhaler Trackers proved to be highly accurate in recording MDI actuations
and their time and date, in keeping with prior short term validation studies (Chan et
al., 2009; Burgess et al., 2006). This monitoring system therefore allows for
accurate monitoring of MDI actuation in the context of a clinical trial and allows data
on medication usage to be collected in both maintenance/low use and high use
settings. These results allow confident interpretations to be made from recorded
data, especially in situations where there is particularly low use (e.g. non-adherence)
or high use (e.g. over-use) of medication.
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In addition, the monitors were highly reliable in retaining stored data for an 8-week
period and in functioning accurately after 24 weeks of testing. This simulates their
use in a clinical trial setting, whereby they would be required to retain stored data in
between study visits and may be used over a prolonged period. Using the validation
process described above, the monitors did not record spurious logs during periods
without use. This reflects the trial setting whereby patients may use their inhalers
intermittently, particularly if given access to more than one inhaler to use
simultaneously. Storage of monitors without use might also occur prior to trial
dispensing or in the case of emergency ‘backup’ inhalers given to trial participants
which remain unused for a period of time. In both of these instances, the validation
process has demonstrated that spurious logs are unlikely to occur.
Monitors were also reliable in functioning accurately after an eight-week period of
storage. In the trial setting, emergency or spare MDIs may be stored for a period of
time and then used or dispensed without any further checks of function. Battery
charge was normal for all monitors. In the trial setting, the number of actuations
recorded per monitor is likely to be greater than the number per monitor recorded in
this laboratory study (108 actuations); hence, this may impact on battery life and
within-trial checks of battery function may be considered.
An important part of this validation process was to also test the integrity of the
software used to upload the data from the monitors as well as the database of
information created from monitor uploads. This is of particular relevance for
multicentre trials, where multiple computers in different locations may be used to
upload information. It was noted that the four extra recorded actuations that
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occurred outside of the testing period happened around the time of connection of the
monitor to the computer for upload or preview, suggesting that either a software
issue or unintentional actuation by the investigator was responsible. On further
discussion with the monitor manufacturer, it was suggested that a cable error in the
connection from the monitor to the computer might also be a factor leading to
spurious extra actuations. This information may have implications for the data
analysis process. Data recorded on the day of the study visit could be removed from
the final database, in order to reduce the chance of erroneous actuations being
included in the analysis. This may also have the effect of removing dose-dumping
data from the analysis (Rand et al., 1992). Apart from this issue, the software
interface and data storage spreadsheets were found to be robust and accurate.
The occurrence of extra (or duplicate) actuations occurring during testing was
extremely low (4/2176 actuations). Three of these four logs were during low use
testing and one was during high use testing. In the RCT setting, the occurrence of
these duplicate actuations may occur equally in both groups due to the process of
random allocation. Considered together, this further supports the view that data
recorded by these monitors reflects actual use of medication and that the occurrence
of duplicate actuation logs is unlikely to affect interpretation of study results.
The results of the testing process described above can have significant implications
for clinical trial conduct utilising these monitors. On initial screening, it was
identified that one salbutamol and one budesonide/formoterol MDI incorrectly
recorded the time or date of actuations, even though the number of actuations
performed was recorded correctly. An initial abbreviated Quality Control protocol
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may be incorporated into the trial process, in which all monitors are tested for
accuracy in recording the number of actuations and date/time prior to use by
participants. This would allow faulty monitors to be removed prior to trial use. This
study did not assess the ‘real-world’ use of the monitors. Although accuracy was
high in monitors that passed the initial screening, there is a potential for malfunction
during real-life use by patients. For example, due to its electronic components, the
monitor may be vulnerable to the effects of moisture, which could affect its
performance in recording actuations. Additional checks of monitor function by
investigators prior to study visits may help to identify monitors damaged during
participant use. Updates to the software and connecting cables may be implemented,
to reduce the possibility of spurious doses being recorded at the time of computer
connection. Data backup processes may be implemented to both safeguard uploaded
data and allow malfunctioning monitors to be returned to the manufacturer for data
retrieval.
A specific limitation of the Trackers, inherent to most electronic MDI monitors, is
that they record inhaler actuation, but not necessarily medication inhalation. Thus,
there is the possibility that some patients may actuate the MDI but not necessarily
inhale the medication. Prior validation studies have suggested that incorrect loading
of the inhaler with a medication canister may be responsible for missed actuations
(Chan et al., 2009; Burgess et al., 2006). To address this issue, the MDI was
actuated every time a canister insertion was performed, to ensure correct loading of
the canister.
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3.7 Conclusions
The Tracker electronic monitors are highly accurate in recording MDI actuations in a
laboratory setting, providing initial pre-use checks are performed. Validating the
function of these electronic monitors has allowed an understanding of their strengths
and limitations and has helped to inform the study protocols for their use in the
SMART study RCT, in order to safeguard data acquisition and minimise erroneous
data collection.
3.8 Key recommendations for the Quality Control protocols for the SMART
study RCT
Based on the above validation process, the key points to be considered for inclusion
into the protocols for the use of these monitors in the SMART study RCT are as
follows:
1. Pre-use checks performed at the coordinating trial site, involving two
actuations separated by 10 to 20 seconds, repeated once at least two hours
later, are recommended for all MDIs prior to trial use.
2. MDIs passing pre-use checks can be stored and then dispensed to
participants at Visit 1 without a requirement for additional checks.
3. Backup emergency MDIs dispensed to participants do not require repeat
testing if they remain unused.
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4. Spare MDIs provided to sites may be dispensed without a requirement for
additional checks.
5. Use of an updated cable to connect monitors to a computer may reduce
the occurrence of spurious actuations due to cable errors.
6. Within-trial checks of monitor accuracy (for example, in recording the
number/date/time of actuations and battery life) at Visits 2, 3 and 4 may
help to identify monitors malfunctioning or damaged after the pre-use
checks.
7. Checks of monitor clock accuracy on return of inhalers from participants
may identify erroneous data prior to upload to the central database.
8. Creating backup copies of the inhaler use data on the computer hard drive
may provide a safety net in case of website malfunction and allow data to
be saved in an alternative format (e.g. compact disc).
9. Medication canisters should be inserted firmly into the monitors at every
canister reload to ensure correct placement.
10. Removal of data on the day of the study visit could prevent the minority
of erroneous actuations occurring during monitor connection to the
computer from being included in the analyses.
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Chapter Four: Methods for the SMART study randomised controlled trial
4.1 Overview
The study was a 24-week, open-label, parallel-group, multicentre randomised
controlled trial of the efficacy and safety of SMART versus Standard therapy in adult
asthma patients at risk of severe exacerbations. The study was conducted at four
primary healthcare practices and one hospital in New Zealand.
The two treatments were:
1. The ‘SMART’ group: 200/6µg budesonide/formoterol MDI (Vannair,
AstraZeneca NZ Limited, Auckland, New Zealand; this is the MDI
formulation of Symbicort Turbohaler), two actuations twice daily as
maintenance with one extra actuation as-needed for relief of symptoms.
2. The ‘Standard’ group: 200/6µg budesonide/formoterol MDI, two actuations
twice daily as maintenance with one to two actuations of 100µg salbutamol
MDI (Ventolin, GlaxoSmithKline NZ Limited, Auckland, New Zealand) as-
needed for relief of symptoms.
The trial was prospectively registered on the Australian New Zealand Clinical Trials
Registry (ACTRN12610000515099). The study protocol is included in Appendix A.
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4.2 Participants
4.2.1 Inclusion criteria
The inclusion criteria were:
1. Physician’s diagnosis of asthma.
2. Age 16 to 65 years.
3. Current prescription for ICS.
4. No change in the ICS dose in the preceding month. The rationale for this
inclusion criterion was to allow a period of stability prior to enrolment for
patients with a recent change in ICS dose. Patients were eligible one month
after the ICS dose change.
5. At least one asthma exacerbation in the preceding year. This was defined as a
presentation to a General Practice (GP) or ED resulting in a prescription of
oral corticosteroids and/or treatment with spacer-delivered or nebulised
bronchodilator, or self-administration of prednisone for asthma for at least
three days. The rationale for the use of this definition for an asthma
exacerbation was to allow enrolment of patients with prior moderate or severe
asthma exacerbations (Reddel et al., 2009).
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4.2.2 Exclusion criteria
The exclusion criteria were:
1. Onset of respiratory symptoms after the age of 40 in current or ex-smokers
ZLWKSDFN\HDUVPRNLQJKLVWRU\7KHSXUSRVHRIWKLVH[FOXVLRQFULWHULRQ
was to reduce the chance of patients with chronic obstructive pulmonary
disease (COPD) being enrolled into the study.
2. Diagnosis of COPD, interstitial lung disease, or bronchiectasis. The purpose
of this exclusion criterion was to screen out any patients in whom asthma was
not the primary respiratory diagnosis.
3. Diagnosis of congestive heart failure. The rationale for this exclusion
criterion was to screen out any patients with left ventricular failure, in whom
use of reliever inhaler therapy may have been due to misattributed symptoms
from heart failure.
4. Unstable coronary artery disease or unstable angina. The purpose of this
exclusion criterion was to screen out patients at high short-term risk of acute
ischaemic cardiac events, in whom the risks of beta-agonist therapy may be
greater (Au et al., 2000).
5. Atrial fibrillation or other cardiac arrhythmias. The purpose of this exclusion
criterion was to screen out patients with diagnosed cardiac arrhythmias, in
whom there may be an increased risk of development of pathological
tachycardias following high-dose beta-agonist use (Kung, Croley and
Phillips, 1987).
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6. Use of an at-home nebuliser [unless patients agreed to withhold nebuliser use
for the study duration]. The rationale for this exclusion criteria was to reduce
the possibility of concurrent nebulised beta-agonist use during study
participation, as this may have increased the risk of delay in seeking medical
help by patients during worsening asthma (Sears et al., 1986).
7. Treatment with oral prednisone in the previous four weeks. The rationale for
this exclusion criterion was to allow a period of stability prior to enrolment,
for patients with a recent severe asthma exacerbation. Patients were eligible
four weeks from the start of their course of prednisone.
8. Uncontrolled depression or anxiety disorder. This exclusion criterion was
included to screen out patients with severe depression or anxiety, who may
not have been able to meet the requirements of the study visits and trial
protocol due to their illness.
9. Malignancy with life expectancy of less than one year.
10. Unwilling or unable to switch from current asthma treatment regimen or
management plan.
11. Inability to understand the study requirements and/or unwillingness to give
consent to participate in the study.
12. Any other safety concern at the investigator’s discretion.
4.3 Study sites
The trial was conducted at three GP practices [Henderson Medical Centre, Auckland,
New Zealand; CentralMed General Practice, Tauranga, New Zealand; Papamoa
154
3LQHV0HGLFDO&HQWUH7DXUDQJD1HZ=HDODQG@RQH0ƗRULSULPDU\KHDOWKFDUHFOLQLF
>7X .RWDKL 0ƗRUL $VWKPD 7UXVW /RZHU +XWW 1HZ =HDODQG@ DQG RQH KRVSLWDO VLWH
[MRINZ, Wellington Regional Hospital, Wellington, New Zealand] (Table 4.1).
4.3.1 Recruitment of participants at the distant sites
Two GP practices [Henderson Medical Centre and CentralMed General Practice]
recruited participants from their patient databases and from advertising in the local
community. One GP practice [Papamoa Pines Medical Centre] recruited solely from
LWVSDWLHQWGDWDEDVH 7KH0ƗRULSULPDU\KHDOWKFDUHFOLQLFUHFUXLWHGIURPLWVSDWLHQW
database.
4.3.2 Recruitment of participants at the MRINZ site
The MRINZ site recruited from ED and hospital attendance databases at two
secondary-level hospitals [Wellington Regional Hospital and Hutt Hospital], local
GP databases and from community advertising.
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Table 4.1: SMART study sites
Site Site lead investigator Site investigators
Auckland
Henderson
Medical Centre
Dr Rodney Marks Dr Bill Mackey
Dr Vikky Qi
Clare McGuinness-Goodwin
(practice manager)
Tyronne Tranquilino (Nurse
Manager)
Dr Dirk Venter
Tauranga
CentralMed
General Practice
Dr Andrew Corin Dr Andrew Corin
Dr Colin Helm
Dr Chris Tofield
Tauranga
Papamoa Pines
Medical Centre
Dr Davitt Sheahan Dr Davitt Sheahan
Lower Hutt
7X.RWDKL0ƗRUL
Asthma Trust
Cheryl Davies Ann Smith (Specialist Nurse)
Dr Mitesh Patel
Wellington
MRINZ
Dr Mitesh Patel (trial
coordinating investigator)
Dr Mitesh Patel
Dr Janine Pilcher
Alison Pritchard (I.T. manager)
Tanya Baker (clinical trials
manager)
Denise Fabian
Maureen Stretch
Mathew Williams
Dr Kyle Perrin
Dr Justin Travers
Professor Mark Weatherall
(study biostatistician)
Professor Richard Beasley
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Hospital patient database searches were performed for asthma patients attending ED
or who were directly admitted to the wards at Wellington Regional Hospital or Hutt
Hospital for the preceding year. Patients who were aged 16 to 65 were sent a letter
inviting them to contact the MRINZ if they were interested in learning more about
study participation. Database searches were repeated every six months from July
2010 to July 2011.
GPs at several Wellington medical centres were contacted and consent was requested
to perform database searches for potentially eligible participants. Searches were
performed at Onslow Medical Centre, Karori Medical Centre, Ngaio Medical Centre,
Brooklyn Central Health Medical Centre and Wadestown Medical Centre.
Potentially suitable patients were sent a letter from their GP informing them of the
study and were asked to contact the MRINZ via email, freephone telephone number
or pre-paid return envelope if they wished to find out more about the study.
Community advertising was undertaken using posters in local libraries and
community centres and by using flyers in local GP practices and after-hours medical
centres. Information about the study was also available on the MRINZ website.
Patients had the option of attending study visits at the MRINZ offices at Wellington
Regional Hospital or Bowen Hospital, at the Respiratory Clinic at Hutt Hospital, or
at their home or workplace.
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4.4 Study procedures
4.4.1 Initial screen
Potentially eligible patients were provided the participant information sheet
(Appendix B). These patients were then asked initial screening questions relating to
the inclusion/exclusion criteria and a date/time was arranged for Visit 1. Patients
continued to take their regular inhaled therapy prior to all study visits, without being
required to withhold their medication prior to spirometry. Patients were asked to
bring all their current inhalers with them to their first study visit, in order to replace
them with study medication.
4.4.2 Visit 1 (Week 0)
At first study visit, written consent was obtained prior to any study-specific
procedures being performed (Appendix B). The participant information sheet was
discussed with patients. The patient’s demographics and medical and medication
history were taken and the patient’s eligibility for the trial confirmed according to the
inclusion and exclusion criteria. Spirometry (FEV1 and FVC) was performed
according to a standardised protocol. The ACQ-7 (Juniper et al., 1999) and
Satisfaction with Asthma Treatment Questionnaire (SATQ) (Campbell, Kiebert and
Partridge, 2003) were completed. All pre-study inhalers were collected from
patients.
158
Patients were randomised to SMART or Standard treatment and study inhalers
incorporating electronic monitoring were provided according to their study group
[see Section 4.6 for details on randomisation]. All participants were given
standardised written asthma self-management plans relating to their randomised
group [see Section 4.8] and had their inhaler technique checked. Spacers were
dispensed to any patients unable to demonstrate adequate MDI inhaler technique
after training. Patients who used peak-flow monitoring prior to study entry
continued to do so during their study participation. Written advice on the care of the
study inhalers was provided (Appendix C). An appointment card identifying the
patient as a participant in a clinical trial was provided, onto which any courses of
systemic corticosteroids taken for asthma could be recorded (Appendix C).
Participants remained under the care of their usual primary care physicians
throughout the study. A letter was sent to the patient’s GP with details of the study
treatment, a copy of the self-management plan and contact details for the study
investigator.
4.4.3 Visits 2, 3 and 4 (Weeks 3, 10 and 17)
At Visits 2 to 4, study participants were asked about any asthma exacerbations, ED
visits or hospital admissions occurring since the preceding visit. Exacerbation data,
dose and duration of corticosteroid therapy for asthma exacerbations and
unscheduled consultations for asthma were collected from patient record (using
events noted contemporarily on the patient’s study appointment card), spontaneous
report and answers to standardised questions at study visits:
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‘Since the last study visit, have you taken a course of systemic steroids for
your asthma?’
‘Since the last study visit, has troublesome asthma led you to seek
unplanned/urgent help for your asthma?’
‘Have you needed to attend ED for your asthma?’
Cross-checks with primary care GP databases and hospital records were performed if
there was uncertainty about dates and/or doses. A conversion factor of 100mg
intravenous (IV) hydrocortisone to 25mg oral prednisone was used for IV
corticosteroid doses.
The ACQ-7 was completed and spirometry was performed. The inhalers previously
dispensed were collected from the participants and replacement inhalers issued [see
Chapter 5 for full details].
In addition, at Visit 3, asthma self-management plans were reviewed with the patient
and inhaler technique was re-checked.
4.4.4 Visit 5 (Week 24)
At Visit 5, study participants were asked about asthma exacerbations as above.
ACQ-7, SATQ and spirometry were completed. All previously dispensed inhalers
were collected from participants. Participants who wished to continue on their study
asthma medication were advised to attend their GP for review. In order to prevent
deterioration in their asthma control in the intervening time, participants had the
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option of being provided with a budesonide/formoterol and salbutamol inhaler to use
whilst awaiting this appointment. A letter was sent to the patient’s GP informing
them of the patient’s study completion.
A summary of the clinic visits and schedule of assessments is shown in Table 4.2.
4.5 Electronic monitoring of MDI use
Smartinhaler Tracker electronic monitors (Nexus6 Limited, Auckland, New Zealand)
were incorporated in all Vannair and Ventolin MDIs dispensed in the study. These
validated monitors measure the number, date and time of MDI actuations (Patel et
al., 2012; Burgess et al., 2006). Participants were told that the total number of
actuations from their inhalers was measured, but not of these additional recording
capabilities. The rationale for this was to minimise the influence that monitoring
adherence may have had on participant behaviour. Covert monitoring was
considered ethically acceptable as the risks to participants were minimal and this
approach allowed the collection of information in a non-biased form (Rand and
Sevick, 2000).
A comprehensive trial quality control programme was implemented in which all
monitors were tested for accuracy prior to dispensing and during the full study period
[see Chapter 5].
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Table 4.2: Schedule of clinic visits and assessments
Visit Number 1 2 3 4 5
Week 0 3 10 17 24
Informed consent X
Demographics and medical history X
Medication history X
Eligibility criteria assessment X
ACQ-7 X X X X X
SATQ X X
Spirometry (FEV1& FVC) X X X X X
Randomisation X
Self-management plan provided X
Inhaler technique checked X X
GP informed of study participation X
Appointment card provided with
integrated section to record steroid use
X X X X
Text/telephone reminder of study visit X X X X X
Adverse events and concomitant
medications review
X X X X
Asthma exacerbations review X X X X
Dispense study treatment X X X X
Inhaler download X X X X
Validation of electronic monitor X X X X
Trial completion X
Patient provided treatment to use whist
awaiting GP appointment
X
GP informed of completion of study X
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Each actuation log was stored on the monitor and data was uploaded via a USB
computer connection and dedicated software after study clinic visits, to a website-
based database via the internet.
All MDIs were actuated during the pre-study testing process. Participants were
advised not to perform ‘test’ actuations, share inhalers, or use non-study inhalers.
Participants were also advised not to self-administer multiple MDI actuations as a
single high dose via spacer, as a substitute for nebulised therapy.
Participants were able to use their study MDIs concurrently during the study window
if they wished. All participants were asked to keep their MDIs free from moisture
during trial participation and were reminded not to discard used or empty inhalers.
Investigators asked participants about their use of non-study inhalers and sharing of
study inhalers at Visits 2 to 5 using the following questions:
‘Have there been any changes in your asthma medication use since the last
visit?’
‘Have you used any non-study asthma medication in the prior 7 weeks?’
‘Has anyone else used your study inhaler apart from you?’
‘Have you had any problems with the inhaler device?’
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4.6 Randomisation, allocation concealment and masking
Randomisation was one-to-one, using a computer generated sequence, with fixed-
size balanced blocks of eight per site. The randomisation schedule was prepared by
the study statistician, who was independent of the investigators undertaking study
visits. The schedule was provided to persons independent of the investigators
undertaking study visits, who prepared the randomisation envelopes. Opaque,
sealed, numbered envelopes were provided to study sites and were opened by
investigators undertaking study visits in sequence, once informed consent had been
obtained, eligibility had been confirmed and baseline clinic measurements had been
recorded.
An open-label trial design was required to be able to reflect real-world clinical
practice. All participants, investigators and the statistician were not masked to group
assignment.
4.7 Dose determination
Maintenance treatment was with budesonide/formoterol 200/6µg two actuations
twice a day for all participants.
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4.7.1 Rationale
As patients at risk of severe asthma exacerbations and poor asthma control were the
target patient group for this study, GINA Step 4/BTS Step 3 (SIGN/BTS, 2012;
GINA, 2011) therapy (medium dose ICS with LABA) was used as the appropriate
maintenance treatment for the anticipated baseline level of asthma control.
4.8 Asthma self-management plans
The SMART plan was based on the National Asthma Council Australia ‘My
Symbicort SMART Asthma Action Plan’ (National Asthma Council Australia,
2013). Two versions of this plan, symptom-based or peak-flow based, were used
(Figure 4.1 and Figure 4.2 respectively).
The Standard plan was based on the Asthma and Respiratory Foundation of New
Zealand 2004 plan (Holt et al., 2004). Two versions of this plan, symptom-based or
peak-flow based, were used (Figures 4.3 to 4.6).
As per their self-management plans, participants were advised to seek review from
their GP, after-hours clinic or ED in the setting of worsening asthma and every time
systemic corticosteroids were commenced. Self-management plans suggested a dose
of 40mg of prednisone for five days for an asthma exacerbation, but the final
decision was as per the treating physician.
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Figure 4.1: SMART symptoms plan
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Figure 4.2: SMART peak flow plan
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Figure 4.3: Standard Symptoms plan - front
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Figure 4.4: Standard Symptoms plan - back
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Figure 4.5: Standard Peak flow plan - front
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Figure 4.6: Standard Peak flow plan - back
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4.9 Asthma Control Questionnaire-7 (ACQ-7)
The ACQ-7 comprised seven questions to give a validated composite score of asthma
control (Reddel et al., 2009; Juniper et al., 1999). There were six self-reported
questions (relating to asthma symptoms and as-needed beta-agonist use in the
preceding one week) and FEV1 % predicted. Each question was scored on a scale of
0 to 6. The final score was a mean of the seven responses, where 0 represents good
FRQWURO DQG  UHSUHVHQWV SRRU FRQWURO  $ VFRUH RI  VXJJHVWV ZHOOFRQWUROOHG
DVWKPDDQGDVFRUHRIVXJJHVWVQRWZHOOFRQWUROOHGDVWKPD-XQLSHUHWDO
The minimal clinically important difference is 0.5 (Juniper et al., 2005).
Investigators informed participants on the SMART regimen that their response to
Question 6 (as-needed beta-agonist use) should reflect the number of reliever puffs
of budesonide/formoterol used (i.e. extra actuations, taken in addition to the four
maintenance doses per day). Interpolation was used for ACQ-7 scores where there
was one missing value.
4.10 Satisfaction with Asthma Treatment Questionnaire (SATQ)
The SATQ was used to measure patients’ satisfaction with their inhaled asthma
treatment (Campbell et al., 2003). The questionnaire comprised 26 questions,
divided into four domains: effectiveness of medication (eight questions); ease of use
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(seven questions); burden of asthma medication (six questions); and side effects and
worries (five questions). Each question was scored on a scale of 1 to 7. Negatively
phrased questions were reversed for analysis. Domain scores were calculated as the
average of the responses for that domain, with higher values indicating greater
satisfaction with treatment (range 1 to 7). The total overall score was calculated as
the mean of the four domain scores (range 1 to 7). The minimal clinically important
difference has not been determined.
4.11 Spirometry
Cardinal Health Micro spirometers (Cardinal Health UK, Kent, UK) were used for
lung function measurements. All spirometers passed validation checks of the
manufacturer’s calibration with a 3 Litre syringe prior to use in the trial and again at
the completion of the trial. On-treatment spirometry was performed according to a
standardised protocol. Participants were not required to withhold their
bronchodilator medication prior to performing spirometry measurements, in order to
reflect clinical practice where regular treatment is not usually withheld prior to
spirometry (Reddel et al., 2009).
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4.12 Medication
Vannair MDIs contained 120 doses per canister and Ventolin MDIs contained 200
doses per canister. The medicine data sheets for Vannair and Ventolin are included
in Appendix D.
4.13 Unscheduled medical care for asthma during study participation
If a study participant had an asthma exacerbation during the study, they were advised
to contact their GP or visit an ED or after-hours clinic. Participants were aware that
they would receive standard medical care (from their GP, after hours or ED) for their
asthma during the course of the study.
Patients who had previously kept a course of prednisone at home for emergency use
were advised to seek medical review as per their self-management plans whenever a
course of prednisone was commenced.
For the three primary care practices, study visits were scheduled separately to usual
clinical care. GP-investigators were part of a larger team of physicians at each site.
Reception and appointment-booking staff were aware that the participants’ medical
care (including urgent and unscheduled care for asthma) remained the responsibility
of the usual primary care physician.
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to usual clinical care and all medical care remained the responsibility of the
participants’ primary care physician.
4.14 Pregnancy in female participants
Female patients who were pregnant at baseline were eligible for study participation.
Patients who became pregnant during study participation were able to continue trial
participation. All pregnancies were reported to the Ethics committee in an expedited
manner and data on all pregnancy outcomes were collected and reported to the Ethics
committee at trial completion.
4.14.1 Rationale
Current clinical practice allows for the use of combination budesonide/formoterol
therapy during pregnancy, as the benefits to both mother and child of adequate
asthma control outweigh the theoretical risks of treatment (Schatz and Dombrowski,
2009). The risks and benefits of commencing or continuing with the study were
discussed with pregnant patients on an individual basis.
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4.15 Visit schedules
Text messages to mobile telephones or telephone calls were made two to three days
prior to study visits, in order to confirm attendance. Study visits were scheduled to
occur within +/- three days of their due date. If this was not possible, the visit
window was extended up to +/- seven days. Patients could also arrange to attend the
clinic if they required further inhalers in between study visits. Patients who did not
attend their study appointments were contacted by telephone and offered the option
of a home or workplace visit.
Participants who withdrew had a recorded date for the cessation of study product (the
withdrawal date). Participants were entitled to NZ$20 per visit (£10) for their travel
expenses.
4.16 Safety Monitoring
4.16.1 Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a study participant
temporally associated with participation in the trial and the administration of study
medication, whether or not considered related to the medicine. An adverse event was
therefore any unfavourable and unintended sign, symptom or disease temporally
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associated with the use of the study treatment. A worsening of a pre-existing
medical condition, other than asthma, was considered an adverse event.
AE and SAE data were collected by patient report and from responses to standard
questions at study visits:
‘Have you had any health or medication-related problems since the last visit?’
‘Is there anything new about your health or medication that you wish to
discuss?’
Investigators notified adverse events to the coordinating investigator as they
occurred, using standardised templates. All adverse events classed as ‘severe’ or that
were unexpected or concerning (as considered by either the investigators reporting
the event or the coordinating investigator) were discussed in a team meeting at the
MRINZ, which involved the principal investigator (Figure 4.7). Adverse event data
were collected and analysed with efficacy data at the end of the study.
177
Figure 4.7: Process for Adverse Event reporting
Adverse event details documented on
standardised forms and faxed to the
coordinating investigator
All adverse events reviewed by the
coordinating investigator and entered onto the
study database
Concerning, severe or unexpected events
discussed at MRINZ team meeting
178
4.16.2 Serious Adverse Events (SAEs)
The following events were considered to be SAEs and required expedited reporting
to the Ethics committee:
Death;
Life-threatening event;
Permanently disabling or incapacitating event;
Hospitalisation or prolongation of hospitalisation [hospitalisation for the
purposes of SAE reporting was defined as an admission to hospital and did
not include a presentation to the Emergency Department followed by
discharge without admission or an admission for elective reasons];
Any event considered serious by the study investigator.
SAEs were notified to the Ethics committee in an expedited manner, usually within
15 days of the investigators becoming aware of them (Figure 4.8). Asthma
exacerbations that did not meet the criteria for being considered an SAE were not
reported as adverse events, as they were analysed in the efficacy outcomes for the
study.
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Figure 4.8: Process for Serious Adverse Events reporting
4.16.3 Validation of ED visits and hospital admissions for asthma during study
participation
All ED visits and hospital admissions for asthma were verified by searching hospital
databases for medical attendances for all participants, from their regional hospital(s)
(after the completion of follow-up for all participants). For participants enrolled at
the Henderson Medical Centre (Auckland) site, database searches for medical
attendances were performed at: Auckland City Hospital; Auckland Middlemore
Hospital; Auckland North Shore Hospital; Auckland Waitakere Hospital. For
SAE details documented on standardised forms
and faxed to the coordinating investigator within
48 hours of investigators becoming aware of them
All SAEs reviewed by the
coordinating investigator and discussed with the
principal investigator
Coordinating investigator responsible for
expedited Ethics notification
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participants enrolled at CentralMed General Practice (Tauranga) and Papamoa Pines
Medical Centre (Tauranga), database searches for medical attendances were
SHUIRUPHG DW  7DXUDQJD +RVSLWDO  )RU SDUWLFLSDQWV HQUROOHG DW 7X .RWDKL 0ƗRUL
Asthma Trust (Lower Hutt), database searches for medical attendances were
performed at: Hutt Hospital (Wellington); Palmerston North Hospital (Palmerston
North); Wellington Regional Hospital and Keneperu Hospital (Wellington). For
participants enrolled at the MRINZ (Wellington), database searches for medical
attendances were performed at: Hutt Hospital (Wellington); Palmerston North
Hospital (Palmerston North); Wellington Regional Hospital and Keneperu Hospital
(Wellington).
4.16.4 Hospital database verification for SAEs at trial completion
The occurrence of all SAEs due to hospitalisation was verified during the hospital
database validation process detailed above (Figure 4.9). Any additional SAEs that
had not previously been reported were recorded during this process.
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Figure 4.9: Hospital database verification for SAEs due to hospitalisation
Database search permissions
obtained from the multi-region
ethics committee and the
institutional review boards of 8
major North Island hospitals
After the completion of follow-up
for all participants, database
searches were undertaken for
emergency medical attendances at
participants’ regional hospital(s)
All hospitalisations classed as
SAEs were verified
Additional ED attendances or
hospital admissions considered to
be SAEs were reported
Auckland participants: Middlemore
Hospital, Auckland City Hospital,
North Shore Hospital and Waitemata
Hospital.
Tauranga participants: Tauranga
Hospital
Wellington and Lower Hutt
participants: Palmerston North
Hospital, Wellington Hospital and
Hutt Hospital
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4.17 Independent Safety Monitoring
An interim safety statistical analysis was conducted by the study statistician,
Professor Mark Weatherall, for all unplanned hospitalisations for asthma, once 150
participants had completed the study. This analysis was performed masked to
treatment allocation (the results for analysis were provided without the participant
identification code, but with the blinded randomised treatment code (e.g. treatment 1
or treatment 2). The results of this analysis were then reviewed by an independent
safety monitor. Dr Andrew Brant, Consultant Respiratory Physician & Chief
Medical Officer [North Shore Hospital, Waitemata District Health Board, Auckland,
New Zealand], who was independent from the study team, acted in this capacity.
The pre-specified interim analysis plan was to compare the proportion of participants
with an unplanned hospital admission for asthma with a reference rate of 4.5% using
the binomial test for proportions. An exact (Clopper-Pearson) confidence interval
was used for the proportion of participants with a hospital admission. The calculated
interim p value for performing a safety review of the study (using the ld98
Programme), assuming one interim analysis halfway through the data collection, was
0.006 (using a one sided O’Brien-Fleming bound). If the observed rate exceeded the
expected rate with a p value less than 0.006, a safety review of the study was to be
undertaken. The p value calculations used the ld98 programme, an alpha spending
function, with alpha nominated as 0.05, evenly distributed analysis times, and
O'Brien Fleming boundaries. The expected proportion was derived from data from
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1999).
In addition, a comparison of the admission rates as a relative risk of at least one
admission using calculated relative risk with asymptotic 95% confidence interval but
Fishers exact test was undertaken; and Poisson regression for the relative rate of
hospital admissions.
The study statistician was blinded to the treatment groups for this analysis.
If the findings of the safety analysis indicated a safety review was necessary, then
termination of the trial was to be considered.
4.18 Primary Outcome Variable
The primary outcome variable was the proportion of participants with at least one
high beta-agonist use (‘high use’) episode during the study. This was defined as the
proportion of participants in the SMART group who at any point within the six-
month study period used greater than eight actuations of budesonide/formoterol in
addition to the four maintenance doses (i.e. equivalent to >12 actuations in total) per
24-hours compared to the proportion of patients in the Standard group who used
greater than 16 actuations of salbutamol per 24-hours.
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4.18.1 Rationale for Primary Outcome Variable
These high use thresholds were based on the limits of beta-agonist use requiring
medical review, defined by the self-management plans (National Asthma Council
Australia, 2013; Holt et al., 2004) and supported by the short-term bronchodilator
equivalence of 6µg formoterol to 200µg salbutamol with repeat dosing in acute
asthma (Balanag et al., 2006; Rubinfeld et al., 2006). In accordance with their self-
management plans, participants were advised to seek medical review at these
thresholds.
A 24-hour period was defined as 0300 to 0259.
4.18.2 Post-hoc sensitivity analysis
A post-hoc sensitivity analysis was undertaken, using a modified definition of a high
use episode for the Standard group, to adjust for the use of budesonide/formoterol in
excess of the four maintenance actuations per 24-hours by some participants on
occasions.
4.19 Secondary Outcome Variables
These analyses included measures of overuse of beta-agonist therapy, overuse
occurring without medical review, underuse of maintenance therapy, asthma control,
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lung function, severe exacerbations, ED/hospital attendances and satisfaction with
asthma treatment.
4.20 Days of high use
This was defined as the number of days of high use over the six-month study period.
4.21 High use without medical review
This was defined as the number of days of high use without medical review in the
following 48-hours, in the sub-group of participants who had at least one high use
episode.
4.21.1 Rationale
This 48-hour window was defined as per the Standard self-management plan, which
recommends that patients should attend for medical review ‘within 1 to 2 days’ in the
setting of worsening asthma. The SMART plan advises patients to seek medical
review on the same day if more than 12 actuations of budesonide/formoterol are
taken.
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4.22 Marked beta-agonist overuse
This was the proportion of participants and number of days of marked beta-agonist
overuse (‘marked overuse’). For SMART, this was defined as >12 actuations of
budesonide/formoterol in addition to maintenance (i.e. >16 actuations in total) and
for Standard, >24 actuations of salbutamol, per 24-hours.
4.22.1 Marked overuse without medical review
This was defined as the number of days of marked overuse without medical review
in the following 48-hours, in the sub-group of participants who had at least one
marked overuse episode.
4.23 Extreme beta-agonist overuse
This was the proportion of participants and number of days of extreme beta-agonist
overuse (‘extreme overuse’). For SMART, this was defined as >16 actuations of
budesonide/formoterol in addition to maintenance (i.e. >20 actuations in total) and
for Standard, >32 actuations of salbutamol, per 24-hours.
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4.23.1 Extreme overuse without medical review
This was defined as the number of days of extreme overuse without medical review
in the following 48-hours, in the sub-group of participants who had at least one
extreme overuse episode.
4.24 Underuse of maintenance budesonide/formoterol treatment
This was the proportion of participants and number of days of underuse of
PDLQWHQDQFH WKHUDS\ GHILQHG DV ]HUR QRQDGKHUHQFH  DFWXDWLRQ DQG 
actuations of budesonide/formoterol per 24-hours.
4.25 Corticosteroid load
4.25.1 ICS dose
This was the mean budesonide dose per day.
4.25.2 Oral corticosteroid dose
This was the oral corticosteroid dose during the study period and the number of
courses of oral corticosteroids per year.
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4.25.3 Composite corticosteroid load
This was the composite systemic corticosteroid exposure per year, in which the total
ICS dose per year, converted to oral prednisone-equivalent dose for systemic effects
on adrenal function using the conversion factor of 5000µg inhaled budesonide to
10mg oral prednisone determined in a previous bioequivalence study (Aaronson et
al., 1998), was added to the oral corticosteroid dose per year.
4.26 Severe asthma exacerbations
This was the risk and the rate of severe asthma exacerbations and the time to first
severe asthma exacerbation.
4.26.1 Definition of severe asthma exacerbations
A severe asthma exacerbation was defined as the use of systemic corticosteroids
(tablets, suspension or injection), or an increase from a stable maintenance dose (for
patients commenced on prednisone after commencement of the study), for at least
three days or a hospitalisation or ED visit because of asthma, requiring systemic
corticosteroids. Courses separated by seven days or more from the completion of the
preceding course were classed as separate severe exacerbations (Reddel et al., 2009).
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4.27 ED visits and hospital admissions for asthma
This was the risk and rate of hospital attendance (ED visits and/or hospital
admission) and hospital admission for asthma.
4.28 Asthma control
This was measured by ACQ-7 score.
4.29 Lung function
This was measured by on-treatment FEV1.
4.30 Satisfaction with inhaled asthma therapy
This was measured by SATQ score.
4.31 AEs
This was recorded as AEs occurring in study participants.
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4.32 SAEs
This was recorded as SAEs occurring in study participants.
4.33 Dose dumping
The pre-specified plan was to remove electronic medication use data on the day of
study visits prior to analysis, because dose dumping may occur at this time (Rand et
al., 1992).
4.33.1 Database searches for the occurrence of possible dose dumping
There is no consensus definition for dose dumping. However, the electronic
medication use database, with and without medication use data from study visit days
included, was searched post-hoc for patterns of use which might be consistent with
dose dumping, in order to quantify the occurrence of these events in the dataset. The
definition of dose dumping used was:
DFWXDWLRQVZLWKLQWKUHHKRXUV>DVSHUDGHILQLWLRQXVHGSUHYLRXVO\5DQG
et al., 1992)].
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For the SMART group, data descriptions summarised the occurrence of possible
dose dumping with budesonide/formoterol inhalers. For the Standard group, data
descriptions summarised the occurrence of possible dose dumping with salbutamol
inhalers.
4.34 Statistical methods
Analysis was by intention-to-treat. SAS version 9.2 was used.
4.34.1 Treatment exposure time
This was defined as the number of days from the Visit 1 date to the date of cessation
of the study product (the last recorded study visit or the withdrawal date).
For analyses relating to electronic medication use data, the number of study visit
days undertaken (one to five) was subtracted from the treatment exposure time, as
electronic medication use data on the day of study visits was removed from the
analysis.
4.34.2 Period of observation (‘follow-up time’)
This was defined as the number of days from Visit 1 to the last recorded study visit
(for both completed and withdrawn participants).
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4.34.3 Statistical methods for the overuse (high use, marked overuse and extreme
overuse) analyses
Analysis of the number of participants with at least one episode of overuse was by
calculation of relative risk with appropriate confidence intervals. Analysis of the
relative rates of overuse, i.e. the number of days with an overuse episode per days of
treatment exposure, was by Poisson regression with an offset for the treatment
exposure. The analysis suggested over-dispersion and a dispersion term was used to
adjust for over-dispersion.
4.34.4 Sensitivity analysis for the primary outcome variable
This post-hoc analysis was undertaken following the observation that 143
participants in the Standard group used in excess of their four maintenance actuations
of budesonide/formoterol on at least one day during their exposure to treatment. A
modified definition of ‘high beta-agonist use’ for the Standard group was utilised for
this analysis by converting budesonide/formoterol actuations in excess of the four
maintenance actuations to bronchodilator equivalent doses of salbutamol, using the
conversion of 6µg of formoterol (one actuation) to 200µg of salbutamol (two
actuations). The formula below was used, whereby a high use episode was defined
as follows:
High use: [(n-4) x 2] + number of salbutamol actuations, is greater than 16, per 24-
hour period, where n is the number of budesonide/formoterol actuations taken, 4
represents the prescribed maintenance budesonide/formoterol doses and the value 2
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is the bronchodilator equivalence conversion factor of 1:2 for budesonide/formoterol
to salbutamol.
4.34.5 Statistical methods for the overuse without medical review analyses
These analyses were undertaken in the subgroup of participants who had an overuse
episode (high use, marked overuse or extreme overuse). The number of days of
overuse without medical review and the adjusted treatment exposure days for the
calculation of rates was determined using the following rules.
For every overuse day (the ‘index day’), the database was checked to determine if the
patient attended for medical review (primary care clinic, after-hours clinic or
hospital) either on the day of overuse or the next day. This 48-hour window was
defined as per the Standard self-management plan, which specifies that the patient
should attend for medical review ‘within 1 to 2 days’ in the setting of worsening
asthma. The SMART plan advises patients to seek medical review on the same day
if more than 12 actuations of budesonide/formoterol are taken.
If the participant attended for medical review, then overuse occurring on the index
day, the day of medical review and in the seven days after medical review was not
counted as overuse (the ‘stand-down’ period). In effect, overuse occurring on these
days was ‘permissible’ as the patient had attended for medical review in the setting
of this exacerbation. If the patient attended for repeated medical reviews during the
stand-down period, then the seven-day period where overuse without medical review
was not counted was restarted.
194
These definitions applied to this outcome variable only and were chosen as
ATS/ERS definitions of exacerbations requiring prednisone separate exacerbations
by seven days (Reddel et al., 2009). The stand-down period was extended using the
rules above in the setting of repeated medical visits as the purpose of this analysis
was to explore the relationship between the ‘index’ overuse episode and the first
episode of medical review following this.
An adjusted treatment exposure was calculated by subtracting the number of stand-
down days from the overall treatment exposure for the participant.
Analysis of the relative rates of overuse without medical review, i.e. the number of
days with an overuse episode without medical review per adjusted treatment
exposure days, was by Poisson regression with an offset for the adjusted days of
treatment exposure. The analysis suggested over-dispersion and a dispersion term
was used to adjust for over-dispersion.
4.34.6 Statistical methods for the underuse variables
Relative risk and appropriate confidence intervals were calculated for the number of
SDUWLFLSDQWVZLWKDW OHDVWRQHHYHQWGD\VZLWK]HURDFWXDWLRQVDFWXDWLRQDQG
actuations of budesonide/formoterol per 24-hours). Relative rates of days of
underuse were calculated by Poisson regression with an offset of the logarithm of the
time of exposure. The variables of days of underuse were over-dispersed and a
deviance-based over-dispersion correction term was used in Poisson regression.
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4.34.7 Statistical methods for severe exacerbations and hospital attendances
Relative risk and appropriate confidence intervals were calculated for the number of
participants with at least one event (severe exacerbation, hospital admission, ED
visits, at least one course of corticosteroids). Relative rates were calculated by
Poisson regression with an offset of the logarithm of the period of observation
(severe exacerbations, hospital admissions, ED visits, number of courses of
corticosteroids).
For hospital attendances where only a one-off dose of IV hydrocortisone was given,
this was counted as a one-day course of prednisone using the conversion 100 mg
hydrocortisone = 25mg of prednisone. For hospital attendances where IV
hydrocortisone was given in addition to oral prednisone, this dose was converted to
prednisone as above and added to the total prednisone exposure for that exacerbation.
Survival analysis was with a Kaplan-Meier plot and Cox Proportional Hazards
calculation for the time to first severe exacerbation. The proportionality assumptions
was tested by fitting an interaction term between treatment and time to first severe
exacerbation; this was not statistically significant (p=0.52) (Collett, 2003). Neither
treatment group had 50% reaching a first severe exacerbation; therefore, a median
time-to-event could not be calculated.
4.34.8 Statistical methods for mean ICS dose/day analysis
ICS use had a skew distribution which was converted to a symmetric distribution
with the natural logarithm transformation. For this calculation, the unit of time was
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the treatment exposure time and the analysis was by converting to ICS use per year
(annualised ICS use). The logarithm of the annualised ICS use was the response
variable in a weighted normal linear model with the randomised treatment as a
predictor and the treatment exposure time as a weight so that individuals with longer
periods of treatment exposure were given more weight and those with shorter periods
of observation less weight in the analysis.
The exponent of the difference in logarithms, SMART minus Standard, is interpreted
as the ratio of mean values of annualised ICS use, although the ratio of mean values
applies to any unit of time e.g. days or years.
4.34.9 Statistical methods for oral corticosteroid dose analysis
The pre-specified analysis for the continuous variables that did not meet normal
distribution assumptions, with or without transformation, was the non-parametric
Mann-Whitney test. There was no prednisone use at all for 80% of the SMART
group and 66% of the Standard group. Analysis with the Mann-Whitney method was
problematic because a large number of participants had no oral corticosteroid use. A
more meaningful way of examining the difference in prednisone use between groups,
categorisation into prednisone bands of use, was undertaken.
Chi-square tests for contingency tables derived from the corticosteroid exposure
measurements were used for oral corticosteroid use. Bands for oral corticosteroid
dose for the contingency table were (mg prednisone): 0; 0 to 200; 200 to 400; 400+.
197
4.34.10 Statistical methods for the composite systemic corticosteroid exposure per
year analysis
The total ICS dose/year, converted to oral prednisone-equivalent dose for systemic
effects on adrenal function using the conversion factor of 5000µg inhaled budesonide
to 10mg oral prednisone determined in a previous bioequivalence study (Aaronson et
al., 1998), was added to the oral corticosteroid dose/year. The unit of time was the
total observation time (follow-up time).
The analysis of composite systemic corticosteroid exposure was calculated by
converting to prednisone dose per year (annualised prednisone dose).
Composite systemic corticosteroid exposure had a skew distribution which was
converted to a symmetric distribution with the natural logarithm transformation.
The logarithm of the annualised prednisone dose was the response variable in a
weighted normal linear model with the randomised treatment as a predictor and the
period of observation as a weight so that individuals with longer periods of
observation were given more weight and those with shorter periods of observation
less weight in the analysis.
The exponent of the difference in logarithms, SMART minus Standard, is interpreted
as the ratio of mean values of annualised composite systemic corticosteroid
exposure, although the ratio of mean values applies to any unit of time e.g. days or
years.
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4.34.11 Sensitivity analysis with one participant in the Standard group removed
from the analyses of oral corticosteroid dose and composite systemic
corticosteroid exposure
One Standard participant self-administered an overdose of 800mg prednisone per day
for five days for asthma. Sensitivity analyses, performed with this one participant in
the Standard group with an overdose of prednisone removed from the dataset, were
performed for oral corticosteroid dose and composite systemic corticosteroid
exposure.
4.34.12 Statistical methods for the asthma control and lung function analyses
The pre-specified analysis method was a mixed linear model examining response
profiles at each time point using random effects for individual subjects and an
unstructured covariance pattern to account for correlation between measurements on
the same subjects. As suggested (Fitzmaurice, Laird and Ware, 2004), the model
forces a common intercept and adjusts for baseline values in this way.
FEV1 % predicted values were calculated using the ECSC reference equations
(Miller et al., 2005).
4.34.13 Statistical methods for the SATQ analysis
Comparisons were performed by ANCOVA with the Visit 1 value as a baseline
covariate, to provide an adjusted treatment difference between the groups.
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4.34.14 Baseline data for study participants
Statistical comparisons of baseline characteristics between groups were not
performed for the following reasons, as per CONSORT guidelines (Schulz, Altman
and Moher, 2010). Firstly, there is generally a lack of power to detect clinically
important differences in the variables at baseline, as the study is powered to detect a
difference in the primary outcome not in baseline variables. Secondly, undertaking
baseline comparisons inflates the overall study type I error rate. Thirdly, it is unclear
what hypothesis is being tested if statistical comparisons of baseline characteristics
are performed e.g. are they to determine whether randomisation has 'worked'.
4.34.15 Exploratory post-hoc analyses
The following analyses were post-hoc: the sensitivity analysis for the primary
outcome variable; overuse without healthcare review in the participants with marked
DQGH[WUHPHRYHUXVHXQGHUXVHGHILQHGDV]HURQRQDGKHUHQFHDQGDFWXDWLRQVRI
budesonide/formoterol per 24-hours; and, oral corticosteroid dose by contingency
tables.
4.35 Power and sample size
The actual use of beta-agonists in the context of an asthma exacerbation has not been
defined and prior studies have shown variable rates of asthma exacerbations in
patients.
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In the RELIEF study (Pauwels et al., 2003b), 43% of the patients with Stage 4
asthma severity had at least one exacerbation over a six-month period. A pooled
analysis of studies in moderate to severe asthma patients showed an exacerbation rate
of 1.5 per year in the control group (Bousquet et al., 2005). One of the primary
SMART studies reported that 22% of patients with a recent severe exacerbation and
who were receiving maintenance fixed-dose budesonide/formoterol and as-needed
terbutaline experienced a severe exacerbation over a 12-month period (Rabe et al.,
2006a). Thus, for the purposes of this study, we predicted that approximately 40% of
asthma patients might have a severe exacerbation (defined as requiring systemic
corticosteroids) over a six-month period.
A prior NZ study showed that 85% of patients admitted to hospital with asthma
H[DFHUEDWLRQV UHSRUWHG XVLQJ  DFWXDWLRQV RI 6$%$ LQ WKH KRXUV SULRU WR
admission (Windom et al., 1990a). There is, however, uncertainty as to the actual
use of beta-agonists in the context of a severe asthma exacerbation not requiring
hospital admission. Also, it is not certain what proportion of patients use greater
than 16 inhalations of salbutamol and are not prescribed oral corticosteroid therapy
and thus do not meet the severe exacerbation definition used above.
We assumed that half of patients would have an episode of high use in the setting of
a severe exacerbation (20% of the control group) and an additional 20% of the
remaining 80% of patients would have an episode of high beta-agonist use (16% of
the control group); thus, approximately 36% of asthma patients were expected to
have a high beta-agonist use episode over six months in the Standard group.
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If 300 individuals were recruited, it was predicted that approximately 108 patients
would have a high use episode over the course of the study. 150 patients in each
WUHDWPHQWDUPKDGSRZHU Į  LQD WZRVLGHG WHVW WRGHWHFWDKLJKEHWD
agonist use rate of 21.4%, an absolute reduction of approximately 15%, a relative
risk of just under 0.6.
4.36 Study sites setup
The process for distant study site set-up [Auckland and Tauranga sites] is
VXPPDULVHGLQ)LJXUH)RUWKH7X.RWDKL0ƗRUL$VWKPD7UXVWVLWHFRPSDUDEOH
training was provided in person.
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Figure 4.10: Study site set-up
Study protocol, case record forms,
investigators’ document provided 3 months
prior to commencement of recruitment at site
Skype videoconferences with study physicians.
Discussion of Good Clinical Practice (GCP)
and study protocol
Recruitment and study visit conduct discussed.
Training on the use of electronic monitors and
software
Start-up visit with discussion of patient
consent and study visit conduct. Spirometry
training and electronic monitor training
Site active for recruitment
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4.36.1 Pre-startup training
Training in good clinical research practice, the study protocol and study processes,
and use of electronic monitoring was undertaken via Skype video conference in the
three months prior to start-up. All investigators were provided with a detailed
Investigators’ document. Study oversight was provided by the clinical coordinating
investigator.
4.36.2 Start-up site visit
A start-up site visit was performed, including training in the use of electronic
monitoring and spirometry. All sites were provided with standardised case record
IRUPVRQµQRFDUERQUHTXLUHG¶GXSOLFDWHSDSHU)RU7X.RWDKL0ƗRUL$VWKPD7UXVW
site, study visits were jointly performed by Mitesh Patel and a study nurse.
4.36.3 Within-trial updates
Regular study newsletters were used to keep all investigators informed of current
study progress and key protocol issues.
4.37 Trial monitoring procedures
Trial data monitoring was performed both by on-site visits and off-site (remote) data
checking.
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4.37.1 Site visits
Sites had within-trial and close-out visits, undertaken by Mitesh Patel. At site visits,
randomisation logs, study box logs, informed consent forms and spare monitor logs
were inspected.
4.37.2 Remote data checking
All sites were responsible for faxing copies of randomisation logs, study box logs
and use of spare monitor logs at regular intervals to the MRINZ.
Sites were required to courier case record forms to the MRINZ as soon as practicable
after study visits. Case record forms were completed on self-duplicating paper,
allowing one copy to remain with the trial site. On receipt of visit documentation at
the coordinating trial site, a standardised protocol was followed whereby database
entry and data completeness checks were performed by an IT manager, together with
review of all CRFs by Mitesh Patel (Figure 4.11). All CRFs were double-checked
for completeness in this manner, in close proximity to the study visit. Data queries
were recorded and subsequently followed up with investigators until resolution.
Tracking of visit scheduling was also performed using this process in order to
identify participants who had missed study visits and who required further follow-up
contact.
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Figure 4.11: Process for data monitoring for remote study sites
Case record forms received from trial sites in
close proximity to the study visit being
completed
Completeness of documentation verified by IT
manager and data entry onto database
Case record forms reviewed by the
coordinating clinical investigator
Data queries registered onto a spreadsheet and
followed up with investigators. Visit
scheduling and missed visits highlighted
Query signed off as complete once response
received from investigator
206
4.38 Database checks at study completion
4.38.1 Clinic recorded measurements
After study completion, database queries were performed to identify erroneous,
outlying or missing data for clinic recorded measurements such as FEV1, ACQ-7 and
SATQ. Database entries for baseline characteristics such as asthma medication use,
smoking history and pre-study exacerbation data were checked for completeness.
The following data were double data entered: all doses, durations and dates of
corticosteroid courses for asthma occurring during study participation; dates of
attendance at GP clinics or ED for worsening asthma during study participation; and,
ACQ-7 scores.
4.38.2 Electronic medication use data
Data on loss of inhalers and use of non-study inhalers was collected prospectively as
described previously.
A specialist database engineer [Craig Boyd, BoydHQ Limited] ‘custom-designed’
the electronic medication database and built the relationships between inhaler
actuation data from participant use of MDIs and clinical outcomes, such as severe
asthma exacerbations. Database programmes were written to generate data queries
to provide results for statistical analysis (Figure 4.12).
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Figure 4.12: Process for database queries and checks for study outcomes
Database query written for an outcome
variable
Results generated from query
Calculations checked for accuracy with the
raw electronic medication use data by 2 people
Results ready for statistical analysis
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Database calculations for study outcome variables were double-checked for accuracy
with a sample of the raw data by two people prior to statistical analysis.
4.39 Standards for asthma clinical trials
The ATS/ERS statement on standardising endpoints for asthma clinical trials (Reddel
et al., 2009) provides detailed guidance on the design of trials, choice of outcome
variables, measurement techniques, data analysis and trial reporting. This was
supplemented in 2012 by guidelines relating to the assessment of asthma outcomes in
clinical trials (Busse et al., 2012). The trial protocol was designed in line with the
2009 ATS/ERS statement and subsequent data analysis and trial reporting followed
the guidance set out in both of the above documents.
Trial reporting adhered to the Consolidated Standards of Reporting Trials
(CONSORT) 2010 guidelines (Moher et al., 2010; Schulz et al., 2010) and extended
guidelines for pragmatic design RCTs (Zwarenstein et al., 2008) and RCTs reporting
on treatment harms (Ioannidis et al., 2004) (Appendix E).
4.40 Ethics
All investigators were trained in Good Clinical Practice Guidelines as per the
International Conference on Harmonisation of Technical Requirements for
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Registration of Pharmaceuticals for Human Use (ICH Harmonised Tripartite
Guideline, 1996). The study received full approval by the New Zealand Multi-
Region Ethics Committee (Reference MEC/09/11/127) on 12 May 2010 (Appendix
F) and was conducted according to the New Zealand Health and Disability Ethics
Committee’s standards of clinical trial conduct (National Ethics Advisory
Committee, 2012). Participants were provided a detailed information sheet
(Appendix B) and discussed the study with a physician prior to enrolment. All
participants provided written informed consent prior to any study-specific
procedures.
The trial was registered with the Australian New Zealand Clinical Trials Registry on
22 June 2010 (Appendix G), number ACTRN12610000515099.
4.41 Funding
The study was fully funded by the Health Research Council of New Zealand, a
government funding organisation. The funding source had no involvement in the
study design; collection, analysis and interpretation of data; or preparation of any
written reports.
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Chapter Five: Electronic monitor setup, software and website functions
5.1 Aims
The aims of this chapter are:
1. To describe the pre-study electronic monitor checking protocol that was
performed in the SMART study RCT.
2. To detail the process of electronic monitor setup and organisation at the
coordinating trial site.
3. To describe the within-trial electronic monitor and data checking protocols.
4. To detail the flow of monitors in the trial from randomisation to study
completion.
5. To describe the functions of the software that was used to access data stored
on the electronic monitors.
6. To detail the functions of the website database that was utilised in the
SMART study RCT.
5.2 Pre-study monitor check protocol
All monitors were loaded with study medication canisters and tested at the
coordinating trial site using the following protocol prior to patient use (pre-study use
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checks). The MDI (i.e. the monitor loaded with a medication canister) was firstly
reset by connecting to a computer via a USB connection and using dedicated
software (this cleared the monitor memory and synchronised the monitor clock to the
computer clock). Two actuations were performed and recorded on a paper diary. A
further two actuations were then performed at least two hours later. The number,
date and time of the four actuations, as well as the unique monitor identification
number, were then checked for accuracy by comparing the data stored on the monitor
to the paper diary. MDIs that were 100% accurate were reset and ready for
packaging for use as described below. Any MDIs that failed this pre-study check
were removed from circulation and returned to the manufacturer for further fault
analysis. Testing was undertaken by one of two trained investigators (Mitesh Patel
and Janine Pilcher) under standardised conditions.
5.3 MDI packaging for trial use
MDIs passing the pre-study checks were packaged at the coordinating trial site into
boxes labelled with the Participant identification (ID) code and either ‘SMART’ or
‘Standard’ (Figure 5.1 and Figure 5.2). A spreadsheet was used to track all MDIs
that were packaged into boxes.
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Figure 5.1: SMART group MDI packaging and monitor flow
Denotes reuse of monitors between visits (with reloading of medication
canister)
Denotes transfer of (unused) emergency MDI between visits
MDIs packed in boxes labelled with Study
ID and Study group. After randomisation,
patient initials were noted on the box
Visit 1 (V1): 2
budesonide/formoterol
MDIs were dispensed,
with 1 additional
‘backup’ emergency MDI
sealed in an envelope
Visit 2 (V2): 3
budesonide/formoterol MDIs
were dispensed plus 1
additional ‘backup’
emergency MDI
Visit 3 (V3): 3
budesonide/formoterol MDIs
were dispensed (2 were
reloaded with new medication
canisters from visit1), plus 1
additional ‘backup’ emergency
MDI
Visit 4 (V4): 3 budesonide/formoterol
MDIs were dispensed (reloaded from
V2) plus 1 additional ‘backup’
emergency MDI
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Figure 5.2: Standard group MDI packaging and monitor flow
Denotes reuse of monitors between visits (with reloading of medication
canister)
Denotes transfer of (unused) emergency MDI between visits
MDIs packed in boxes labelled with Study
ID and Study group. After randomisation,
patient initials were noted on the box
Visit 1 (V1): 1
budesonide/formoterol &
1salbutamol MDI were
dispensed, with 1
additional ‘backup’
emergency MDI each,
sealed in an envelope
Visit 2 (V2): 2
budesonide/formoterol & 2
salbutamol MDIs were
dispensed plus 1 additional
‘backup’ emergency MDI of
each type
Visit 3 (V3): 2
budesonide/formoterol & 2
salbutamol MDIs were
dispensed (1 of each monitor
type was reloaded from V1)
plus 1 additional ‘backup’
emergency MDI each
Visit 4 (V4): 2 budesonide/formoterol
& 2 salbutamol MDIs were dispensed
(reloaded from V2) plus 1 additional
‘backup’ emergency MDI each
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5.4 Coordinating trial site checks of monitor packaging
After packaging into boxes, the accuracy of the spreadsheet tracking log and the
website database were verified by an investigator independent of the team
undertaking study visits. The MDIs packaged in the boxes were checked with the
spreadsheet log. The spreadsheet log was, in turn, used to verify that the monitors
allocated to a Participant ID on the website were correct (Figure 5.3). In this way,
every monitor was correctly accounted for and traceable both on the spreadsheet log
and the website database. Each site was then provided with a supply of SMART and
Standard boxes ready for use. A separate stock of replacement monitors was also
available to each trial site to substitute for lost, damaged or malfunctioning monitors.
5.5 Monitor flow in the SMART study RCT
After gaining informed consent and confirming eligibility, participants were
randomly allocated to the SMART or Standard treatment groups. Investigators
selected the next unused box (by group) from their stock of study boxes (Figure 5.4).
The code on the box determined the Participant ID. The box was annotated with the
patient’s initials to signify that it was now ‘active’ in the trial. This process of
allocation of study boxes is summarised in Figure 5.5.
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Figure 5.3: Coordinating trial site MDI packaging verification process
MDIs packaged into SMART or Standard boxes after
passing pre-use checks.
MDIs allocated to each patient ID logged on a
spreadsheet during this process
Independent investigator verified that MDIs were
correctly packaged according to the spreadsheet log
Independent investigator verified that spreadsheet log
and online database of monitor allocation were
identical
Monitor boxes approved for trial use
SMART and Standard MDI boxes sent to sites ‘ready
to use’
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Figure 5.4: Study boxes supplied to sites
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Figure 5.5: Allocation of study boxes after randomisation
Informed consent, eligibility confirmed and
randomisation to SMART or Standard groups
Investigator selected the next available study box by
randomised group and completed a study box log
ID code on the box was now the Participant ID. ID
comprised of a number and site code (A for
Auckland, T for Tauranga,W for Wellington, K for
Lower Hutt). Box annotated with patient’s initials to
signify active use in the trial
Investigator dispensed Visit 1 MDIs from the box and
recorded the monitor IDs on a monitor
tracking log
After the completion of the study visit, investigator
entered the patient’s initials and date of birth on to the
Participant ID record on the website database and
confirmed the monitor IDs dispensed with the website
database
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5.5.1 Flow of MDIs for participants randomised to the SMART group
For the SMART group, two budesonide/formoterol MDIs were provided for the
initial three-week long study window (Figure 5.1). One further
budesonide/formoterol MDI was provided in a sealed envelope, as the emergency
‘backup’ inhaler (Figure 5.1). Each monitor had a unique ID number; investigators
documented these monitor IDs on a paper tracking log at the time of dispensing.
At study Visits 2 to 4, all the previously dispensed MDIs were collected from
participants and were set aside for upload after the study visit. The monitor ID
numbers were recorded on the paper tracking log. Three budesonide/formoterol
MDIs were then provided for seven-week long study windows (Figure 5.1). The
emergency backup inhaler was re-issued to participants at study Visits 2 to 4,
provided it remained unused (Figure 5.1). If used by participants, it was replaced
with a new budesonide/formoterol MDI.
After the study visit was completed, data upload was performed from all the
collected MDIs. The plastic monitor casings were reused so that following data
upload, new medication canisters were inserted into the monitors, in preparation for
dispensing at the next visit. Thus, monitors that were dispensed at Visit 1 were
collected at Visit 2, and dispensed again at Visit 3 (Figure 5.1). Monitors that were
dispensed at Visit 2 were collected at Visit 3 and dispensed again at Visit 4 (Figure
5.1).
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Each SMART participant had a minimum allocation of seven budesonide/formoterol
monitors for the 24-week trial period. Monitors remained patient-specific during the
trial.
5.5.2 Flow of MDIs for participants randomised to the Standard group
For the Standard group, one budesonide/formoterol and one salbutamol MDI were
provided for the initial three-week long study window (Figure 5.2). One further
budesonide/formoterol and salbutamol MDI each were also provided in sealed
envelopes, as emergency ‘backup’ inhalers (Figure 5.2). As previously, monitor ID
numbers were logged on a paper tracking log on dispensing and collection of MDIs
at study visits.
At study Visits 2 to 4, all the previously dispensed MDIs were collected from
participants and were set aside for upload after the study visit. Two
budesonide/formoterol and two salbutamol MDIs were provided for seven-week long
study windows (Figure 5.2). The emergency backup inhalers were re-issued to
participants at study Visits 2 to 4, provided they remained unused (Figure 5.2). If
used by participants, they were replaced with a new budesonide/formoterol or
salbutamol MDI.
After the study visit was completed, data upload was performed from all the
collected MDIs. The plastic monitor casings were reused so that following data
upload, new medication canisters were inserted into the monitors, in preparation for
dispensing at the next visit. Thus, monitors that were dispensed at Visit 1 were
collected at Visit 2, and dispensed again at Visit 3 (Figure 5.2). Monitors that were
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dispensed at Visit 2 were collected at Visit 3 and dispensed again at Visit 4 (Figure
5.2). Each Standard participant therefore had a minimum allocation of five
budesonide/formoterol monitors and five salbutamol monitors for the 24-week trial
period. Monitors remained patient-specific during the trial.
5.6 Computer software development for the trial
From February 2010 to June 2010, customised software (Connection Centre, Nexus6
Limited, Auckland, New Zealand) for the management of data from the electronic
monitors was developed. This involved collaboration with a software engineer at
Nexus6 Limited, who tailored the software according to the requirements for the
trial. An online, website-based database was also created for the trial. The key
elements of the software and online database are described below.
The software allowed investigators to perform five key functions: ‘Preview’;
‘Move’; ‘Backup’; ‘Test’; and ‘Reset’ (Figure 5.6). These will be discussed in turn.
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Figure 5.6: Software home page
Test function button
Preview function button Move function button
Reset function button
Internet connectivity displayed
Backup function
Current PC clock time
and date
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5.6.1 Software ‘Preview’ function
Preview allowed investigators to view data stored on the electronic monitor on their
personal computer (PC). Investigators were firstly required to check that the date
and time set on their PC was correct, as the monitor clock was synchronised to the
PC clock. A monitor could then be connected to the PC using a USB computer
connection. By selecting the ‘Preview’ button, data on the monitor was displayed in
numerical and graphical format (Figure 5.7). This allowed investigators to verify
that data was present on the monitor, prior to transfer to the online database. Monitor
ID, PC clock, internet connectivity and monitor battery charge were also displayed
(Figure 5.7).
5.6.2 Software ‘Move’ function
The Move function allowed data stored on the monitor to be transferred to the
website database. On selecting the Move button, computerised processes occurred in
sequence to simultaneously check the monitor clock, backup stored data to the PC
and transfer data to the online database (Figure 5.8).
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Figure 5.7: Software Preview function
PC date & timeMonitor ID number Preview button
Internet connection &
monitor battery charge
Actuation data stored on the
monitor
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Figure 5.8: Computerised processes during data Move
* The product information for the Tracker monitor specified that the monitor clock accuracy
was +/- 15 minutes per year without update. PC: Personal computer.
Move button selected
Computerised check of
monitor clock accuracy
with PC clock
Monitor clock +/- 15
minutes of PC clock*
Monitor clock greater than
15 minutes different to PC
clock*, or monitor fault
Backup copy of data stored
on PC hard drive in Excel
format
Backup copy of data stored
on PC hard drive in Excel
format
Data transferred from
monitor to website database
(password protected)
Data assigned to correct
Participant ID on website
automatically
Monitor reset (data cleared
from memory) and monitor
clock synchronised to PC
clock
Data prevented from upload
to website
Error message advised
Investigator to return
monitor to coordinating
trial site for fault analysis
and data retrieval
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During successful data upload, investigators were prompted to enter a password to
allow data transfer to the website database (Figure 5.9). The PC software was linked
to the online database, so that data from the monitor was automatically allocated to
the correct Participant ID on the website. After upload, the monitor was
automatically reset (data was cleared from its memory) and investigators could
reload the monitor with a new medication canister in preparation for dispensing at
the next visit.
Excel files containing actuation data were automatically saved into a folder on the
PC, identified by the date of upload and the Participant ID. One file was created for
each monitor. Each file was labelled by the Participant ID, inhaler ID and date and
time of upload. The monitor clock date and time were also saved in the file.
Data upload failure as a result of monitor clock fault or monitor damage resulted in
an error message advising investigators to return monitors to the coordinating trial
site for fault analysis, data retrieval and data cleanup (Figure 5.10). The process of
fault identification and data retrieval occurred constantly throughout the study.
If connection to the internet was not available at the time of upload, then data was
stored on the computer hard drive and automatically uploaded as above when an
internet connection was sensed.
Data Move was performed for all returned monitors from participants, regardless of
whether or not the participant had reported using the MDI. If no data was stored on
the monitor, a backup (blank) Excel file was still created on the PC hard drive.
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Figure 5.9: Software Move function: successful data upload
Password entry prior
to data transfer
Information bar to confirm data
ready for upload to the online
database
Move button
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Figure 5.10: Monitor fault during data Move
Error message to advise Investigators
that data move has failed
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5.6.3 Software ‘Backup’ function
The Backup function allowed investigators to copy data stored on the PC hard drive
to a CD. This function allowed an off-site copy of the data to be made; thus, together
with the primary website database, backup data was stored on the PC hard drive and
a CD.
After data was uploaded from all MDIs returned by a participant, investigators were
required to ‘burn’ a CD with the data from these monitors. Thus, one CD per visit
per participant was created. After selecting the backup function on the software and
inserting a blank CD into the PC, investigators were automatically prompted to a
directory on the PC hard drive containing the backup data, in folders organised by
date of upload and Participant ID (Figure 5.11 and Figure 5.12). After selecting the
correct files for backup, data were backed up automatically to a CD.
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Figure 5.11: Software Backup function (A)
Backup data was stored in folders
organised by date of upload
CD backup selected from the
Tools bar
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Figure 5.12: Software Backup function (B)
After selecting the folder with the date of upload,
backup Excel files (labelled by Participant ID, inhaler
ID and date/time) were selected and a CD created
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5.6.4 Software ‘Test’ function
The Test function was designed to allow computerised within-trial checks of monitor
function.
After connecting the monitor to the PC, the Test function was selected. The monitor
was automatically reset by the software. Investigators were prompted by the
computer software to actuate the MDI twice; five seconds were allowed after
prompting for actuation to occur. The software checked that the number and
time/date of the two actuations performed were accurate (to within five seconds) and
also checked the monitor battery charge.
At the end of the Test function, the monitor was automatically reset and the monitor
clock synchronised with the computer. If all elements of monitor check were
accurate, the software displayed a ‘green tick’ to inform the investigator that the
MDI could be used in the trial. If any elements of the check failed, investigators
were prompted with a ‘red cross’ and advised to remove the monitor from circulation
and return it to the coordinating site (Figure 5.13). Test reports could be saved or
printed for reference.
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Figure 5.13: Software Test Function
Software check of the
monitor ID and clock
Monitor synchronised to the
PC clock at the start & end of
the Test process
The monitor battery
charge displayed
The report could be
printed or saved
Green tick: monitor had passed
all elements of testing. Red
cross: monitor had failed testing
The software checked that the
correct number and date/time of
actuations were recorded by the
monitor (to +/- 5 seconds)
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5.6.5 Software ‘Reset’ function
This function cleared the monitor memory of all data and synchronised the monitor
clock to the PC clock.
5.7 Within-trial monitor checking protocol
Monitors loaded with medication canisters were checked for correct functioning by
investigators using the Test function described above, prior to dispensing to
participants at Visits 2, 3, and 4. The purpose of these within-trial monitor checks
was to ensure that there had been no loss of function in the period following pre-
study checks and to identify damaged monitors prior to repeat dispensing.
Investigators were advised to perform the checks in the 48-hours preceding the study
visit.
5.8 Within-trial participant data check protocol
Data from the MDIs collected from participants at Visits 2, 3, 4 and 5 were uploaded
using the Move function described above. The computer software automatically
compared the monitor clock with the computer clock prior to data upload; a time
discrepancy of more than 15 minutes prevented data upload and prompted the
investigator to return the MDI to the coordinating site for analysis. The purpose of
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this within-trial data check was to identify monitors with incorrect clocks prior to
data transfer, thus reducing the risk of erroneous data being uploaded to the database.
A 15 minute discrepancy was allowed as the product information for the
Smartinhaler Tracker specifies that the monitor clock accuracy is +/- 15 minutes per
year without update.
5.9 Website database of actuation data from uploaded MDIs
Data from uploaded MDIs was stored on a password-protected, website-based
database (www.asthma-track.com). The coordinating trial site had complete access
to the data on the website (‘principal investigator access’) and could supervise trial
progress remotely. Investigators at trial sites had access restricted to that required to
conduct the trial according to the protocol (‘investigator access’). Investigator log-
ins did not allow viewing of any uploaded inhaler data. Access to the website also
provided training resources (Figure 5.14). The key features of the website are
detailed below.
5.9.1 Participant study IDs
Study IDs were pre-allocated on the website, so that once randomisation had
occurred, investigators could assign patient initials and date of birth to the relevant
ID (Figure 5.15). Investigators were restricted in being able to view only participant
IDs allocated to their own trial site.
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Figure 5.14: Asthma-track website home page
Tabs allowed access to training
resources and download of software
required to manage data on the monitors
Participant IDs for the trial site were
displayed by randomised group
Investigator logins restricted website
access to participants allocated to that
specific trial site only. In this example,
participants from the Lower Hutt site
are displayed
Participant IDs were pre-allocated to sites. After
randomisation, investigators could allocate patient
initials and DOBs to the ID. In this example, IDs
K053-K059 and K205 have been allocated to
patients; K060 has not yet been allocated (hence the
blank row)
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Figure 5.15: Viewing participants on the asthma-track website
By clicking on the ‘View’ icon, MDIs pre-allocated to
participants were displayed by study visit.
Clicking on the ‘Edit’ icon allowed patient initials and DOB to
be entered after randomisation
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5.9.2 Monitor allocation
By selecting the ‘View’ icon, the MDIs pre-allocated to a Participant ID could be
displayed by study visit (Figure 5.15). Investigators were able to add further MDIs
to the participant record (for example, to replace a lost or damaged monitor), but
were not able to alter or remove any pre-allocated MDIs (Figure 5.16).
Figure 5.16: Allocating MDIs to the website after randomisation
MDIs pre-allocated to the study visits are displayed. Selecting the ‘Add
Smartinhaler’ icon allowed investigators to add new monitors to the participant
record, but not to adjust or remove pre-allocated monitors
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5.10 Website supervision by the coordinating trial site
Principal investigator access to the website allowed real-time supervision of trial
sites. The website allowed the coordinating trial site to review data uploads from all
sites (Figure 5.17), to track investigator login to the website (Figure 5.18) and to
check if replacement monitors had been correctly assigned to a Participant ID.
5.10.1 Electronic data supervision following Visit 1
By viewing assignment of patient initials and DOBs to the pre-allocated IDs on the
website, the rate of recruitment at trial sites could be supervised. This was
performed after the Visit 1 case record form documentation was received by the
coordinating investigator.
5.10.2 Electronic data supervision summary for Visits 2 to 5
On completion of a study visit by an investigator, case record form documentation
and CDs were forwarded to the coordinating trial site (Figure 5.19). CDs were
checked to ensure the correct number of MDIs from the preceding study visit had
been uploaded and backed-up. The website was then checked to ensure data from
the upload had successfully transferred and that emergency inhalers (including any
new monitors allocated to replace malfunctioning monitors) were correctly assigned.
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Figure 5.17: Supervising data upload from trial sites
Medication use by inhaler or Participant ID
could be viewed by the coordinating trial
site to monitor data acquisition
Data for an individual participant or for all
data on the website could be backed up by
exporting to Excel and saving to a PC
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Figure 5.18: Supervising investigator logins and actions on the website
Investigator data uploads, login to the website and actions
performed during login were all able to be supervised remotely by
the coordinating trial site
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Figure 5.19: Electronic data supervision summary for Visits 2 to 5
Study visit completed: documentation and
CDs received by coordinating investigator
CDs checked for the correct number of MDIs
uploaded and backed-up
Website checked for presence of uploaded
data and correctly assigned backup spare
monitors
Query generated with
investigator if any
discrepancies noted
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5.11 Summary of trial monitor and data checking protocols
The pre-study and within-study monitor checking protocols and the within-study data
checking protocols are summarised in Table 5.1.
5.12 Summary
All electronic monitors were tested according to the pre-study use checks prior to
packaging for use. Once packaged into boxes, allocation of monitors to Participant
IDs was verified on both the spreadsheet log and online database, ensuring that every
monitor was accounted for and traceable. All monitors underwent within-study
monitor checking and data checking protocols. The computer software and online
database were developed in order to safeguard data acquisition and allow remote
supervision in the setting of a multicentre trial.
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Table 5.1: Pre-study and within-study monitor and data checking protocol
Monitor checks Pre-study
monitor check
*
Within-study
monitor check
†
Within-study
data check †
Loading with medication
canister ‡
X X
Reset § X X X
Check for external structural
faults
X X
Pre-study MDI actuations ۅ ;  
Within-study MDI
actuations ¶
X
Diary log of actuations X
Computerised testing
process
X
Check of accuracy of
number of actuations
X X
Check of accuracy of
actuation time and date
X X
Check of monitor ID number
**
X X
Check of battery charge X X
Printable test report
generated
X
Preview of data stored on
monitor ††
X X
Computerised check of
monitor clock accuracy ‡‡
X
Data from faulty monitors
prevented from upload to
website
X
Upload of data from
functioning monitors to
website
X
Data retrieval and cleanup
from faulty monitors
X
Fault analysis for
malfunctioning monitors
X X X
[Table legend is on the following page]
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*: Pre-study checks were performed at the coordinating trial site prior to study use;
†: Within-study monitor checks and data checks were performed during trial use;
‡: The MDI was actuated during every canister reload to ensure firm insertion of the
canister;
§: Data was cleared from the monitor memory and clock synchronised with the computer;
ۅ7KH0',ZDVDFWXDWHGWZLFHZLWKDIXUWKHUWZRDFWXDWLRQVDWOHDVWKRXUVODWHU
¶: The MDI was actuated twice, prompted by computer software ‘Test’ function;
**: Each monitor had a unique identification (ID) number visible externally and on computer
connection;
††: Visual inspection of data monitor without upload to the website;
‡‡: Computerised check of monitor clock accuracy to +/- 15 minutes of actual time.
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Chapter Six: Results
6.1 Trial timelines
303 participants were enrolled between 29 June 2010 and 14 September 2011, with
the last participant completing the study on 29 February 2012. The study timelines
are summarised in Table 6.1. The recruitment of participants by site is shown in
Table 6.2. Mitesh Patel recruited all the participants at the MRINZ site and also
UHYLHZHGSDUWLFLSDQWVDW WKH7X.RWDKL0ƗRUL$VWKPD7UXVW /RZHU+XWWVLWH $OO
external site monitoring, trial coordination and Ethics reporting were performed by
Mitesh Patel.
6.2 Dataset
Total follow-up time was 24,347 days (66.66 years) for the SMART group and
24,977 days (68.38 years) for the Standard group. Mean ± SD follow-up time was
161.2 ± 35.8 days per SMART participant and 164.3 ± 31.1 days per Standard
participant. Mean ± SD treatment exposure was 155.8 ± 39.1 days per SMART
participant and 159.2 ± 34.1 days per Standard participant.
One participant, who was ineligible due to a prior history of paroxysmal atrial
fibrillation, was randomised to the SMART group and completed the study.
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Table 6.1: Study timelines
Date Milestone
October 2009 x Initial ethics application
x Funding confirmed from the Health Research
Council of New Zealand
February-April 2010 x Protocol updates
x Electronic monitor testing
x Monitor software development
x Case record form drafting
x Development of patient-seen documents (asthma
plans, appointment cards, information sheets,
consent forms)
x Collaboration with Nexus6 and Lower Hutt site
7X.RWDKL0ƗRUL$VWKPD7UXVW
x Ethics re-submission
May 2010 x Full ethics approval
June 2010 x Clinical trial registration (ANZCTR
12610000515099)
x Recruitment commencement (Wellington)
July 2010 x Set up of 2nd site (Lower Hutt)
September 2010 x Set up of 3rd site (Tauranga CentralMed GP)
December 2010 x 25% recruited
January 2011 x Set up of 4th site (Tauranga Papamoa Pines GP)
February 2011 x Set up of 5th site (Auckland Henderson Medical
Centre GP)
March 2011 x 50% recruited
May 2011 x 75% recruited
August 2011 x 150 participants completed: interim safety
statistical analysis performed
September 2011 x 100% recruited
February 2012 x Final participant completed
March-June 2012 x Hospital attendance validation performed
May 2012 x Database checks complete and analysis
commenced
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Table 6.2: Recruitment of participants by site
Site Number of participants
randomised
7X .RWDKL 0ƗRUL $VWKPD 7UXVW /RZHU
Hutt
15
CentralMed GP, Tauranga 96
Papamoa Pines GP, Tauranga 24
Henderson Medical Centre GP, Auckland 62
Medical Research Institute of New
Zealand, Wellington
106
Total 303
Use of non-study inhalers (n=12 participants for SMART and n=9 participants for
Standard) and sharing of inhalers (n=4 participants for SMART and n=3 participants
for Standard) were reported infrequently.
Dose and duration for courses of systemic corticosteroids (including IV doses) were
collected for all participants experiencing asthma exacerbations. All hospital
attendances for asthma were verified with hospital records. Two extra ED visits for
asthma were identified during the hospital database verification.
One extra SAE (a hospital admission for chest pain determined by the treating
physicians to be non-cardiac in origin), was identified during the hospital database
verification.
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Out of a maximum possible 1515 study visits (five visits per patient, 303
randomised), 60 did not occur due to patient withdrawal, leaving 1455 potential
visits. There were 11 non-attendances for visits; for seven of these visits,
exacerbation, adverse effects and questionnaire data could be obtained by telephone.
ACQ-7 results were measured for 1450 of 1455 visits (99.7%) (one non-completion
of ACQ-7 and four non-attendances where telephone contact not possible).
Interpolation for one missing value was performed for 12/1450 (0.83%) of the ACQ-
7 questionnaires. FEV1 results were measured for 1438 of 1455 visits (98.8%) (11
non-attendances, four participants declining spirometry and two non-completion of
spirometry).
6.3 Protocol updates after study commencement
Protocol version 2 (dated 19 April 2010) was the current version at the time of trial
commencement in June 2010. Updates to the protocol after trial commencement are
detailed in Table 6.3.
6.4 Electronic monitor performance results
282,466 actuations from participant use of their inhalers over 49,149 days of
treatment exposure were stored on the database at study completion.
249
Table 6.3: Protocol version updates after trial commencement
Date of update Update details Rationale
9 September
2010 (to
protocol version
3)
Inclusion Criteria:
Clarification of
exacerbation definition for
patients who self-
administer prednisone
A proportion of severe asthmatics
will have been prescribed prednisone
by their physician or GP for self-
administration at home in the event
of an exacerbation, as per their self-
management plan. Prednisone use
for at least 3 days fulfils the
definition of a severe asthma
exacerbation used in the ATS/ERS
consensus asthma clinical trial
guidelines (Reddel et al., 2009) and
so the wording of this inclusion
criterion was updated in order to
allow eligibility to the study for these
patients.
Exclusion Criteria:
Clarification of use of a
home nebuliser
Patients with asthma who used a
home nebuliser were eligible to enter
the study if they agreed to withhold
nebuliser use for the study duration,
as discussed with the patient by the
investigator at the first visit.
Visit 1 Three, rather than two, Vannair
inhalers were provided to each
patient in the SMART group at Visit
1, to allow patients greater flexibility
when using their inhalers.
20 October
2010 (to
protocol
Version 4)
Prior Intensive Care Unit
(ICU) admission removed
as an exclusion criterion
As the study aimed to study the
potential benefits of the SMART
regimen specifically in severe and
high-risk asthmatics, patients who
had prior ICU admissions for asthma
formed part of the target group for
this study. The removal of prior ICU
admission as an exclusion criterion
therefore allowed a representative
group of severe asthmatics to be
eligible for this study.
Protocol version 2 (dated 19 April 2010) was the current version at the time of trial
commencement in June 2010.
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6.4.1 Pre-study monitor checks
2728 monitors in total (839 salbutamol monitors and 1889 budesonide/formoterol
monitors) underwent pre-study checks. 2678 of the 2728 monitors tested (98.2%)
passed this check (Figure 6.1). Of the 50 monitors which failed testing, 26 did not
record actuations that were performed, 20 recorded extra actuations and four had
structural faults. Of these 50 monitors, 15 were subsequently repaired and passed for
use in the trial, while the remaining 35 monitors were not utilised any further.
6.4.2 Within-study monitor checks
2642 monitors (806 salbutamol monitors and 1836 budesonide/formoterol monitors)
were dispensed to patients in the trial. A total of 93 of 2642 monitors (3.5%) (33
budesonide/formoterol monitors in the SMART group and 29 budesonide/formoterol
and 31 salbutamol monitors in the Standard group) were lost or thrown away by
participants during the study.
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Figure 6.1: Monitors identified as faulty during pre-study use checks
*: 27 budesonide/formoterol monitors and 23 salbutamol monitors; †: 10 budesonide/formoterol
monitors and 16 salbutamol monitors; ‡: 16 budesonide/formoterol monitors and 4 salbutamol
PRQLWRUVEXGHVRQLGHIRUPRWHUROPRQLWRUVDQGVDOEXWDPROPRQLWRUV ۅ WKHVHGHYLFHVZHUHQRW
reused in the trial.
2728 monitors
tested
Not recording
actuations†:
26
Duplicate
actuations‡:
20
Structural
fault§:
4
Fault found
and fixed:
12
No fault
foundۅ:
14
Fault found
and fixed:
0
No fault
foundۅ:
20
Fault found
and fixed:
3
No fault
foundۅ:
1
Broken
switch: 9
Nut missing:
1
Flat battery:
2
Electronics
fault:
1
Blocked
nozzle:
2
50 monitors failed
testing*
2678 passed testing
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There were 76 monitors (2.9% of the total dispensed) that failed testing and were
removed from trial use by investigators as a result of the within-study monitor
checking process (Figure 6.2). 33 of these monitors failed testing because the battery
was not fully charged; in 31/33 of these monitors, actuation recording was not
affected. 25 monitors failed checks due to a medication plume fault as a result of
MDI nozzle blockage and 12 did not record test actuations correctly. Four monitors
were found to record duplicate actuations.
6.4.3 Within-study participant data checks
There were 51 monitors (1.9% of the total dispensed) which failed the data upload
checks (Figure 6.3). In all cases, data was stored on the monitor from use of the
MDI during the preceding study window. An error message from the computer
software alerted the investigator that there was a fault preventing data transfer or that
the monitor clock had malfunctioned. In the majority of monitors, evidence of fluid
immersion as the cause for malfunction was determined during manufacturer
analysis. All of these monitors were returned to the manufacturer and in 48, data
could be retrieved to the point of monitor malfunction. In three monitors, data
extraction was unable to be performed due to the severity of fluid damage.
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Figure 6.2: Monitors identified as faulty during within-study checks at Visits 2
to 4
*: 37 budesonide/formoterol monitors and 39 salbutamol monitors; †: 3 budesonide/formoterol
monitors and 1 salbutamol monitor (no fault found on these monitors; not reused in the trial); ‡: 23
budesonide/formoterol monitors and 10 salbutamol monitors; §: 7 budesonide/formoterol monitors
DQGVDOEXWDPROPRQLWRUVۅEXGHVRQLGHIRUPRWHUROPRQLWRUVDQGVDOEXWDPROPRQLWRUV
salbutamol monitors.
2642 monitors dispensed
to participants
Duplicate
actuations†:
4
Low battery‡:
33
Not recording
doses§:
12
76 monitors failed
within-trial checks*
Plume
problemۅ:
25
Electronics
fault¶:
2
Low battery
confirmed:
26
No battery
fault:
7
Broken switch:
9
Mechanical
damage:
1
No faults
identified:
2
Nozzle
blocked:
24
No fault found:
1
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Figure 6.3: Monitors identified as faulty during within-study data upload checks
at Visits 2 to 5
*: 32 budesonide/formoterol monitors and 19 salbutamol monitors; †: 29 budesonide/formoterol
monitors and 19 salbutamol monitors; ‡: 3 budesonide/formoterol monitors.
2642 monitors dispensed to
participants
Monitors with data retrieved†:
48
Monitors with data retrieval
failure‡:
3
51 monitors failed data
upload checks*
Fluid immersion:
33
Battery fault:
9
Monitor clock fault:
4
Electronics fault:
2
Corroded by fluid exposure:
3
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6.4.4 Overall monitor performance
93/2642 (3.5%) monitors were lost or thrown away by participants. 51/2642 (1.9%)
monitors malfunctioned prior to data upload. Complete data was therefore available
from 2498/2642 (94.5%) of dispensed monitors and 2498/2549 (98.0%) of returned
monitors.
6.5 Electronic medication use data on study visit days
After removal of medication use data from study visit days (n=11,576 actuations),
270,890 actuations were included in the analyses.
6.6 Interim statistical safety analysis
2/85 (2.35%) participants randomised to the SMART group had at least one hospital
admission for asthma; one participant had one and the other had two admissions.
2/82 (2.44%) participants randomised to the Standard group had one hospital
admission each for asthma, a total of two hospital admissions.
The total number of participants with at least one hospital admission for asthma was
4/167, 2.40% (95% CI 0.66 to 6.0). The p value for whether the proportion was
different to 4.5% was 0.25. There was therefore no evidence that the proportion of
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participants with at least one hospital admission for asthma was different from the
pre-specified reference rate.
2/85 (2.35%) participants randomised to the SMART group and 2/82 (2.44%)
participants randomised to the Standard group had at least one hospital admission for
asthma. The Relative risk of admission SMART versus Standard was 0.96 (95% CI
0.14 to 6.7), Fishers exact p=1.0.
There were three hospital admissions for asthma in 85 participants in the SMART
group and two hospital admissions for asthma in 82 participants in the Standard
group. The Relative rate of hospital admissions for asthma SMART versus Standard
was 1.4 (95% CI 0.24 to 8.3), p=0.69.
There was therefore no evidence that the rate of hospital admissions for asthma
overall was different from 4.5% or that there was any difference in the rate of
hospital admissions for asthma by treatment group. The independent safety monitor,
Dr Andrew Brant, did not recommend a safety review for the study.
6.7 Study flow of participants
Study flow of participants is shown in Figure 6.4.
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Figure 6.4: Study flow of participants
Study sites:
3 Primary care clinics
0ƗRULKHDOWKFOLQLF
1 Secondary care (hospital) site
1243: Assessed for eligibility
869 from Primary care
IURP0ƗRULVLWH
313 from Hospital site
940: Ineligible
515: Not meeting inclusion
criteria
287: Not wishing to participate
56: Smoking history
33: Cardiovascular disease
30: Additional lung pathology
19: Other exclusion criteria
303: Randomised
182: Primary care sites
  0ƗRULVLWH
106: Hospital site
151: Allocated to SMART
151: Received allocated
intervention
152: Allocated to Standard
152: Received allocated
intervention
17:Discontinued
7: Worsening asthma (pt
decision)
5: Due to patient choice
3: Adverse Event (pt decision)
1: Worsening asthma
(investigator decision)
1: Lost to follow-up
11:Discontinued
2: Worsening asthma (pt
decision
3: Due to patient choice
5: Adverse Event (pt decision)
0: Worsening asthma
(investigator decision)
1: Lost to follow-up
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analysis
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940/1243 (75.6%) of patients screened were ineligible for study entry. 515/940
(54.8%) of these patients did not meet eligibility criteria as they had not experienced
an asthma exacerbation in the preceding 12 months or were not on ICS, and therefore
were outside the target group of ‘at-risk’ patients.
Loss to follow-up occurred infrequently (2/303 (0.7%) of participants). A final visit
assessment was completed in 21/28 (75%) participants who otherwise withdrew from
the study. All patients randomised to treatment were included in the analysis for the
primary outcome.
6.8 Baseline characteristics of participants
Baseline characteristics of participants are shown in Table 6.4.
Approximately 60% of participants had poorly controlled asthma at baseline, as
measured by ACQ-7 score. 90% of participants had at least one severe asthma
exacerbation in the 12 months preceding study entry. 40% of participants had 2 or
more severe asthma exacerbations in the preceding 12 months.
Baseline budesonide dose was approximately 800µg and approximately 65% of
participants were on LABA therapy pre-study. Half of the 303 participants had a
step-up of therapy at study entry, as defined by GINA criteria (GINA, 2011).
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Table 6.4: Baseline characteristics of trial participants*
Characteristic SMART group
(N = 151)
Standard group
(N = 152)
Age, years
Mean±SD 41.3±13.7 42.6±14.5
Median (IQR) 41.6 (29.2 to
52.3)
42.4 (31.0 to
56.0)
Male gender, n (%) 48 (31.8) 46 (30.3)
Ethnicity, n (%)
European 113 (74.8) 118 (77.6)
0ƗRUL  
Pacific Islander 5 (3.3) 10 (6.6)
Other 8 (5.3) 5 (3.3)
Duration of asthma, years
Mean±SD 26.7±14.5 26.2±14.6
Median (IQR) 25 (17 to 36) 23 (15 to 36)
ACQ-7 Score
Mean±SD 1.87±0.96 1.90±1.13
Median (IQR) 1.86 (1.14 to
2.57)
1.71 (1.14 to
2.43)
Number of participants with:
6FRUHQ  
Score 0.76 – 1.49, n (%) 34 (22.5) 39 (25.7)
6FRUHQ  
On-treatment FEV1, Litres
Mean±SD 2.62±0.91 2.50±0.78
Median (IQR) 2.54 (2.00 to
3.07)
2.48 (1.92 to
3.01)
On-treatment FEV1 % predicted
Mean±SD 81.6±18.9 80.4±20.5
Median (IQR) 82.1 (69.8 to
93.8)
82.5 (66.1 to
91.9)
Number of participants with:
FEV1 <40 % predicted, n (%) 0 (0) 3 (2.0)
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FEV1 40 - <60 % predicted, n (%) 22 (14.6) 25 (16.4)
FEV1 60 - <80 % predicted, n (%) 46 (30.5) 39 (25.7)
FEV1 80 - <100 % predicted, n (%) 58 (38.4) 61 (40.1)
FEV1 SUHGLFWHGQ  
Severe exacerbations in the prior 12 months
Mean±SD 1.55±1.31 1.73±1.22
Median (IQR) 1 (1 to 2) 1 (1 to 2)
Number of participants with:
0 severe exacerbations, n (%) 14 (9.3) 11 (7.2)
1 severe exacerbation, n (%) 86 (57.0) 75 (49.3)
2 severe exacerbations, n (%) 29 (19.2) 31 (20.4)
3 severe exacerbations, n (%) 10 (6.6) 22 (14.5)
4 severe exacerbations, n (%) 5 (3.3) 6 (3.9)
VHYHUHH[DFHUEDWLRQVQ  
Number of hospital admissions ever for
asthma
Mean±SD 3.13±6.13 4.64±10.90
Median (IQR) 1 (0 to 4) 1 (0 to 4)
Medication use
Daily ICS dose (budesonide or
equivalent), µg
Mean±SD 804.5±352.7 812.6±370.4
Median (IQR) 800 (800 to 800) 800 (800 to 800)
LABA, n (%) 92 (60.9) 103 (67.8)
Combination ICS/LABA
inhaler, n (%)
73 (48.3) 82 (53.9)
Step-up, n (%) 76 (50.3) 64 (42.1)
Step-neutral, n (%) 75 (49.7) 88 (57.9)
ICS dose reduction, n (%) 14 (9.3) 15 (9.9)
Self-reported reliever use as per ACQ
question 6, median (IQR)
2 (1 to 3) 2 (1 to 3)
Number of participants with:
Self-report score of 0, n (%) 26 (17.2) 22 (14.5)
Self-report score of 1, n (%) 45 (29.8) 49 (32.2)
Self-report score of 2, n (%) 39 (25.8) 40 (26.3)
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Self-report score of 3, n (%) 25 (16.6) 21 (13.8)
Self-report score of 4, n (%) 8 (5.3) 11 (7.2)
Self-report score of 5, n (%) 5 (3.3) 3 (2.0)
Self-report score of 6, n (%) 3 (2.0) 6 (3.9)
Spacer use, n (%) 75 (49.7) 75 (49.3)
Pre-study use of a written asthma self-
management plan, n (%)
15 (9.9) 20 (13.2)
Use of within-study symptoms-based plan,
n (%)
125 (82.8) 125 (82.2)
Use of within-study peak flow-based plan, n
(%)
26 (17.2) 27 (17.8)
Current smokers, n (%) 30 (19.9) 29 (19.1)
Pack year history:
Mean±SD 9.5±8.8 12.5±11.6
Median (IQR) 7 (3 to 12) 9 (4 to 16)
Ex-smokers, n (%) 49 (32.5) 48 (31.6)
Pack year history:
Mean±SD 8.3±8.5 8.1±10.4
Median (IQR) 5 (1 to 10) 4 (2 to 10)
Non-smokers, n (%) 72 (47.7) 75 (49.3)
Pregnant during study participation, n (%) 4 (2.6) 5 (3.3)
* Plus-minus values are means ± SD. IQR: Inter-quartile range. A severe exacerbation is defined as
the use of systemic corticosteroids for at least 3 days; or, a hospitalisation or ED visit because of
asthma, requiring systemic corticosteroids. Courses of corticosteroids separated by 7 days or more
were treated as separate severe exacerbations. ACQ-7 score is a composite score of asthma control,
comprising questions on asthma symptoms, rescue bronchodilator use and FEV1 % predicted (overall
VFRUHV UDQJH IURP  WR  ZLWK VFRUHV  VXJJHVWLQJ µZHOOFRQWUROOHG¶ DVWKPD DQG VFRUHV 
suggesting ‘not well-controlled’ asthma).
ICS dose conversion: 500µg fluticasone = 800µg budesonide; 1000µg beclomethasone = 800µg
budesonide. Low daily budesonide dose was defined as 200-400µg; medium daily budesonide dose
was defined as >400-800µg; high daily budesonide dose was defined as >800µg. Step-up patients
were defined as having no pre-study treatment with LABA (at any ICS dose) or pre-study treatment
with low dose budesonide and LABA; step-neutral was defined as pre-study treatment with medium
or high dose budesonide and LABA. ICS dose reduction was defined as the subgroup of step-neutral
patients who were on pre-study high dose budesonide and LABA [based on GINA (2011)].
ACQ question 6 is a categorical score of reliever use over the preceding 7 days in the following bands:
score 0, none; score 1, 1 to 2 salbutamol inhalations most days; score 2, 3 to 4 salbutamol inhalations
most days; score 3, 5 to 8 salbutamol inhalations most days; score 4, 9 to 12 salbutamol inhalations
most days; score 5, 13 to 16 salbutamol inhalations most days; score 6, more than 16 salbutamol
inhalations most days.
There are no missing data from Table 6.4.
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80% of participants were provided with a symptoms-based asthma self-management
plan and 20% a peak-flow based plan for use during the study.
6.9 Primary outcome variable
There was no significant difference in the proportion of participants with at least one
high use episode: SMART 84/151 (55.6%) versus Standard 68/152 (44.7%), relative
risk (95% CI) 1.24 (0.99 to 1.56), p=0.058 (Table 6.5). In the sensitivity analysis,
which also incorporated the overuse of budesonide/formoterol in the Standard group,
there was no significant difference in the proportion of participants with at least one
high use episode: SMART 84/151 (55.6%) versus Standard 94/152 (61.8%), relative
risk (95% CI) 0.90 (0.74 to 1.09), p=0.27 (Table 6.5).
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Table 6.5: Primary outcome variable
Outcome
SMART
group
(N = 151)
Standard
group
(N = 152)
Relative Risk
SMART vs
Standard
(95% CI)
P value
Primary outcome
At least one episode of high use,
n (%)
84 (55.6) 68 (44.7) 1.24
(0.99 to 1.56)
0.058
At least one episode of high use
(adjusted for
budesonide/formoterol use above
maintenance in Standard), n (%)*
84 (55.6) 94 (61.8) 0.90
(0.74 to 1.09)
0.27
High use is defined as >12 actuations per 24-hours of budesonide/formoterol for SMART and >16
actuations per 24-hours of salbutamol for Standard.*: Sensitivity analysis, using a modified definition
of a high use episode for the Standard group, to adjust for the use of budesonide/formoterol in excess
of the four maintenance actuations by some participants on occasions.
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6.10 Number of days of high use
The SMART regimen was associated with significantly fewer high use days (Table
6.6).
Table 6.6: High use days and high use days without medical review
Outcome
SMART
group
(N = 151)
Standard
group
(N = 152)
Relative
Rate
SMART vs
Standard
(95% CI)
P
value
High use days
Number of days of high use 5.1±14.3 8.9±20.9 0.58
(0.39 to 0.88)
0.01
Number of days of high use in
participants with at least one
high use episode*
9.1±18.2 19.9±27.7 - -
High use days without medical
review
Number of days of high use without
medical review in participants with
at least one high use episode*
8.5±17.8 18.3±24.8 0.49
(0.31 to 0.75)
0.001
Plus-minus values are means ± SD.
High use is defined as >12 actuations per 24-hours of budesonide/formoterol for SMART and >16
actuations per 24-hours of salbutamol for Standard.
Estimates are weighted as part of the analysis and may be numerically different to the values
calculated from the tabulated mean values.
Analysis of the relative rates of days of overuse was calculated by Poisson regression with an offset
for the treatment exposure. The analysis suggested over-dispersion and a dispersion term was used to
adjust for the over-dispersion.
*: n=84 for SMART and n=68 for Standard.
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6.11 Number of days of high use without medical review
In participants who had at least one high use episode, there were significantly fewer
days of high use without medical review in the SMART group (Table 6.6).
The proportion of high use days that were without medical review were 8.5/9.1 days
(93.4%) in the SMART group and 18.3/19.9 days (92.0%) in the Standard group
(Table 6.6 and Figure 6.5).
Figure 6.5: Number of days of high use in participants with at least one high use
episode
*refers to the comparison of days of high use without medical review
9·1
19·9
p=0.001*
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6.12 Marked overuse
The risk of at least one marked overuse episode was similar between groups (Table
6.7). The number of days with marked overuse was significantly less for the
SMART group (Table 6.7).
6.13 Number of days of marked overuse without medical review
In participants who had at least one marked overuse episode, the number of days of
marked overuse without medical review was not significantly different between the
groups (Table 6.7).
The proportion of marked overuse days that were without medical review were
6.7/7.4 days (90.5%) in the SMART group and 11.7/13.1 days (89.3%) in the
Standard group (Table 6.7).
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Table 6.7: Marked overuse days and marked overuse without medical review
Outcome
SMART
group
(N = 151)
Standard
group
(N = 152)
Relative Risk
or Rate
SMART vs
Standard
(95% CI)
P
value
Marked overuse
At least one episode of marked
overuse, n (%)
54 (35.8) 56 (36.8) 0.97
(0.72 to 1.31)
0.85
Number of days of marked
overuse
2.6±10.2 4.8±14.9 0.56
(0.35 to 0.88)
0.013
Number of days of marked
overuse in participants with at
least one marked overuse
episode*
7.4±16.0 13.1±22.3 - -
Marked overuse without
medical review
Number of days of marked
overuse without medical review
in participants with at least one
marked overuse episode*
6.7±15.7 11.7±19.0 0.62
(0.37 to 1.06)
0.079
Plus-minus values are means ± SD.
Marked overuse is defined as >16 actuations per 24-hours of budesonide/formoterol for SMART and
>24 actuations per 24-hours of salbutamol for Standard.
Estimates are weighted as part of the analysis and may be numerically different to the values
calculated from the tabulated mean values.
Analysis of the relative rates of days of overuse was calculated by Poisson regression with an offset
for the treatment exposure. The analysis suggested over-dispersion and a dispersion term was used to
adjust for the over-dispersion.
*: n=54 for SMART and n=56 for Standard.
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6.14 Extreme overuse
The risk of at least one extreme overuse episode was similar between groups (Table
6.8). The number of days with extreme overuse was significantly less for the
SMART group (Table 6.8).
6.15 Number of days of extreme overuse without medical review
In participants who had at least one extreme overuse episode, the number of days of
extreme overuse without medical review was not significantly different between the
groups (Table 6.8).
The proportion of extreme overuse days that were without medical review were
5.2/5.8 days (89.7%) in the SMART group and 9.6/11.0 days (87.3%) in the Standard
group (Table 6.8).
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Table 6.8: Extreme overuse days and extreme overuse without medical review
Outcome
SMART
group
(N = 151)
Standard
group
(N = 152)
Relative Risk
or Rate
SMART vs
Standard
(95% CI)
P
value
Extreme overuse
At least one episode of
extreme overuse, no. (%)
41 (27.2) 40 (26.3) 1.03
(0.71 to 1.50)
0.87
Number of days of extreme
overuse
1.6±6.7 2.9±12.2 0.56
(0.34 to 0.91)
0.02
Number of days of extreme
overuse in participants with
at least one extreme overuse
episode*
5.8±11.9 11.0±22.1 - -
Extreme overuse without
medical review
Number of days of extreme
overuse without medical
review in participants with at
least one extreme overuse
episode*
5.2±11.9 9.6±18.3 0.59
(0.31 to 1.10)
0.096
Plus-minus values are means ± SD.
Extreme overuse is defined as >20 actuations per 24-hours of budesonide/formoterol for SMART and
>32 actuations per 24-hours of salbutamol for Standard.
Estimates are weighted as part of the analysis and may be numerically different to the values
calculated from the tabulated mean values.
Analysis of the relative rates of days of overuse was calculated by Poisson regression with an offset
for the treatment exposure. The analysis suggested over-dispersion and a dispersion term was used to
adjust for the over-dispersion.
*: n=41 for SMART and n=40 for Standard.
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6.16 Underuse of maintenance budesonide/formoterol treatment
Most participants had at least one episode of underuse (Table 6.9). The number of
GD\V ZLWK  DFWXDWLRQV ZDV QRW VLJQLILFDQWO\ GLIIHUHQW EHWZHHQ WKH WZR UHJLPHQV
(Table 6.9).
There were significantly fewer days with zero actuations (non-adherence) in the
SMART group (Table 6.9).
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Table 6.9: Underuse of maintenance budesonide/formoterol treatment
Outcome
SMART
group
(N = 151)
Standard
group
(N = 152)
Relative Risk
or Rate
SMART vs
Standard
(95% CI)
P
value
At least one day with zero
actuations, n (%)
120 (79.5) 126 (82.9) 0.96
(0.86 to 1.07)
0.45
Number of days with zero
actuations
23.9±32.6 33.6±42.8 0.72
(0.55 to 0.95)
0.022
At least one day with one or
zero actuations, n (%)
129 (85.4) 132 (86.8) 0.98
(0.90 to 1.08)
0.72
Number of days with one
or zero actuations
28.8±35.4 36.9±44.6 0.80
(0.62 to 1.03)
0.087
At least one day with two or
less actuations, n (%)
143 (94.7) 150 (98.7) 0.96
(0.92 to 1.00)
0.052
Number of days with two
or less actuations
61.3±47.4 70.6±51.0 0.89
(0.76 to 1.05)
0.19
Plus/minus values are mean ± SD.
Estimates are weighted as part of the analysis and may be numerically different to the values
calculated from the tabulated mean values.
Analysis of the relative rates of days of underuse was calculated by Poisson regression with an offset
of the logarithm of the treatment exposure. The variable days of underuse was over-dispersed and a
deviance-based over-dispersion correction term was used in the Poisson regression.
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6.17 Corticosteroid load
6.17.1 Daily ICS dose
Participants randomised to the SMART regimen had a significantly greater mean
exposure to budesonide of 259.2µg per day (Table 6.10).
The distribution of mean daily budesonide dose is shown in Figures 6.6 and 6.7.
25/151 (16.6%) and 32/152 (23.0%) participants in the SMART and Standard groups
respectively had mean daily budesonide doses of less than 400µg per day. 64/151
(42.4%) participants in the SMART group and 40/152 (26.3%) participants in the
Standard group had mean daily budesonide doses greater than 800µg per day
(Figures 6.6 and 6.7).
6.17.2 Oral corticosteroid dose
Participants randomised to the SMART regimen had a significantly lower mean
exposure to prednisone of 49.1mg over the study period (Table 6.10) and had
significantly fewer courses of oral prednisone per year of follow-up (Table 6.10).
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Table 6.10: ICS dose, oral corticosteroid dose and composite systemic
corticosteroid exposure
Outcome
SMART
group
(N = 151)
Standard
group
(N = 152)
Relative Risk
or Rate
SMART vs
Standard
(95% CI)
P
value
Daily ICS dose *
Daily budesonide dose, µg 943.5±1502.5 684.3±390.5 1.22
(1.06 to 1.41) †
0.006
Oral corticosteroid dose ‡
Oral corticosteroid dose,
mg prednisone
77.5±240.5 126.6±382.1 0.011
§
Number of courses of oral
corticosteroids per year of
IROORZXSۅ
0.80±2.5 1.1±1.9 0.58
(0.41 to 0.84)
0.004
Composite systemic
corticosteroid exposure
(ICS plus oral) ¶
Composite systemic
corticosteroid exposure, mg
prednisone equivalent per
year
793.7±893.1 772.1±1062.7 1.03
(0.86 to 1.22) †
0.76
Plus/minus values are mean ± SD. *: The logarithm of the annualised ICS use was the response variable in
a weighted normal linear model, with the randomised treatment as a predictor and the treatment exposure
time as a weight (individuals with longer periods of treatment exposure were given more weight and those
with shorter periods of treatment exposure less weight in the analysis). n=150 for SMART and n=151 for
Standard (logarithm zero cannot be defined and therefore one participant in each group, whose measured
ICS dose was zero, was not included in the analysis). The SMART participant had a treatment exposure
period of one day prior to discontinuation and the Standard participant discontinued immediately after the
first study visit. †: Ratio of mean values of annualised corticosteroid use (Exponent of the difference in
logarithms of SMART minus Standard). ‡: One Standard patient self-administered an overdose of 800mg
prednisone per day for 5 days for asthma (sensitivity analysis for oral corticosteroid dose with this
participant excluded from the data is shown in Table 6.11). Corticosteroid conversion: 100mg intravenous
hydrocortisone:25mg oral prednisone. §: Chi-squared 11·1, degrees of freedom 3 (bands for contingency
WDEOHV     ۅ Q  IRU 6WDQGDUG GXH WR RQH SDUWLFLSDQW ZKR GLVFRQWLQXHG
immediately after the first study visit. ¶: Budesonide dose per year was converted to prednisone-equivalent
dose (5000µg inhaled budesonide=10mg oral prednisone). The annualised systemic corticosteroid exposure
was the sum of the prednisone-equivalent dose per year and the oral corticosteroid dose per year. The
logarithm of the annualised systemic corticosteroid exposure was the response variable in a weighted
normal linear model, with the randomised treatment as a predictor and the period of observation as a weight
(individuals with longer periods of observation were given more weight and those with shorter periods of
observation less weight in the analysis). n=150 for SMART and n=151 for Standard (logarithm zero cannot
be defined and therefore one participant in each group, whose measured ICS and prednisone dose was zero,
was not included in the analysis).
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Figure 6.6: Mean daily budesonide dose for the SMART group
Figure 6.7: Mean daily budesonide dose for the Standard group
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6.17.3 Composite systemic corticosteroid exposure
Overall composite annual systemic corticosteroid exposure was similar between the
two treatment groups (Table 6.10 and Figure 6.8).
Figure 6.8: Corticosteroid exposure
Daily ICS dose (Panel A), oral corticosteriod dose (Panel B) and composite annual systemic
corticosteriod exposure (Panel C). ICS: Inhaled corticosteroid.
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6.17.4 Sensitivity analysis with one Standard participant removed from the
analyses of oral corticosteroid dose and composite systemic corticosteroid
exposure
One participant in the Standard group self-administered an overdose of 800mg
prednisone per day for five days for asthma. A sensitivity analysis was performed
for the analyses of oral corticosteroid dose and composite systemic corticosteroid
exposure, with this participant excluded from the data (Table 6.11). The results of
these analyses supported the intention to treat analyses.
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Table 6.11: Sensitivity analyses with one Standard participant removed from
the analyses of oral corticosteroid dose and composite systemic corticosteroid
exposure
Outcome SMART
group
(N = 151)
Standard
group
(N = 151)
P value
Oral corticosteroid dose
Sensitivity analysis of oral corticosteroid
dose, mg prednisone
77.5±240.5 99.9±194.5 0.011*
Composite systemic corticosteroid
exposure (ICS plus oral)
Sensitivity analysis of composite systemic
corticosteroid exposure, mg prednisone
equivalent per year
793.7±893.1 696.9±525.8 0.62 †
Plus/minus values are mean ± SD.* Chi-squared 11.1, degrees of freedom 3 (bands for contingency
tables: 0, 0-200, 200-400, 400+). P value to 3 figures is 0.0114. † The ratio of mean values (95% CI)
of annualised systemic corticosteroid exposure [Exponent of the difference in logarithms of SMART
minus Standard], was 1.04 (0.88 to 1.23). N=150 for SMART (logarithm zero cannot be defined and
therefore one participant, who had measured ICS and prednisone doses of zero, was not included in
the analysis. This participant had a treatment exposure period of one day prior to discontinuation) and
N=150 for Standard (logarithm zero cannot be defined and therefore one participant, who had
measured ICS and prednisone doses of zero, was not included in the analysis. This participant
discontinued immediately after the first study visit). The P value to 3 figures for the oral
corticosteroid dose sensitivity analysis is 0.0114. The P value to 3 figures for the oral corticosteroid
dose intention to treat analysis (i.e. with the outlier participant included in the dataset) is 0.0112. The
apparent discrepancy between the large change in mean values for oral corticosteroid dose and much
smaller change in P values is because only one outlying participant is taken from the fourth band of
the contingency table and so had virtually no influence on the contingency table analysis.
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6.18 Severe asthma exacerbations
The SMART regimen was associated with significantly fewer severe exacerbations
(Table 6.12). The Hazard ratio for the time to first severe asthma exacerbation was
significantly less for the SMART group (Figure 6.9). 225 participants had no severe
exacerbations, 62 had one severe exacerbation and 16 had two or more severe
exacerbations.
Table 6.12: Severe asthma exacerbations
Outcome
SMART
group
(N = 151)
Standard
group
(N = 152)
Relative Risk or
Rate SMART vs
Standard
(95% CI)
P
value
Severe asthma exacerbations *
Participants with at least one
severe exacerbation, n (%)
28 (18.5) 50 (32.9) 0.56
(0.38 to 0.84)
0.004
Number of severe
exacerbations, (weighted mean
rate per year)
35 (0.53) 66 (0.97) 0.54
(0.36 to 0.82)
0.004
Estimates are weighted as part of the analysis and may be numerically different to the values
calculated from the tabulated mean values.
The weighted mean rate per year is the total number of events in the study group divided by the total
person follow-up time in years for the study group.
Relative rates were calculated by Poisson regression with an offset of the logarithm of the period of
observation (for the analyses of severe exacerbation).
*: A severe exacerbation is defined as the use of systemic corticosteroids for at least 3 days or a
hospitalisation or ED visit because of asthma, requiring systemic corticosteroids. Courses of
corticosteroids separated by 7 days or more were treated as separate severe exacerbations.
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Figure 6.9: Kaplan-Meier plots of time to first severe asthma exacerbation
Hazard ratio (95% CI) for time to first severe asthma exacerbation, SMART versus Standard: 0.53
(0.33 to 0.84), P=0.008.
Symbol: Censored values; Continuous line: SMART group; Dashed line: Standard group.
6.19 Hospital admissions and ED attendances for asthma
There was no difference in the risk of a hospital admission or hospital attendance
(hospital admission and/or ED attendance) for asthma between the groups (Table
6.13). The number of hospital admissions or hospital attendances (hospital
admission and/or ED attendance) for asthma was similar between the groups (Table
6.13).
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Table 6.13: Hospital admissions and ED attendances for asthma
Outcome
SMART
group
(N = 151)
Standard
group
(N = 152)
Relative Risk or
Rate SMART vs
Standard
(95% CI)
P
value
Hospital and ED
attendances for asthma
Participants with at least one
hospital admission or ED
attendance, n (%)
7 (4.6) 9 (5.9) 0.78
(0.30 to 2.05)
0.62
Number of hospital
admissions and/or ED
attendances, (weighted mean
rate per year)
10 (0.15) 12 (0.18) 0.85
(0.37 to 2.00)
0.71
Hospital admissions for
asthma
Participants with at least one
hospital admission, n (%)
2 (1.3) 2 (1.3) 1.01
(0.14 to 7.05)
0.99
Number of hospital
admissions, (weighted mean
rate per year)
3 (0.05) 2 (0.03) 1.54
(0.26 to 9.09)
0.91
Estimates are weighted as part of the analysis and may be numerically different to the values
calculated from the tabulated mean values.
The weighted mean rate per year is the total number of events in the study group divided by the total
person follow-up time in years for the study group.
Relative rates were calculated by Poisson regression with an offset of the logarithm of the period of
observation (for the analyses of hospital admission and ED attendance).
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6.20 Asthma control
There was a marked reduction in ACQ-7 score in both groups (Table 6.14 and Figure
6.10). There was a significant treatment by time interaction term for ACQ-7
(p=0·02) and the pair-wise comparisons between treatments at each measurement
time suggested the ACQ-7 was significantly lower in the SMART group at the fourth
visit but not the other visits (Table 6.14).
62/135 (45.9%) participants in the SMART group and 50/142 (35.2%) participants in
WKH 6WDQGDUG JURXS KDG DQ $&4 VFRUH RI  DW VL[ PRQWKV 9LVLW  
(23.0%) participants in the SMART group and 39/142 (27.5%) participants in the
6WDQGDUGJURXSKDGDQ$&4VFRUHRIDWVL[PRQWKV
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Table 6.14: Asthma control by ACQ-7 score
Visit
SMART
group
(N = 151)
Standard
group
(N = 152)
SMART minus
Standard
(95% CI)
P value
ACQ-7 *
Visit 1 1.87±0.96 1.90±1.13 - -
Visit 2 1.21±0.79 1.41±1.01 -0.20
(-0.40 to 0.01)
0.058
Visit 3 1.12±0.73 1.33±0.97 -0.19
(-0.39 to 0.01)
0.063
Visit 4 1.02±0.75 1.42±1.08 -0.36
(-0.58 to -0.15)
0.001
Visit 5 1.04±0.76 1.30±1.08 -0.20
(-0.42 to 0.02)
0.08
Plus/minus values are mean ± SD. *: ACQ-7 score is a composite score of asthma control, comprising
questions on asthma symptoms, rescue bronchodilator use and FEV1 % predicted (overall scores range
IURPWRZLWKVFRUHVVXJJHVWLQJµZHOOFRQWUROOHG¶DVWKPDDQGVFRUHVVXJJHVWLQJµQRW
well-controlled’ asthma). The minimal clinically important difference for ACQ-7 score is 0.5.
ACQ-7 was analysed by mixed linear model examining response profiles at each time point using
random effects for individual subjects and an unstructured covariance pattern to account for
correlation between measurements on the same subjects (this model forces a common intercept and
adjusts for baseline values in this way). P-value for treatment by time interaction term was
statistically significant, p=0.02, consistent with the difference between SMART and Standard being
different at different times.
Visit 2: SMART: n=150, Standard: n=150; Visit 3: SMART: n=143, Standard: n=147; Visit 4:
SMART: n=139, Standard: n=141; Visit 5: SMART: n=135, Standard: n=142.
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Figure 6.10: Asthma control over the study period
Plot of mean ACQ-7 score ± 1 SD by time. Solid line is SMART, dashed line is Standard.
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6.21 Lung function
Lung function measurements (FEV1 or FEV1 % predicted) were similar between the
groups at all visits (Table 6.15 and Figure 6.11).
The p-value for the treatment by time interaction term was not statistically significant
(p=0·51), meaning that there was no evidence that the difference between SMART
and Standard was different at different measurement times, for both FEV1 and FEV1
% predicted. The overall effect of treatment averaged over all measurement times
for FEV1 was also not statistically significant: SMART minus Standard (95% CI)
0.12 L (-0.07 to 0.31), p=0.23. The overall effect of treatment averaged over all
measurement times for FEV1 % predicted was also not statistically significant:
SMART minus Standard (95% CI) 1.5% (-2.6 to 5.6), p=0.47.
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Table 6.15: Lung function results
Outcome
SMART
group
(N = 151)
Standard
group
(N = 152)
SMART minus
Standard
(95% CI)
P value
FEV1 (Litres) *
Visit 1 2.62±0.91 2.50±0.78
Visit 5 2.80±0.91 2.64±0.93 0.15
(-0.06 to 0.36)
0.16
FEV1 % predicted *
Visit 1 81.6±18.9 80.4±20.5
Visit 5 87.1±17.0 84.1±22.0 2.5
(-2.0 to 7.0)
0.28
Plus/minus values are mean ± SD. * FEV1 and FEV1 % predicted were analysed by mixed linear
model examining response profiles at each time point using random effects for individual subjects and
an unstructured covariance pattern to account for correlation between measurements on the same
subjects (this model forces a common intercept and adjusts for baseline values in this way). P-value
for the treatment by time interaction term was not statistically significant (p=0.51). Visit 5: SMART:
n=133, Standard: n=141.
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Figure 6.11: Lung function
A: FEV1
B: FEV1 % predicted
Plot of mean FEV1 (Panel A) and mean FEV1% predicted (Panel B) ± 1 SD by time.
Solid line is SMART, dashed line is Standard.
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6.22 Satisfaction with inhaled asthma treatment (SATQ)
Ease of use of medication scores were significantly higher in the SMART group at
the end of the study (Table 6.16). Domain scores for effectiveness of medication,
burden of medication, side effects and the overall SATQ score were similar between
groups (Table 6.16).
6.23 Adverse events
The adverse events were similar between treatment groups and are detailed in full in
Appendix H. The most frequently occurring adverse events were upper respiratory
tract infection [SMART 66/151 (44%) and Standard 65/152 (43%) participants],
injury/trauma/musculoskeletal ailment [SMART 27/151 (18%) and Standard 17/152
(11%) participants] and adverse taste [SMART 19/151 (13%) and Standard 19/152
(13%) participants].
17/151 (11.3%) of participants in the SMART group and 11/152 (7.2%) of
participants in the Standard group discontinued study treatment. Discontinuations
due to adverse events are shown in Table 6.17.
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Table 6.16: SATQ results
Domain
SMART
group
(N = 151)
Standard
group
(N = 152)
SMART minus
Standard
(95% CI)
P
value
Effectiveness of treatment
Visit 1 5.0±1.2 4.9±1.3
Visit 5 6.1±1.2 6.1±1.0 0.04
(-0.29 to 0.20)
0.73
Ease of use of medication
Visit 1 5.4±1.2 5.4±1.2
Visit 5 6.2±0.9 6.0±1.0 0.23
(0.03 to 0.42)
0.021
Burden of asthma medication
Visit 1 4.5±1.3 4.6±1.4
Visit 5 5.0±1.1 5.1±1.2 -0.04
(-0.27 to 0.19)
0.73
Side effects and worries
Visit 1 4.6±1.2 4.7±1.3
Visit 5 5.0±1.2 5.2±1.2 -0.13
(-0.40 to 0.13)
0.32
Overall score
Visit 1 4.9±0.9 4.9±1.0
Visit 5 5.6±0.8 5.6±0.9 -0.002
(-0.18 to 0.17)
0.98
Plus/minus values are mean ± SD. The SATQ is a questionnaire used to measure patients' satisfaction
with their inhaled asthma treatment (Campbell et al., 2003). The questionnaire comprised 26
questions, divided into four domains: effectiveness of medication (8 questions); ease of use (7
questions); burden of asthma medication (6 questions); and side effects and worries (5 questions).
Each question was scored on a scale of 1 to 7. Negatively phrased questions were reversed for
analysis. Domain scores were calculated as the average of the responses for that domain, with higher
values indicating greater satisfaction with treatment (range 1 to 7). The total overall score was
calculated as the mean of the four domain scores. The minimum clinically important difference for the
SATQ has not been defined. SATQ was analysed by ANCOVA with the Visit 1 value as a baseline
covariate, to give an adjusted treatment difference for SMART minus Standard. Visit 5: SMART:
n=144, Standard: n=150.
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Table 6.17: Discontinuation due to adverse events
SMART
(N = 151)
Standard
(N = 152)
Adverse event Number of
participants
% Number of
participants
%
Palpitations 1 0.7 2 1.3
Headache 1 0.7 0 0
Voice change 0 0.0 1 0.7
Mucous in throat 0 0.0 1 0.7
Diarrhoea, vomiting and
medication taste
0 0.0 1 0.7
Medication taste, dry
throat and voice change
1 0.7 0 0.0
6.24 Serious adverse events
There were no deaths, or asthma-related intensive care unit admissions or
intubations. No participants required assisted ventilation (e.g. CPAP or NIV). All
serious adverse events, eight in the SMART group and seven in Standard group,
were considered by their treating physicians to be unrelated to study participation
(Table 6.18).
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Table 6.18: Serious adverse events
SMART
(N = 151)
Standard
(N = 152)
Serious adverse event Number of
participants
% Number of
participants
%
Hospital admission for
asthma*
2 1.3 2 1.3
Cellulitis 0 0.0 3 2.0
Heart failure secondary to
idiopathic dilated
cardiomyopathy †
1 0.7 0 0.0
Non-cardiac chest pain, self-
limiting
1 0.7 0 0.0
Metabolic derangement due
to self-administered
prednisone overdose
0 0.0 1 0.7
Calf myositis 0 0.0 1 0.7
Pneumonia 1 0.7 0 0.0
Frozen shoulder 1 0.7 0 0.0
Missed miscarriage
requiring hospital admission
1 0.7 0 0.0
*: one SMART participant had 2 hospital admissions for asthma †: Symptoms pre-dated enrollment
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6.25 Pregnancy in study participants
Four participants in the SMART group and five in the Standard group were pregnant
during study participation. The outcomes for each pregnancy are detailed in Table
6.19.
Table 6.19: Pregnancy in study participants
Study group Pregnant at study
entry
Outcome Detail
Standard Yes Healthy baby delivered
Standard No Healthy baby delivered
Standard No Healthy baby delivered
Standard No Healthy baby delivered
Standard No Miscarriage in early
pregnancy
Miscarriage after
study completion
SMART No Miscarriage in early
pregnancy
Continued study
participation
SMART No Miscarriage in early
pregnancy
Continued study
participation
SMART No Healthy baby delivered
SMART Yes Healthy baby delivered
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6.26 Dose dumping database search
A similar number of participants in both groups, 2/151 (1.3%) participants in the
SMART group and 5/152 (3.3%) participants in the Standard group, met the dose
dumping criteria applied to the dataset in which actuation data on study visit days
were removed (Table 6.20). Dose dumping days were observed infrequently in both
groups (Table 6.20).
The number of participants with at least one episode of dose dumping and the
number of days meeting dose dumping criteria increased when the dataset in which
actuation data on study visit days were included was used (Table 6.21).
Table 6.20: Dose dumping in which actuation data on study visit days were
removed from the dataset*
Outcome SMART
(N = 151)
Standard
(N = 152)
Participants with at least one episode of
dose dumping, n (%) †
2 (1.3) 5 (3.3)
Number of days of dose dumping 2 7
7KHGRVHGXPSLQJFULWHULDXVHGZDVDFWXDWLRQVRFFXUULQJZLWKLQKRXUV5DQGHWDO
in the dataset in which actuations on study visit days were removed. For the SMART group, this was
the number of days meeting dose dumping criteria with budesonide/formoterol inhalers; for the
Standard group, this was the number of days meeting dose dumping criteria with salbutamol inhalers.
† In all of these participants, high use not meeting dose dumping criteria was observed on at least one
other day during study participation.
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Table 6.21: Dose dumping in which actuation data on study visit days were
included in the dataset*
Outcome SMART
(N = 151)
Standard
(N = 152)
Participants with at least one episode of
dose dumping, n (%)
3 (2.0) 6 (3.9)
Number of days of dose dumping 5 8
7KHGRVHGXPSLQJFULWHULDXVHGZDVDFWXDWLRQVRFFXUULQJZLWKLQKRXUV5DQGHWDO
in the dataset in which actuations on study visit days were included. For the SMART group, this was
the number of days meeting dose dumping criteria with budesonide/formoterol inhalers; for the
Standard group, this was the number of days meeting dose dumping criteria with salbutamol inhalers.
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Chapter Seven: Discussion
7.1 The SMART study randomised controlled trial findings
This study demonstrates that combination budesonide/formoterol inhaler therapy
prescribed according to the SMART regimen has a favourable safety and efficacy
profile compared to the Standard regimen of maintenance budesonide/formoterol
inhaler therapy and salbutamol as reliever in adult asthma patients at risk of severe
exacerbations. The SMART regimen reduces the risk of severe asthma
exacerbations without increasing the risk of beta-agonist overuse without medical
review or increasing the long-term systemic corticosteroid burden. Although no
significant difference was found between groups in the risk of at least one high beta-
agonist use episode, the number of days with high use, marked overuse and extreme
overuse were approximately 40% lower in patients randomised to the SMART
regimen. The number of high use days without medical review was significantly
lower in the SMART group, although when an overuse episode occurred, the
likelihood of a patient seeking medical review was similar between groups. This
suggests that the increasing use of budesonide/formoterol during worsening asthma
with the SMART regimen does not lead to greater delay in seeking medical help.
This observation is important, as delay in seeking medical assistance in the setting of
severe exacerbations is one of the most important factors contributing to a fatal
outcome (Fraser et al., 1971). Patients treated with the SMART regimen experienced
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46% fewer severe asthma exacerbations, similar to previous studies in moderate to
severe asthma (Cates and Lasserson, 2009; Rabe et al., 2006a; O'Byrne et al., 2005).
Asthma patients prescribed the SMART regimen had a greater mean daily ICS
exposure. However, due to the reduction in severe exacerbations, the SMART group
had a lower oral corticosteroid exposure, with a similar overall systemic
corticosteroid burden between the two regimens. Our data also inform the debate
regarding the potential mechanisms by which use of the SMART regimen reduces
severe asthma exacerbations. Patients in both treatment groups underused their
maintenance budesonide/formoterol therapy, but the SMART group had fewer days
of non-adherence, on which no maintenance therapy was taken. This reduction in
non-adherence may contribute to reducing the risk of severe exacerbations, together
with the self-titrated escalation of budesonide/formoterol use in response to
worsening asthma (Sovani et al., 2008; Barnes, 2007). In support of this latter
mechanism, the frequent use of ICS, such as that self-administered by patients in the
SMART group on days of high, marked and extreme overuse, has substantial
efficacy in the treatment of acute severe asthma (Rodrigo, 2006).
This was a study of patients at risk of severe asthma exacerbations (O'Connor et al.,
2010), 90% of whom had at least one severe exacerbation, and 40% of whom had
two or more severe exacerbations, in the preceding year. Around one in four patients
self-administered >32 actuations per day of salbutamol (or equivalent) on at least one
occasion during the study. Furthermore, in patients with a high use episode,
approximately 90% of high use days occurred without medical review within the
next 48 hours, despite this advice documented in the asthma self-management plans
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provided. These findings illustrate the extent of unsupervised beta-agonist overuse
by patients at risk of severe asthma exacerbations.
Beta-agonist overuse was used as an indirect measure of risk of mortality (Abramson
et al., 2001; Eisner et al., 2001; Suissa et al., 1994; Spitzer et al., 1992). In
consideration of this risk, there is a concern that because formoterol has greater
intrinsic activity than salbutamol (Hanania et al., 2002), it could potentially result in
greater maximum adverse effects in the situation of beta-agonist overuse. This
pharmacological property is common to both isoprenaline and fenoterol (Hanania et
al., 2002), of which the high-dose preparations have been implicated in epidemics of
asthma mortality (Crane et al., 1989; Stolley and Schinnar, 1978). The reduction in
both overuse episodes and severe exacerbations (Crane et al., 1992) with the
SMART regimen, together with the previously reported reduction in ED visits or
hospital admissions (Rabe et al., 2006a), may indicate an accompanying reduced risk
of mortality. However, this interpretation comes with the caveat that this study and
the SMART clinical trial programme (Sears and Radner, 2009) have insufficient
power to rule out an effect on asthma mortality risk, and further study of this issue is
required.
In this study, asthma control over six months improved markedly in both groups, in
excess of the 0.5 points considered to be a clinically important improvement in
ACQ-7 score (Juniper et al., 1999). The reductions (improvements) in ACQ-7 scores
were similar for three of four visits between the SMART and Standard groups.
Regarding other patient reported outcomes, improvements in overall satisfaction
scores for inhaled treatment were similar between groups. However, patients treated
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with the SMART regimen had greater improvements in the ease of treatment use
domain of the SATQ. Considered together, these data suggest that the use of the
SMART regimen achieves at least comparable improvements in asthma control
compared to Standard therapy (Bateman et al., 2010) and that patients regard this
treatment as acceptable for use in clinical practice.
In the Standard group, 21% of patients used less than 400µg of budesonide per day
on average throughout the study period, with 26% of the group using more than the
prescribed maintenance dose of 800µg per day. These findings complement the
previous observation that patients prescribed a different combination ICS/LABA
inhaler (fluticasone/salmeterol) as fixed-dose maintenance treatment may vary their
use of treatment according to perceived need (Perrin et al., 2010). These different
patterns of use may also apply to fixed-dose therapy with other combination
ICS/LABA inhalers.
In summary, this study has demonstrated that in asthma patients at risk of severe
exacerbations, combination budesonide/formoterol therapy prescribed according to
the SMART regimen has a favourable risk/benefit profile compared to Standard
maintenance therapy. The SMART regimen may be considered as the preferred
approach in asthma patients at BTS Steps 2, 3 or 4 (SIGN/BTS, 2012) who are at risk
of severe exacerbations.
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7.2 Strengths of the study
7.2.1 Real-world study design
A number of design features allowed the study to enrol patients representative of
those seen in clinical practice. Recruitment occurred from both community and
hospital settings, in order to enrol a heterogeneous group of patients. The trial was
conducted in both primary and secondary care, to allow improved accessibility to the
study. Inclusion/exclusion criteria were broad, to enable the inclusion of patients
with asthma and co-existing conditions. Patients at risk of poor adherence or beta-
agonist overuse were eligible and there was no upper limit for pre-study ICS dose.
Finally, day-to-day asthma care remained with the patient’s primary care physician,
reflecting real-world clinical practice.
These features are consistent with key recommendations regarding the importance of
conducting real-world ‘effectiveness’ research (Holgate, 2012; Krishnan, Schatz and
Apter, 2011; Lieu et al., 2011; Ware and Hamel, 2011).
7.2.2 Monitor performance
Validated electronic monitors were used with extensive trial quality control
processes, as the optimal method to measure actual use of medication. This allowed
assessment of the potential risks associated with high doses of ICS and beta-agonist
with both short-term and cumulative exposure. This study has shown that the
Smartinhaler Tracker is a highly reliable monitor of MDI use by patients and that
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implementing an extensive pre- and within-trial monitor and data checking process
can help to safeguard data acquisition (Bender, 2013).
In pre-trial checks, 98% of monitors were found to be fully functional and ready for
patient use. The pre-trial checks identified a minority of malfunctioning devices that
required repair prior to dispensing, highlighting the importance of investigator-led
post-production testing of monitor function. The within-trial checking process
allowed monitors damaged by participant use to be identified and removed from
circulation, thus reducing the occurrence of data loss as a result of device
malfunction. The rate of complete data loss due to missing monitors was 3.5% (93
of 2642 monitors), whereas data loss due to monitor malfunction in returned devices
was 1.9% (51 of 2642 monitors). Using systems incorporated into the software used
for monitor upload, data which was potentially corrupted was identified and
prevented from database entry.
Complete data was available from 2498/2642 (94.5%) of the monitors dispensed to
patients in this trial. Of the 144 monitors from which there was missing data,
approximately two-thirds (93/144) were lost or thrown away by participants in this
real-world study, despite repeated advice to the contrary. Thus, complete data in
2498/2549 (98.0%) of returned monitors was present. In the remaining 51 (2.0%) of
returned monitors, monitor malfunction prevented complete data retrieval. In
comparison, a trial in 380 asthmatics reported a 14.7% monitor failure rate with the
MDILog and an additional 1.6% of missing monitors (Rand et al., 2007). In
another recent study measuring adherence in 333 patients utilizing the Diskus
Adherence Logger (DAL) and MDILog, 20% of monitors failed to download (Apter
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et al., 2011). A prior paediatric study reported that 8% of Doser CT monitors failed
with mechanical faults (O'Connor et al., 2004).
Smartinhaler malfunction during trial use was generally a consequence of a
combination of patient and monitor-related factors. Problems such as fluid
immersion, low battery, or electro-mechanical damage are likely to have been caused
by both real-world use of MDIs by patients and the inherent vulnerability of
electronic monitors to damage from environmental conditions. Many of these risks
are difficult to reduce without affecting patient behaviour, which could then affect
the generalisability of the data obtained. However, the within-trial checks allowed
identification and subsequent removal of malfunctioning devices from further use
and were a key factor in limiting data loss.
7.2.3 Dataset
The use of primary care clinic and hospital records ensured reliability in the
collection of exacerbation and safety data. The integrity and completeness of the
dataset for both electronic and clinic-recorded measurements minimised the effect of
bias due to missing data.
7.2.4 Independent funding
The study was funded by the Health Research Council of New Zealand, a
government funding organisation. AstraZeneca Limited (the manufacturer of
Vannair and Symbicort) and Nexus6 Limited (the manufacturer of the electronic
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monitors) had no involvement with the funding, concept, design, conduct or analysis
of this study. The lack of non-commercially funded research has recently been
identified as a possible limitation of the previous evidence base for the SMART
regimen (Aalbers, 2013; DTB, 2011).
7.3 Generalisability of study findings
It is acknowledged that an open-label trial design allows the potential for bias.
However, if a double-blind trial design had been used, patients randomised to the
SMART regimen would have been required to use two inhalers, negating the
potential advantages of single inhaler therapy and limiting the generalisability of the
findings. High-risk patients from both primary care and hospital settings were
recruited in this study and patients were not excluded on the basis of baseline beta-
agonist overuse (Rabe et al., 2006a; O'Byrne et al., 2005) or lack of significant
bronchodilator reversibility (Rabe et al., 2006a; O'Byrne et al., 2005). Furthermore,
it was ensured that all patients were prescribed GINA Step 4 maintenance ICS and
LABA therapy (GINA, 2011), thereby overcoming a criticism of previous studies
(Cates and Lasserson, 2009), in which there was a reduction in maintenance ICS
dose at randomisation (Rabe et al., 2006a; O'Byrne et al., 2005). These features
ensure generalisability of the study findings to patients at risk of severe
exacerbations in clinical practice (Rothwell, 2005).
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MDIs rather than Dry Powder Inhalers (Turbohaler) were used to deliver
budesonide/formoterol, as reliable, validated electronic monitors for the Turbohaler
were not available. As the SMART regimen has only been approved for use with the
budesonide/formoterol Turbohaler, the use of the budesonide/formoterol MDI in
patients randomised to the SMART regimen can be considered ‘off label’. Given
that clinical comparability has been demonstrated for budesonide/formoterol via
MDI and Turbohaler (Morice et al., 2008; Morice et al., 2007), it is proposed that
the results are generalisable to the use of the budesonide/formoterol Turbohaler.
For the primary outcome variable, 56% and 45% of patients in the SMART and
Standard groups respectively had at least one high beta-agonist use episode. Whilst
this difference was not statistically significant, the lower margin of the confidence
interval of the relative risk was close to one. However, this finding needs to be
interpreted in the context of the unexpectedly common occurrence of
budesonide/formoterol use above the four maintenance actuations by some patients
on the Standard regimen. When this use was adjusted for in the sensitivity analysis,
the proportion of Standard patients with at least one high use episode increased to
62%. Consequently, it is considered that these findings are consistent with the
overall favourable risk/benefit profile of the SMART regimen demonstrated in this
study.
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7.4 Study Limitations
7.4.1 Equivalence ratio for budesonide/formoterol to salbutamol
For the definition of beta-agonist overuse, a 1:2 actuation ratio for
budesonide/formoterol to salbutamol was used, based on recommended limits of
beta-agonist use requiring medical review (National Asthma Council Australia,
2013; Holt et al., 2004) and supported by the short-term bronchodilator equivalence
of 6µg formoterol to 200µg salbutamol with repeat dosing in acute asthma (Balanag
et al., 2006; Rubinfeld et al., 2006). It is acknowledged that both higher and lower
actuation ratios have been derived from single-dose studies in stable asthma (Hampel
et al., 2008; Rosenborg et al., 2002).
7.4.2 Bioequivalence of oral prednisone to inhaled budesonide for the calculation
of composite systemic corticosteroid exposure
For the calculation of composite systemic corticosteroid exposure, bioequivalent
doses of 10mg oral prednisone to 5mg inhaled budesonide per day were used,
determined in a prior dose-response study (Aaronson et al., 1998). This study
(Aaronson et al., 1998) used adrenocorticotropic hormone (ACTH) infusion, which is
a sensitive method for assessing the systemic effect of ICS on hypothalamic-
pituitary-adrenal axis function (Barnes et al., 1998; Pedersen and O'Byrne, 1997).
While the inherent limitations of such an estimate are acknowledged, this is the only
study from which a validated measure of bioequivalence could be obtained.
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7.4.3 Potential for dose dumping
Prior studies have reported that dose dumping has occurred in 12% to 32% of study
participants who are electronically monitored (Rand et al., 1992; Mawhinney et al.,
1991). In this current trial, dose dumping criteria were met in approximately 3% of
the patients and on 0.5% of high use days when a previously used definition (Rand et
al., 1992) was applied to the dataset. These findings indicate that the occurrence of
dose dumping had limited impact on the dataset and justify the pre-specified plan to
remove electronic medication use data on study visit days prior to analysis.
7.5 Future areas for further research
In the coming years, further research on the use of novel ICS/fast-onset LABA
combination inhalers with the SMART regimen may provide clinicians with a greater
range of inhaler devices which may be prescribed according to the SMART regimen.
The recommended treatment for patients with mild persistent asthma is regular ICS
for maintenance therapy with SABA for relief. However, the potential benefits of
regular ICS therapy may be limited by poor adherence to treatment. Prior studies
have demonstrated that symptom-driven as-needed ICS with SABA therapy is an
effective treatment in patients with mild asthma compared to regular ICS for
maintenance with SABA for relief (Calhoun et al., 2012; Papi et al., 2007). Future
research may study the use of symptom-driven as-needed ICS/fast-onset LABA
therapy in patients with mild persistent asthma, as a novel approach which could
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improve adherence to ICS treatment and asthma control compared with regular ICS
therapy with SABA for relief.
7.6 Conclusion
This study has shown that combination budesonide/formoterol inhaler therapy
prescribed according to the SMART regimen reduces severe exacerbations in ‘real-
world’ at-risk asthma patients with high reliever medication use. This reduction in
risk of severe exacerbations, compared with maintenance budesonide/formoterol and
salbutamol reliever use, occurs without increasing the risk of beta-agonist overuse
without medical review. Through electronic monitoring of actual medication use, it
was possible to determine that the greater effectiveness with the SMART regimen
was associated with both a reduction in non-adherence to maintenance
budesonide/formoterol treatment, and the self-titrated escalation of
budesonide/formoterol use in response to worsening asthma. Although patients
prescribed the SMART regimen had a greater mean daily inhaled corticosteroid
exposure, they had a lower oral corticosteroid exposure due to the reduction in severe
exacerbations, resulting in a similar overall systemic corticosteroid burden.
Overall, the data suggest that the SMART regimen has a favourable risk/benefit
profile and can be recommended for use by adult asthma patients at risk of severe
exacerbations.
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APPENDIX H: ADVERSE EVENTS IN THE SMART STUDY RCT
All adverse events occurring in the study are reported below.
SMART
(n=151)
Standard
(n=152)
Adverse event Number of
participants
% Number of
participants
%
Upper respiratory tract infection 66 43·7 65 42·8
Injury/trauma/musculoskeletal
ailment
27 17·9 17 11·2
Adverse taste 19 12·6 19 12·5
Voice change (including hoarseness) 15 9·9 6 3·9
Lower respiratory tract infection/
pneumonia/chest infection/bronchitis
12 7·9 15 9·9
Throat or mouth irritation 10 6·6 6 3·9
Tremor 8 5·3 5 3·3
Sinusitis 8 5·3 9 5·9
Headache 7 4·6 8 5·3
Dry mouth or throat 7 4·6 9 5·9
Palpitations 6 4·0 5 3·3
Conjunctivitis or eye infection 6 4·0 1 0·7
Thrush (oral or genital) 5 3·3 5 3·3
Sleep disturbance or insomnia 5 3·3 0 0·0
Ear infection 4 2·6 4 2·6
Gynaecology ailment 4 2·6 0 0·0
428
Muscle cramp 3 2·0 6 3·9
Migraine 3 2·0 3 2·0
Hayfever or allergic rhinitis 3 2·0 8 5·3
Gastrointestinal illness 3 2·0 3 2·0
Cough 2 1·3 4 2·6
Weight gain 2 1·3 0 0·0
Skin rash 2 1·3 6 3·9
Miscarriage 2 1·3 1 0·7
Mouth ulcers 2 1·3 1 0·7
Urinary tract infection 2 1·3 3 2·0
Indigestion or reflux 2 1·3 1 0·7
Diarrhoea and/or vomiting 2 1·3 7 4·6
Tachycardia (self-limiting) * 1 0·7 0 0·0
Light headed 1 0·7 0 0·0
Nausea 1 0·7 5 3·3
Non cardiac chest pain (all self-
limiting)
1 0·7 2 1·3
Restless 1 0·7 0 0·0
Pelvic infection 1 0·7 0 0·0
Skin bruising 1 0·7 0 0·0
Seizure 1 0·7 1 0·7
Pleurisy 1 0·7 0 0·0
Itch (pruritis) 1 0·7 0 0·0
Anxiety 1 0·7 0 0·0
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Pre-existing mental health problem 1 0·7 1 0·7
Swelling of ankles 1 0·7 0 0·0
Dental problem 1 0·7 2 1·3
Sarcoid 0 0·0 1 0·7
Dizzyness 0 0·0 4 2·6
Tiredness 0 0·0 1 0·7
Weight loss 0 0·0 1 0·7
Diabetes 0 0·0 3 2·0
Mucous in throat 0 0·0 2 1·3
Food allergy 0 0·0 1 0·7
Skin cancer 0 0·0 1 0·7
Skin infection 0 0·0 1 0·7
Smoke inhalation 0 0·0 1 0·7
Cataract 0 0·0 2 1·3
*: documented by palpation by investigator; self-limiting
